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Acute myeloid leukemia (AML) is a heterogeneous malignancy where disruption of 
normal intracellular signaling occurs due to mutations or abnormal external signaling. 
Many pathways have emerged as potential targets for pharmacological intervention, 
including the PI3K-Akt-mTOR pathway. Aberrantly upregulated PI3K-AKT-mTOR 
signaling characterizes many types of cancers and may represent an adverse prognostic 
parameter; this is possibly also true for AML since several observations suggest that this 
pathway is important in leukemogenesis. Targeting of this pathway with specific 
inhibitors could therefore result in suppression of leukemic cell growth. Our hypothesis 
was that AML patients differ with regard to the impact of PI3K-Akt-mTOR signaling in 
leukemogenesis and chemosensitivity, and that patients thereby differ with regard to 
their susceptibility to various PI3K-Akt-mTOR inhibitors.  
The aim of this thesis was to further characterize the patient heterogeneity in human 
AML through studies of (i) the constitutive expression of selected mediators in the 
PI3K-Akt-mTOR pathway; (ii) how the signaling pathway is modulated by the agonist 
insulin and by various pathway inhibitors; and (iii) through molecular studies to try to 
elucidate possible mechanisms behind the heterogeneity of PI3K-Akt-mTOR signaling 
in AML. 
Our studies confirmed that constitutive activation of the PI3K-Akt-mTOR pathway 
differed between patients and two main subsets with high and low pathway activation 
were identified based on PI3K-Akt-mTOR activation profiles. Our overall results 
described in this thesis showed that AML patients are heterogeneous with regard to 
constitutive PI3K-Akt-mTOR activation, and the same was observed when studying the 
effect of agonistic insulin and the effects of various pathway inhibitors in the presence 
of insulin. Insulin increased the phosphorylation of mediators in the PI3K-Akt-mTOR 
pathway, and this effect was especially seen for mediators upstream of mTOR. 
Our studies showed that patients differed with regard to the energy, amino acid, and 
arachidonic acid metabolism in their leukemic cells, and the metabolic profile seemed 
to differ between primary AML cells that were susceptible or resistant to the 
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antiproliferative effect of PI3K-Akt-mTOR pathway inhibitors. Susceptible and 
resistant cells to pathway inhibitors then seemed to differ especially in arachidonic acid, 
proline and/or energy metabolism. However, our studies also suggest that differences in 
redox homeostasis may be important.  
In the final work, we demonstrated that clonal heterogeneity could be reflected in the 
activation status of mediators in the PI3K-Akt-mTOR pathway. We found that this 
heterogeneity was associated with adverse prognosis, i.e. the survival after intensive 
antileukemic treatment was decreased for patients showing evidence for clonal 
heterogeneity when analyzing the pathway activation profile. Patients with and without 
evidence for clonal heterogeneity differed in their global gene expression profiles, 
especially with regard to expression of genes encoding proteins that are important for G 
protein coupled receptor signaling.  
To conclude, the possible importance of the differences found between AML patients 
should be considered when designing and/or analyzing the results in future clinical 
studies of PI3K-Akt-mTOR inhibitors, and possibly also when considering combination 
of pathway inhibitors with other targeting therapies or conventional chemotherapy. 
Biological heterogeneity reflected in the intracellular signaling status should also be 
further investigated as a potential prognostic biomarker in human AML both in patients 
receiving intensive and possibly curative treatment, and in elderly/unfit patients 
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1.1 Acute myeloid leukemia 
1.1.1 Definition and classification 
Acute myeloid leukemia (AML) is an aggressive malignancy characterized by the 
proliferation of immature myeloid leukemia cells [1, 2]. In most cases, this disease 
involves a bone marrow malignancy, but malignant cells may also be detected in 
peripheral blood or as extra medullary infiltration. In exceptional patients, soft tissue 
infiltrates can be the first and/or only manifestation of the disease [1, 3, 4]. The acute 
promyelocytic leukemia (APL) variant of AML is characterized by specific genetic 
abnormalities in the leukemic cells and severe coagulopathy, and treatment differs from 
that of other types of AML [5-7]. In this thesis, we use the term AML to refer to non-
APL variants of the disease. 
For a significant majority of patients, non-APL variants of AML primarily affect the 
bone marrow, and for a large percentage of these patients, at least 20% of the nucleated 
bone marrow cells are immature or undifferentiated leukemia blasts [2]. However, for 
patients with inv(16), t(16;16) and t(8;21) abnormalities, the minimum threshold of 20% 
of bone marrow blasts is not required. The erythroleukemic variant of AML also has 
other distinct diagnostic criteria [2]. A detailed description of the various subsets of 
AML is given in the original publication [2]. Additional strategies for subclassification, 
such as micro-RNA, epigenetic, transcriptomic, and proteomic characterization, have 





Table 1. A summary of the World Health Organization (WHO) 2016 classification of 
AML [2, 13]. 
Categories 
Acute myeloid leukemia with recurrent genetic abnormalities 
 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1  
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
APL with t(15;17)(q22;q12); PML-RARA  
AML with t(9;11)(p22;q23); MLLT3-MLL  
AML with t(6;9)(p23;q34); DEK-NUP214  
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1  
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1  
Provisional entity: AML with mutated NPM1  
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified (NOS) 
 
Acute myeloid leukemia with minimal differentiation  
Acute myeloid leukemia without maturation  
Acute myeloid leukemia with maturation  
Acute myelomonocytic leukemia  
Acute monoblastic/monocytic leukemia  
Acute erythroid leukemia  
Pure erythroid leukemia  
Erythroleukemia, erythroid/myeloid  
Acute megakaryoblastic leukemia  
Acute basophilic leukemia  
Acute panmyelosis with myelofibrosis (syn.: acute myelofibrosis; acute 
myelosclerosis) 
Myeloid sarcoma (syn.: extramedullary myeloid tumor; granulocytic sarcoma; 
chloroma) 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis (syn.: transient myeloproliferative disorder) 
Myeloid leukemia associated with Down syndrome 
Comments:  
More details can be found in Döhner et al. [1, 13]. 
 
1.1.2 Treatment of AML 
Intensive chemotherapy is the only treatment that can cure AML, and autologous or 
allogeneic stem cell transplantation can be a part of this intensive treatment [3]. 
Treatment is initiated with an induction cycle that often consists of treatment with an 




referred to as standard 7 + 3 induction therapy and combines cytarabine for seven days 
with an anthracycline for three days. The goal of this first induction cycle is to achieve 
complete remission, i.e. a normal number of bone marrow blasts based on a 
morphological evaluation and at the same time a normalization of peripheral blood cell 
counts.  
If complete remission is not reached after the first cycle, a second induction cycle is 
attempted. If remission still is not achieved after this cycle, the patient is considered to 
have resistant AML. For patients achieving complete remission, a second phase of 
treatment, often referred to as consolidation therapy, is begun. The intention of 
consolidation therapy is to eradicate any residual disease and thereby avoid a later AML 
relapse; the intensity of this treatment is therefore based on a prognostic evaluation of 
the individual patient with regard to the risk of treatment-related complications versus 
the risk of AML relapse (see below).  
Intensive chemotherapy is administered either as intensive conventional chemotherapy 
alone, or in combination with autologous or allogeneic stem cell transplantation. 
Conventional chemotherapy with autotransplantation has a relatively low risk of 
treatment-related mortality. Allotransplantation has a stronger antileukemic effect, 
resulting in a lower risk of later AML relapse than chemotherapy alone or with 
autotransplantation; however, this alternative is associated with a higher rate of 
treatment-related mortality 
Patients classified as chemoresistant can be treated with (i) additional intensive 
induction cycles to try to achieve complete remission; (ii) allogeneic stem cell 
transplantation either directly after the second induction cycle or when remission is 
achieved after a later induction cycle; or (iii) supportive or less intensive AML 
stabilizing treatment [3]. A small percentage of primary chemoresistant patients will 
become long-term survivors if treated with allotransplantion without previous complete 
remission.  
For patients who cannot tolerate intensive treatment (e.g. elderly patients over 70-80 




and transfusions should be offered, and a less intensive AML-stabilizing treatment 
should be considered. The most commonly used antileukemic treatments for these 
patients are demethylating agents (azacitidine, decitabine) and low-dose cytarabine [3, 
14-17]. 
1.1.3 Prognostic evaluation of patients with AML 
AML is a very aggressive disease and survival based on supportive treatment alone 
(including low-toxicity chemotherapy to control peripheral blood leukocytosis), without 
antileukemic treatment, is short and depends on the patient’s age [18]. The average 
survival for patients between 65 and 75 years of age, given only supportive treatment, 
is approximately three months. Whereas, for patients over 85 years of age, it is only one 
month. However, there are exceptional patients who survive as long as two years, given 
supportive treatment alone [19]. 
The most commonly used disease-stabilizing treatments in AML are low-toxicity 
cytarabine and demethylating agents. The effect of these agents is not dependent on 
induction of complete remission. However, the median overall survival is less than 12 
months for both strategies, and low-dose cytarabine does not prolong survival for 
patients with adverse prognoses [17, 20-22].  
Several strategies for prognostic classification (i.e. the probability of long-term, 
leukemia-free survival) of AML patients treated with intensive chemotherapy have been 
used. These are usually based on AML-associated cytogenetic abnormalities; additional 
mutations detected by molecular analyses (especially fms-like tyrosine kinase 3 (FLT3), 
nucleophosmin 1 (NPM1) and CCAAT/enhancer-binding protein alpha (CEBPA) 
abnormalities); the response to the first induction chemotherapy cycle (whether a 
complete hematological remission is reached); and, for certain subsets of patients, the 
peripheral blood AML blast counts [23]. Cornelissen et al. used these four parameters 
for the classification of patients receiving intensive chemotherapy/autologous stem cell 
transplantation and further subdivided patients into four risk categories: (i) favorable, 
with 35-40% relapse risk; (ii) intermediate, with 55-60% relapse risk; (iii) Poor, with 




peripheral blood AML blast count has been questioned, but a recent retrospective study 
suggested that the blast count has an independent impact on prognosis after allogeneic 
stem cell transplantation [24]. However, the prognostic impact of a marker may be 
treatment-dependent and therefore may change in relation to new therapies. 
Risk stratification can also be based on genetic abnormalities alone [1]; the stratification 
given by the European Leukemia Net is summarized in Table 2. This classification 
system defines the FLT3 allelic ratio as low when it is <0.5 and high when it is ≥0.5 (i.e. 
FLT3-ITD versus FLT3-wt).  
Table 2. The ELN 2017 risk stratification based on genetics alone [1]. 
Risk category Genetic abnormality 
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD or with FLT3-ITD low 
Biallelic mutated CEBPA 
Intermediate Mutated NPM1 and FLT3-ITD high 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITD low 
(without adverse-risk genetic lesions) 
t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse t(6;9)(p23;q34.1); DEK-NUP214 
t(v;11q23.3); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 
−5 or del(5q); −7; −17/abn(17p) 
Complex karyotype, monosomal karyotype 





The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse–risk gene 
mutations. Complex karyotype mean three or more unrelated chromosome abnormalities in the absence 
of 1 of the WHO–designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), 
t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3). Monosomal karyotype is defined by the presence of 1 
single monosomy (excluding loss of X or Y) in association with at least 1 additional monosomy or 
structural chromosome abnormality (excluding core–binding factor AML). Mutated RUNX1 or ASXL1 
should not be used as an adverse prognostic marker if they co–occur with favorable–risk AML subtypes. 
TP53 mutations are significantly associated with AML with complex and monosomal karyotype. More 





These prognostic stratifications are primarily used along with comorbidity scores and 
the European Group for Blood and Marrow Transplantation (EBMT) score when 
deciding whether an allogeneic stem cell transplantation should be recommended for 
younger patients [23]. 
1.2 Leukemic cell populations in human AML 
1.2.1 Hierarchical organization of AML cell populations 
The normal presentation of hematopoietic organization is one of highly regulated 
cellular hierarchy. Hematopoietic stem cells (HSCs) reside in the bone marrow, and 
mature cells are continuously generated from progenitors, giving rise to the different 
types of blood cells including erythrocytes, platelets, monocytes, granulocytes, natural 
killer cells (NK-cells), and T-cell and B-cell lineages [25] (Figure 1). The HSCs have a 
unique ability to both self-renew and differentiate, which enables life-long blood cell 
production due to the replacement of a stem cell with daughter cells during mitosis [25].  
Normal HSC are defined as linage negative (Lin-) CD34+CD38-CD90+CD45RA- cells 
and generate multipotent progenitors (MPPs) with lymphomyeloid potential, defined as 
Lin-CD34+CD38-CD90-CD45RA- cells [26]. Downstream progenitor cells, such as 
common lymphoid progenitors (CLP) and common myeloid progenitors (CMP), 
granulocyte-macrophage progenitors (GMP), and megakaryocyte-erythroid progenitors 
(MEP) all have the same Lin-CD34+CD38-CD90-CD45RA- phenotypes. They can be 
further distinguished based on their differential expressions of the IL3 receptor subunit 
α (IL3Rα+/CD123), the thrombopoietin receptor CD110/myeloproliferative leukemia 
(MPL) protein, and CD45RA [27, 28].  
AML was one of the first diseases for which the existence of a population of cancer stem 
cells was suggested [29]. Consequently, human AML LSCs represent one the most well 
characterized populations of cancer stem cells [30]. However, these cells are defined by 
functional assays (i.e. long-term culture or xenograft models), and these functionally 
defined stem cells can be detected in different cell subsets (i.e. they differ in their 




Reduced differentiation in AML results in the excess production of 
undifferentiated/immature leukemic blasts that show limited proliferative capacity and 
acquired critical genetic or epigenetic alterations that disrupt important growth-
regulatory pathways [33]. AML is expressed as abnormal development in one of the 
major blood lineages; however, the blasts from patients are heterogeneous with respect 
to the lineage antigens they express [33].  
  
Figure 1. Normal human hematopoiesis. Normal human hematopoiesis is structured 
as a cellular hierarchy initiated and maintained by self-renewing HSC. Self-renewing 
HSCs are located at the top of the hierarchy, generating multipotent progenitors, which 
subsequently generate lineage-committed progenitors that ultimately give rise to 
terminally differentiated blood cells. These include erythrocytes, platelets, 
granulocytes, macrophages, dendritic cells and the lymphocytes T, B and NK cells. 
The lineage-committed progenitors and the mature cells are shown in the colored box. 
The abbreviations shown in the figure can be found in the list of abbreviations. 
Thus, a balance between cell proliferation, differentiation, and survival controls the 




in all three fundamental cell characteristics. The leukemic cells have an increased 
proliferative capacity but, at the same time, a limited capacity for differentiation and an 
increased ability to survive (i.e. resistance to apoptosis). This leads to disease 
progression with an increasing accumulation of immature leukemic myeloblasts [34].  
The hierarchical organization within the leukemia clone is also reflected in its cellular 
heterogeneity (e.g. with respect to morphology, cell surface markers, functional 
characteristics) and is similar to that of normal hematopoiesis [35]. However, further 
definition of the phenotype of LSCs has revealed several differences between LSCs and 
normal HSCs. Most leukemic cells in AML express CD34, which is the normal surface 
marker for hematopoietic stem/progenitor cell (HSPC) [36, 37]. Within the total AML 
cell population, LSCs are always a minority, and patients can have AML stem cells with 
CD34+38-, CD34+CD38+ and/or CD34- phenotypes [38, 39]. However, for 
approximately 25% of AML patients, more than 90% of the total AML cell population 
is CD34- [38, 40, 41], and this phenotype can be associated with the NPM1 mutation 
[39, 40]. Finally, the Lin-CD34+ fraction of AML patients can be divided into two 
subpopulations based on AML stem cells. These two populations are similar to normal 
lymphoid-primed MPPs (CD38-CD90-CD45RA+), and GMP-like cell populations 
(CD38+CD123+CD45RA+) [41]. In most patients, both populations coexist and possess 
LSC potential [41].  
The phenotypic characterization of AML stem cells can be further distinguished based 
on the presence of antigens. These include CD25 [42], CD123 [43], CD47 (integrin-
associated signal transducer) [44], interleukin (IL)1 receptor accessory protein 
(IL1RAP) [45], and C-type lectin-like receptors (CCL-1) [46]. Furthermore, markers 
such as CD13, CD96 (adhesion molecule), and CLEC12A [46, 47] are expressed on 
AML stem cells but not on normal HSC, while the expression of others, such as CD90 
and CD117 (c-Kit), is found on HSCs but not on AML stem cells [45, 48, 49].  
1.2.2 The pre-leukemic versus the leukemic stem cells 
Hematopoietic cells that have acquired genetic and/or epigenetic modifications can give 




initiating cells (LIC), that sustain the disease (Figure 2). The first mutation in HSPC 
originates in the leukemia cell-of-origin (LCO). These pre-leukemic stem cells preserve 
the ability to differentiate, but need additional mutations to be fully transformed [50]. In 
the LCO and subsequent pre-LSC stage, the cells gradually obtain more abnormalities, 
finally generating fully transformed LSC/LIC. The different aberrations in the 
hematopoietic pathway may include genes that control DNA methylation (DNMT3A, 
IDH2, TET2); the cohesion expression complex (RAD21, MAU2, SMC1A); chromatin 
modification (SAP130, MIER3, ASXL1, MTA2, KAISO, CTCF); the fusion protein 
inv(16); and NPM1 mutations [34, 50-52]. Due to their involvement in global chromatin 
changes, these genes have formerly been denoted as landscaping genes [34]. LSC/LIC 
are self-renewing with genetic and epigenetic alterations that block differentiation and 
results in the accumulation of dysfunctional leukemic blasts.  
Differences between LSCs and the majority of the AML cell population make them 
more difficult to eliminate with standard chemotherapy, a property that may give rise to 
later chemoresistant AML relapse. Consistent with LSCs showing high therapy 
resistance and being a source of relapse in AML [53], the presence of a stem cell 
expression signature in the main AML cell population as well as high LSC frequencies 
correlate with poorer survival [54]. Identification of the presence of therapy-resistant 
cells at the time of diagnosis indicates two major patterns of relapse in AML [53]. 
Relapse can either originate from infrequent LSCs with HSPC phenotypes or from the 
development of larger subclones of committed leukemia cells with immune phenotypes 
that contain strong stemness transcriptional signatures [53]. With regard to genetic 
abnormalities, relapses are thought to be derived from (i) the original predominating 
AML clone; (ii) a minor subclone also existing at the time of first diagnosis; or (iii) 






Figure 2. Overview of the transformation of LSC. Leukemia cells develops from 
HSCs with genetic and/or epigenetic modifications and are transformed to self-
renewing LSC/LIC. The transforming events (e.g. oncogenic mutations) can occur in 
either long-term HSC or in progenitor cells. Mutations in HSC may give rise to a pre-
leukemic state associated with an increase in HSCs and genetic instability. A second 
genetic event (here indicated by lightning bolts) is necessary for the development of 
the full leukemic phenotype. Mutations occurring within progenitor cells may counter 
the property of self-renewal, giving rise to the full leukemic phenotype. The 
abbreviations shown in the figure can be found in the list of abbreviations. 
1.2.3 Stem cell niche 
A stem cell niche is a spatial structure that houses and maintains stem cells by facilitating 
self-renewal in the absence of differentiation. Niches are specialized local cellular and 
molecular microenvironments that control and preserve stem cells, and regulate the 
balance between HSC self-renewal and differentiation [55]. Hematopoiesis provides a 




are located in the aorta-gonad-mesonephros (AGM) region, fetal liver, placenta, and 
spleen during embryonic development, and the bone marrow serves as the primary post-
natal reservoir for HSC maintenance and hematopoiesis [55].  
The production of blood cells happens continuously inside a complex tissue framework 
established by highly systematized stromal cell networks of mesenchymal, neural, and 
vascular origin inside the bone marrow cavities. Together, stromal cells have two main 
functions: first as primary contributors to bone remodeling and metabolism, and second 
as main controllers of the various stages of production and development of blood cells 
[56, 57].  
Stromal cells include almost all non-hematopoietic cells in the bone marrow 
microenvironment, including endothelial cells, osteoblasts, macrophages, adipocytes, 
fibroblasts, HSCs and HSC progeny cells. These cells support the maturation of 
precursor blood cells and produce the signals that drive the commitment, differentiation, 
and maturation of hematopoietic cells. Within the bone marrow environment, the 
stromal cell types are located in unique combinations and distinct anatomical areas in 
order to generate suitable niches for the hematopoietic system [58].  
The stromal cell-derived factor 1 (SDF1), also known as C-X-C motif chemokine 12 
ligand (CXCL12), is one of the growth factors that contributes to bone marrow 
microenvironments and local cytokine networks. It is an essential chemokine for 
maintenance of the quiescent HSC pool through CXCL12-CXC receptor 4 (CXCR4) 
signaling in adult bone marrow [59, 60]. Maintenance and self-renewal of HSCs in the 
niches are performed by various cells including perivascular, nestin-positive, immature 
mesenchymal stem cells (MSCs) and endothelial cells together with 
macrophages/monocytes, sympathetic nerves, non-myelinated Schwann cells and 
osteoclasts [61]. Osteoblasts affect HSC self-renewal directly through the secretion of 
CXCL12 and other factors [62-64]. The CXCL12-abundant reticular (CAR) cells, leptin 
receptor-positive stromal cells, and the nestin-GFP-positive stromal cells are all cell 
populations that expresses high levels of CXCL12 [56]. CAR cells are defined as 




the main source of CXCL12 in the bone marrow. In addition, CAR cells can prominently 
express other adhesion molecules, such as VCAM-1 [57]. Adipocytes are stromal 
components of the bone marrow that control the function of HSCs in a negative manner, 
by reducing the number of HSCs [84]. Moreover, the transcriptional coactivator paired-
related homeobox 1 (PRX1) and the hypoxia-inducible factors (HIF) -1α and HIF-2α 
are identified as determinants of HSC maintenance [65, 66]. 
Due to the heterogeneity of AML, the relative involvement of the various non-leukemic 
cells in leukemogenesis can differ among patients [34]. However, osteoblasts [67-69], 
endothelial cells [70-72], MSCs [73-75] and monocytes [76, 77] appears to function as 
important AML supporting cells in a majority of patients. Multiple soluble mediators 
released by the primary AML cells and the non-leukemic stromal cells can support or 
influence leukemogenesis. Among these are cytokines, soluble adhesion molecules, and 
various proteases [49, 69, 73, 78-80]. Several of these soluble mediators are important 
for autocrine or paracrine AML cell stimulation, and they can be constitutively released 
by both leukemic and non-leukemic cells. The bidirectional crosstalk between leukemic 
and non-leukemic cells can further increase local production levels of many cytokines 
[81-83]. 
In the presence of MSCs, an increased long-term in vitro proliferation of primary human 
AML cells that is dependent on both direct cell-to-cell contact and cytokine-mediated 
crosstalk has been described [75], with integrins and cadherin/catenin proposed to be 
important mediators [84]. The expression of integrin mRNA varies between AML 
patient cells, and for a subgroup of patients, this is associated with chemokine-induced 
growth enhancement [79]. Thus, despite the patient heterogeneity and possible 
differences between individual patients, normal leukemia-supporting crosstalk involves 





Figure 3. Bone marrow stem cell niches. A bone marrow niche is made up of a 
heterogeneous mixture of cell types, including MSCs, osteoblasts, osteoclasts, and 
endothelial cells. The combination of bone lining cells, a hypoxic environment, as well 
as proximity of MSCs and sinusoidal vessels provide a unique environment for HSCs 
and MSCs. HSC can be associated with CXCL12-abundant reticular CAR cells close 
to the endosteal surface and in the periphery of sinusoids and perivascular nestin-
expressing cells. Blood vessels in bone marrow are often located near the bone. 
Osteoblast cells express factors that participate in HSC retention; osteoclasts control 
the osteoblastic cell function by inducing bone remodeling, while the macrophages 
regulate osteoblastic cell activity and the retention of HSCs. These cells are all located 
at the endosteal surface. In the bone marrow stroma, HSCs are associated with CAR 
cells, which express factors that promote HSC retention, whereas adipocytes 
negatively regulate HSCs, causing a reduction in HSCs. The abbreviations shown in 





The marrow vasculature is composed of a dense network of various types of vessels 
such as arterioles and sinusoids, showing differences with regard to surface markers and 
function. They consist of a single layer of endothelial cells, surrounded by perivascular 
MSCs and different non-circulating hematopoietic cells [85]. However, arterioles and 
sinusoids are structurally different components of bone marrow. Arterioles are 
surrounded by sympathetic nerves, layers of smooth muscle cells, and matrix 
components, and together they form an important niche that preserves HSC quiescence 
in the bone marrow [86]. Arterioles are associated with quiescent HSCs, suggesting that 
the vessel itself may be a critical gatekeeper of stem cell quiescence in the bone marrow 
[86]. Bone marrow MSCs provide an environment for regulation of HSC proliferation 
and quiescence. Bone marrow MSCs are located close to the arteriole and sinusoid 
vessels and are in direct contact with the non-luminal side of the endothelial cells [87]. 
MSCs are important both for the extravascular microenvironment of HSCs and for cell 
trafficking to and from this microenvironment. In addition, MSCs can be located in the 
extravascular space found between the vessels and close to the osteoblasts in the 
endosteum, where they release extracellular matrix molecules [85]. Quiescent HSCs are 
known to associate with arterioles that are preferentially found in endosteal bone 
marrow. 
Different signals are provided locally by the bone marrow niche cells [88, 89], including 
secreted factors such as stem cell factor (SCF), transforming growth factor beta-1 (TGF-
β1), platelet factor 4 (PF4 or CXCL4), angiopoietin 1 (ANGPT1), and thrombopoietin 
(TPO), and they are important contributors to HSC quiescence [90]. Various selectins 
and extracellular matrix proteins constitute some of the essential components for the 
regulation of HSC homing and anchoring, while cell-bound molecules like Notch 
ligands or locally secreted cytokines like IL-7 or erythropoietin (EPO) act as important 
regulators of HSC proliferation and differentiation [90]. 
Osteopontin (OPN) is a glycoprotein found in the bone marrow microenvironment, 
where it is produced by osteoblasts and MSCs [91]. OPNs contributes to bone marrow 




regulator of HSCs through inhibition of cell division [93]. Hematopoietic cells can be 
found next to the endosteal bone surface, which is primarily lined with osteoblasts 
(Figure 3). This anatomic organization suggests a mutual communication between the 
osteoblasts and HSCs as well as a possible role for osteoblasts in the regulation of HSCs 
[94]. Most studies have shown that OPN levels are increased at both the mRNA and 
blood protein levels in AML patient cells [95], and high levels of OPN have been 
associated with poor prognoses of AML patients [96]. However, our group found that 
high levels of OPN released in AML supernatants could be associated with favorable 
prognoses [97].  In addition, in the bone marrow environment, the leukemic cells are 
physiologically exposed to low oxygen levels (20-21%), and studies applying low 
oxygen pressure showed increased levels of in vitro cytokine expression, including 
OPN, in primary AML cells [98].  
1.2.4 AML cell metabolism and its possible clinical importance 
One of the hallmarks of cancer cells, as  proposed by Hanahan and Weinberg in 2000, 
is their altered metabolic state [33]. The interest in clarifying how metabolism is altered 
in cancer cells, based on observations that components of signal transduction pathways 
frequently regulate nutrient metabolism, has increased in the past decade. Central for 
this research is the notion that metabolic pathways are reprogrammed in cancer cells to 
divert nutrients towards anabolic processes for heightened growth and proliferation. 
Normally, access to and subsequent utilization of nutrients is highly regulated by 
physiological cellular signaling mechanisms, providing an important barrier to 
transformation. Cancer cells are able to meet their bioenergetic needs by altering their 
metabolism to promote growth, survival, proliferation, and long-term maintenance. In 
normal cells, mitochondria are the main components in the generation and regulation of 
cellular bioenergetics and are responsible for the main production of ATP by oxidative 
phosphorylation. Cancer cells do not follow the normal pathway for energy production, 
and this altered metabolism found in cancer cells includes a switch from mitochondrial 
oxidative phosphorylation to provide an increased glucose uptake and fermentation of 
glucose to lactate; this is observed even in the presence of fully functioning 




be reprogrammed from a homeostatic state, with high nutrient catabolism or storage, to 
an anabolic state where nutrients are transformed into biomass [99]. 
Lately, it has been shown that the switch to aerobic glycolysis provides tumor cells with 
a proliferative advantage, prompting an investigation into the mechanisms by which this 
process is triggered and regulated in order to determine the best means of exploiting this 
pathway for therapeutic gain [100]. Consequently, it is becoming more evident that 
given the importance of promotion of nutrient uptake and utilization in cell building 
processes, cancer cells repeatedly select for mutations that augment signal transduction 
through pathways that unite upon a common set of metabolic processes. 
The phosphoinositide 3-kinase (PI3K) -Akt -mechanistic target of rapamycin (mTOR) 
pathway in normal cells responds to extracellular stimuli, such as insulin and growth 
factors, by regulation of a wide range of cellular functions. Cell proliferation requires 
energy and the synthesis of cellular molecules, and the PI3K-Akt-mTOR pathway 
contributes to the regulation of cellular metabolism by upregulation of glucose 
transporters/transport, lipid metabolism, and protein synthesis [101, 102]. 
AML cells can adapt to meet the increased energy or substrate demand during stress 
conditions in the bone marrow microenvironment. While normal HSCs apply glycolysis 
mainly as a source for energy homeostasis, recent studies show that AML cells, 
including LICs, are dependent on oxidative phosphorylation for survival [103]. In newly 
diagnosed patients, variable proportions of both high and low oxidative phosphorylation 
are found in AML cells, whereas in post-chemotherapy patients, there is an excess of 
high oxidative phosphorylation cells. This indicates that mitochondrial oxidative 
phosphorylation may be associated with AML chemoresistance. High oxidative 
phosphorylation signatures and metabolism are identified as hallmarks of 
chemoresistance in vivo [103]. Malignant cells often have a reprogrammed and 
upregulated metabolism with glucose consumption for energy generation, use of 
glutamine for the refilling of the intermediates of the tricarboxylic acid (TCA) cycle 
(also called citric acid cycle or Krebs cycle), and fatty acid synthesis for the building of 




The PI3K-Akt-mTOR pathway is upregulated in AML cells, potentially contributing to 
metabolic reprogramming, e.g. a study reported that preserved hematopoietic cells 
altered by a constitutively active mutant of Akt show aerobic glycolysis, displaying 
increased rates of glycolysis without effects on the rate of oxidative phosphorylation. 
As a regulator of glucose metabolism, Akt causes upregulation of the glycolysis 
phenotype [107]. There is no correlation between this increased glycolysis and oxygen 
consumption rates, suggesting that Akt hyperactivation promotes aerobic activation 
through the Warburg effect [107]. In addition, Akt interacts with PDK1, influencing the 
entrance of pyruvate into the mitochondrial metabolism [108].  
In addition to its effect on glycolysis, Akt may also affect oxidative phosphorylation: 
Akt could promote an indirect oxidative phosphorylation through elevated levels of 
substrates essential to activity of the TCA cycle and oxidative phosphorylation, such as 
pyruvate, ADP, and NADH. 
Regulation of cellular metabolism by mTOR is more complex, as it involves activation 
of Akt by mTORC1 and upregulation of HIF1, for the promotion of glycolysis by 
converting pyruvate to ATP molecules and lactate [109]. During normal oxygen 
concentrations, HIF1 is deregulated, but can accumulate with increased signaling of 
mTORC1 and the downstream mediators, 4E-BP and eIF4E [110]. Furthermore, by 
promoting translation of particular mitochondria-related mRNAs, mTORC1 can 
regulate mitochondrial function and oxidative metabolism [99]. mTORC1 also responds 
to intracellular and environmental stresses,  such as low ATP levels, hypoxia, or DNA 
damage, and participates in regulation of cell growth and metabolism by inducing a shift 
in glucose metabolism from oxidative phosphorylation to glycolysis [99]. Activation of 
mTORC1 is reliant on growth factors and amino acids, such as glutamine, leucine, and 
arginine; this facilitates feedback mechanisms for increased uptake of nutrients to act as 
fuel for anabolic reactions. However, the activity of mTORC1 is reduced upon 
starvation [99], and during conditions of high-energy stress, the metabolic regulator 
AMPK is activated. AMPK represses mTORC1 activity indirectly through 
phosphorylation and activation of TSC2, and directly through the phosphorylation of 




Interestingly, besides promoting the expression of the enzymes of lipid synthesis and 
the pentose phosphate pathway, mTORC1 has also been found to increase expression of 
GLUT1 and other enzymes of glycolysis [110]. Activated mTORC1 participates in 
regulation of autophagy, mRNA translation, lipid synthesis, glycolysis and the pentose 
phosphate pathway. Poulain and colleagues demonstrated that constitutive activation of 
mTORC1 signaling makes AML cells dependent on glucose metabolism [111], 
implementing mTORC1 as one of many contributors to the glycolytic switch contained 
in most cancer cells. 
1.3 Intracellular signaling in leukemogenesis - The importance of 
PI3K-Akt-mTOR signaling in AML 
The cells in multicellular organisms are continuously exposed to and thereby must 
respond to a wide range of extracellular signals, such as growth factors, cytokines, and 
nutrients, which impact cell fate, including proliferation, growth, survival, 
differentiation, motility, and metabolism. To effectively process these signals, cells have 
established intricate signaling networks that allow them transduce extracellular signals 
into cellular decisions [112]. Receptor ligation initiates signal transmission from the cell 
surface through a series of molecular events often including protein phosphorylation 
catalyzed by protein kinases, and this ultimately results in a cellular response. There are 
numerous receptors and pathways involved in intracellular signal transduction, and there 
is extensive cross-talk and cross-activation between different signaling pathways [113]. 
Disturbed signaling caused by mutations in pathway components are important factors 
in leukemogenesis [114-116]. 
1.3.1 The PI3K-Akt-mTOR pathway  
The PI3K-Akt-mTOR pathway has been extensively studied in normal and malignant 
cells [113]. The signaling cascade is activated by a wide variety of extracellular stimuli, 
including receptor tyrosine kinases, various integrins, B and T cell receptors, and G-
protein-coupled receptors (GPCRs). Family members of PI3K are Serine 




classes based on their structural characteristics and substrate specificity [117]. Class I 
enzymes are separated into class IA and class IB enzymes, both of which are activated 
by cell surface receptors. Class IA enzymes can be activated by receptor tyrosine kinases 
(RTKs), GPCRs, and various oncogenes such as the small G protein Ras, whereas class 
1B enzymes are activated solely by GPCRs. 
Class 1A PI3K enzymes include a catalytic (p110) and a regulatory subunit (p85 or 
p101) [118, 119]. In response to extracellular stimuli, recruitment scaffolding proteins, 
such as the growth factor receptor-bound protein 2 (GRB2) -associated binding protein 
2 (GAB2) or insulin receptor substrates (IRS) 1/2, bind to the regulatory p85 subunit of 
PI3K. Sequentially, the catalytic subunits of PI3K are activated, and phosphorylation of 
phosphatidylinositol 4,5-bisphosphate (PIP2) generates the second messenger 
phosphatidylinositol 3,4,5- trisphosphates (PIP3) [120]. This facilitates the recruitment 
of proteins that contain pleckstrin-homology (PH) domains, including the Ser/Thr 
kinase Akt (also known as protein kinase B or PKB) and its upstream activator 3-
phosphoinositide-dependent kinase-1 (PDK1)  
Akt can function as a proto-oncogene, and there are three structurally active forms of 
Akt in mammalian cells termed Akt1, Akt2, and Akt3 or PKB α, β, γ, respectively [121]. 
All three isoforms comprise an N-terminal PH domain, a T-loop region of the catalytic 
domain containing a Thr308 phosphorylation site, and a C-terminal regulatory tail with 
a Serine-473 Ser473 phosphorylation site [121, 122]. Whereas Akt is cytosolic in 
unstimulated cells, an activation mediated by PI3K requires translocation of Akt to the 
membrane, where PIP3 serves as an anchor [123]. At the plasma membrane, PDK1 
phosphorylates Akt at Thr308, leading to its partial activation. A subsequent 
phosphorylation at Ser473 is required for full enzymatic activation. This 
phosphorylation is achieved by the mTOR complex 2 (mTORC2) as well as by members 
of the PI3K-related kinase (PIKK) family [121, 122]. Phosphorylation of homologous 
residues in Akt2 and Akt3 occurs in the same way. This activation leads to the relocation 
of Akt to the cytosol or the nucleus, and it has been postulated that Akt then can 
phosphorylate more than 9000 downstream substrates [124], thereby regulating 




survival. The mTOR complex 1 (mTORC1) is an important downstream target of Akt. 
This is summarized in Figure 4. 
  
Figure 4. Overview of the PI3K-Akt-mTOR signaling pathway. Following ligation 
of cell surface receptors (e.g. growth factor receptors) phosphorylated RTK recruits 
scaffolding proteins, which bind to the regulatory p85 subunit of PI3K. A subsequent 
activation of the catalytic subunits of PI3K generates PIP3. PDK1 and Akt proteins 
are then recruited to the plasma membrane, inducing the phosphorylation of Akt on 
Thr308 by PDK1. This is followed by activation of Akt on Ser473 by the mTORC2 
complex; this second phosphorylation is necessary for complete activation. Akt 
controls the activation of mTORC1 by constraining the GTPase activity of the 
TSC1/TSC2 complex towards the Ras-related GTP-binding protein RHEB that 
associates to mTORC1 and phosphorylates mTOR. mTORC1 induces cap-dependent 
mRNA translation by phosphorylating 4EBP1, leading to the formation of eIF4F and 
the inhibition of autophagy. The abbreviations shown in the figure can be found in the 




The Ser/Thr protein kinase mTOR was first identified in the budding yeast 
Saccharomyces cerevisiae during a trial for resistance to the immunosuppressant drug 
rapamycin [125]. It belongs to the PIKK family and has a COOH-terminal catalytic 
domain with sequence homology to PI3Ks. It is a large, multi-domain protein with 
protein kinase activity, adding phosphate groups to Ser or Thr residues in a wide range 
of substrates, many of which are involved in anabolic pathways [126]. Insulin and 
insulin growth factors (IGFs) [127], nutrients (such as amino acids) [128], various forms 
of stress (e.g., hypoxia and DNA damage), and the accessibility of ATP are the main 
regulators of mTOR.   
The activity of mTOR is accomplished by the two separate multi-protein complexes, 
mTORC1 and mTORC2. The two complexes differ in their protein components, 
substrate specificity, and regulation, and they have dissimilar responses to rapamycin 
and its derivatives (rapalogs). The mTORC1 is composed of mTOR, regulatory-
associated protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 
(mLST8), DEP domain-containing mTOR-interacting protein (Deptor) and the proline-
rich Akt substrate of 40 kDa (PRAS40) [129]. Both Deptor and PRAS40 function as 
inhibitors. The mTORC2 is composed of mTOR, mLST8, Deptor, the rapamycin 
insensitive companion of mTOR (Rictor), the mammalian stress-activated protein 
kinase-interacting protein 1 (mSIN1), and Protor [127, 130].  
Raptor is responsible for the phosphorylation of downstream substrates, and this action 
is blocked by rapamycin. As mTORC2 contains Rictor rather than Raptor, it 
phosphorylates a different set of substrates, although the regulation of mTORC2 activity 
remains poorly understood. The mTOR complexes have different upstream mechanisms 
of activation as well as different downstream substrates. The most common substrates 
of TORC1 are the ribosomal protein S6 kinase (S6K) and eukaryotic initiation factor-
4E (eIF4E) -binding proteins (4EBP1), while the main substrates of TORC2 are Akt and 
related kinases [131]. The S6K protein plays a central yet moderately defined role in 
cellular and organismal physiology. There are two identified isoforms of S6K, termed 
p70 and p85, produced by differential splicing from a common gene. Both isoforms are 




attention, and the function of the p85S6K remains poorly characterized. Downstream 
targets of mTORC1 play critical roles in the regulation of translation. The translation 
initiation complex eIF4F is a heterotrimeric protein complex composed of eIF4E, 
eIF4A, and eIF4G [131]. The eIF4E binds to the messenger RNA (mRNA) 5´-cap 
structure to promote the initiation of translation. In the unphosphorylated state, 4EBPs 
binds to eIF4E, hindering its association with the complex, and blocking it from binding 
to mRNA. However, in response to stimuli such as growth factors, mitogens, and amino 
acids, mTORC1 phosphorylates 4EBPs, causing it to lose its inhibitory effect. This 
allows the formation of the eIF4F complex and the subsequent initiation of translation 
[131]. In addition, PDK1 and mTORC1 phosphorylates the S6 kinase, which in turn 
phosphorylates numerous substrates that are involved in translation.  
The FK506-binding protein 38 (FKBP38, also known as FKBP8) is a unique member 
of the FKBP-family and acts as an upstream regulator of the PI3K-Akt-mTOR pathway 
[132]. FKBP38 was identified as an endogenous inhibitor of mTORC1 that binds to the 
FKBP-C domain of mTOR. This binding interferes with mTOR function in a manner 
comparable to the FKBP12-rapamycin complex [132]. Under conditions rich in growth 
factors and nutrients, the FKBP-C domain might interact with Ras homologue enriched 
in brain (RHEB) -GTP, releasing mTOR from FKBP38 and activating downstream 
mTOR signaling [132, 133]. 
A negative feedback loop can be formed in the PI3K-Akt-mTOR pathway by activation 
of mTORC1. Phosphorylated S6K will sequentially phosphorylate IRS proteins, 
triggering their proteasomal degradation and inhibiting insulin/IGF-1-mediated PI3K 
activation (Figure 4). 
The PI3K-Akt-mTOR pathway is negatively controlled by the phosphate and 
homologue protein deleted on chromosome 10 (PTEN) protein and Src Homology 2 
(SH2) domain-containing inositol 5-phosphatases (SHIP1 and SHIP2) that directly 
antagonize PI3K by dephosphorylating PIP3 back to PIP2, thus averting activation of 
Akt [117]. PTEN is the third most commonly mutated gene in human cancers, 
underlining its functional significance [134]. The activity of mTOR is also negatively 




Upon activation, Akt will phosphorylate and inhibit heterodimeric TSC, which then acts 
as a GTPase-activating protein (GAP) for small GTPase RHEB [135]. This activation 
leads to hydrolysis of bound GTP with subsequent RHEB inhibition. The inactivation 
of TSC2 maintains RHEB in its GTP-bound state, thereby supporting augmented 
activation of mTOR [135].  
The mTORC1 can also be regulated by cellular stress and energy status through TSC, 
in addition to growth factors. Moreover, a low energy status can activate AMP-activated 
protein kinase (AMPK), which in turn phosphorylates Raptor and TSC2, leading to the 
inhibition of mTORC1 [135, 136]. Amino acids regulate mTORC1 in a TSC-
independent pathway. Thus, multiple stimuli modulate mTORC1 to control cell growth 
and autophagy. 
1.3.2 PI3K-Akt-mTOR signaling in AML 
Dysregulation of the PI3K-Akt-mTOR signaling pathway subsequent to oncogene 
activating mutations, oncogene amplification, upstream activation of RTKs, or 
inactivation of tumor suppressor genes has been demonstrated in many human 
malignancies, including AML. The PI3K-Akt-mTOR pathway plays an important role 
in the regulation of proliferation, differentiation, and survival of hematopoietic cells. 
Constitutive activation of this pathway has been observed in more than 60% of AML 
patients and is associated with decreased overall survival [137-139]. Mutations in 
membrane bound-proteins, such as RTKs or GTPases, are major causes of dysregulated 
PI3K-Akt-mTOR signaling and are observed in 55% of AML cases [11, 134].  
Signaling initiated through FLT3 is one of the most important causes of the 
dysregulation of PI3K-Akt-mTOR signaling in AML, and mutations in this gene lead to 
abnormal activation of the pathway [140]. Mutations in FLT3 are among the most 
frequent mutations seen in AML. These mutations can be classified as internal tandem 
duplications (FLT3/ITD) and mutations in the tyrosine kinase domain (FLT3/TKD), 
with the former being more common in AML [141]. Because FLT3/ITDs are located in 




the activation loop of the TDK, while other mutations are effectively isolated, resulting 
in the substitution of single amino acids in the loop[141]. 
The three classes of PI3Ks (Class I-III) have different structure, cellular distribution, 
mechanism of action, and preference of substrates [142]. Class I PI3Ks are most 
frequently linked to carcinogenesis [119]. Expression of the regulatory p85α subunit of 
PI3K Class IA was examined in a previous study, which included 40 AML patients; 
expression of the regulatory subunit was then detected in nearly all samples, and 21 
cases exhibited increased PI3K activation [143]. Furthermore, PI3K expression 
correlated with proliferation capacity of AML blasts [143]. The catalytic subunits 
termed p110α, p110β, p110γ and p110δ are responsible for activation of Akt, and p110δ 
is the only form that constantly shows elevated expression in human AML [119, 144].  
Constitutive phosphorylation activates Akt in human AML cells, and the constitutive 
activation of the PI3K-Akt-mTOR pathway is necessary for the survival of AML cells 
[138, 145]. Furthermore, the constitutive activation of Akt is facilitated by 
phosphorylation at Thr308 by PDK1 and at Ser473 by mTORC2. Constitutive activation 
at both Thr308 and Ser473 has been detected in a majority of AML patients [138, 146]. 
Akt phosphorylation at these two sites has been associated with decreased overall 
survival in several studies [138, 147] [113], though independently, phosphorylation at 
Ser473 may constitute a favorable prognostic factor [146]. Finally, aberrant AML cell 
activation of mTORC1, causing the phosphorylation of downstream targets such as 
p70S6K, S6RP, and 4EBP1, has also been detected for a large majority of patients [148], 
but this activation of mTORC1 may not depend on PI3K/Akt activity alone in human 
AML [149]. 
The IGF-1/IGF-1 receptor (IGF-1R) signaling pathway is important in the development 
of many malignancies [150]. IGF-1/IGF-1R-initiated signaling is facilitated by PI3K 
activation both in myeloid leukemia cell lines and in primary AML cells [146, 151]. 
The constitutive activation of Akt in AML is supported by autocrine IGF-1/IGF-1R 
signaling and inhibition of IGF-1R results in decreased activation of Akt for most 




Even though PTEN is the third most frequently mutated gene in human cancer, it is 
rarely mutated in AML [11, 134]. However, abnormal PTEN have been detected in a 
small subset of AML patients with adverse prognoses; this abnormality leads to a lack 
of inhibitory pathway control and thereby increased Akt signaling [152, 153]. Activation 
of the PI3K-Akt-mTOR pathway due to mutations of its components is observed in 
nearly 30% of all human cancers [154] but is rarely seen in human AML [147, 155].  
1.3.3 SYK as a regulator of PI3K-Akt-mTOR signaling 
Spleen tyrosine kinase (SYK) is a cytoplasmic protein-tyrosine kinase known to 
facilitate interaction between immune cell receptors and the intracellular signaling 
pathways important for the regulation of cellular responses to extracellular antigens as 
well as the antigen-immunoglobulin complexes central to initiation of inflammatory 
responses [156]. SYK is widely expressed in hematopoietic cells and is involved in 
proliferation, differentiation, and phagocytosis. The importance of SYK in 
hematological malignancies has been demonstrated in lymphoma, leukemia, and 
myelodysplastic syndrome (MDS) [156, 157]. Targeting SYK diminishes viability and 
stimulates differentiation in AML. However, knowledge related to downstream 
signaling effectors for SYK in AML is scarce. There has been much interest in mTOR 
as a target in AML, and mTOR is activated in most primary AML blasts [158]. 
Furthermore, the inhibition of mTOR in AML has been linked to both anti-proliferative 
and pro-differentiating effects [148, 149, 158]. Consequently, studies suggest that 
inhibition and constitutive activation of SYK leads to corresponding activation and 
inhibition of mTOR signaling, and simultaneous inhibition of SYK and the PI3K 
pathway is postulated to promote differentiation and inhibit viability in AML cells [159].  
SYK is an important mediator of FLT3 in AML, and patients often display mutations in 
the FLT3 gene resulting in constitutively active RTK [160]. In an active and 
phosphorylated state, FLT3 associates with SYK through its C-terminal SH2 domain, 
and this association increases the activity of FLT3 through phosphorylation. This 
cooperative activation of FLT3 and SYK results in an increase in the expression of c-




signaling in AML, and inhibition of PI3K-Akt-mTOR pathway activity enhances the 
effects of SYK inhibition on AML cell differentiation and viability [160, 161].  
Chemical inhibition of SYK has been tested in multiple cells lines and results in a dose-
dependent inhibition of mTOR [159]. Furthermore, in some AML cell lines and primary 
cells, both p70S6K and 4EBP1/eIF4E signaling pathways are influenced by 
manipulations in SYK activity, and combined chemical inhibition of SYK and eIF4E 
has shown a synergistic effect on AML viability in multiple AML cell lines [159]. This 
is supported by inhibition of eIF4E through SYK knockdown, indicating that there are 
enhanced inhibitory effects of SYK on cell viability. Inhibition of eIF4E enhanced AML 
differentiation when combined with SYK inhibition using either chemical or SYK-
directed short hairpin RNA [159].  
1.3.4 The importance of PI3K-Akt-mTOR for the bone marrow stem cell niche 
Through interaction between leukemic cells and bone marrow-derived MSC, a 
pleiotropic range of proliferative and anti-apoptotic signaling pathways can be activated, 
including the PI3K-Akt-mTOR signaling pathway.  
This pathway is central to stress responses, such as the adaptation of MSCs to the 
hypoxic microenvironment in the bone marrow, induction of autophagy, and regulation 
of MSC metabolism. MSCs possess functional alterations depending on the age of the 
patient, and changes in pathway activation can influence the aging process and age-
dependent variations of bone marrow MSCs. Additionally, the PI3k-Akt-mTOR 
pathway is associated with MSC differentiation, and AML-supporting osteoblasts and 
adipocytes are among the major differentiated mesenchymal cells in bone marrow. 
Finally, the PI3K-Akt-mTOR pathway is central to the balance between osteogenic and 
adipogenic differentiation and supports the regulation of communication between MSCs 
and their adjacent cells. 
Studies have confirmed the upregulation of numerous survival signaling pathways, 
including PI3K-Akt-mTOR, in primary AML cells co-cultured with stromal MSC [162], 
indicating the importance of this pathway for the regulation of several biological 




apoptosis in primary samples cultured with or without stroma [163]. PP242 functions 
by weakening the activities of both mTOR complexes, which results in their inhibition 
by phosphorylated Akt, S6K, and 4EBP1. Simultaneously, chemokine receptor CXCR4 
expression in primary leukemic cells, as well as stromal cells cultured alone or co-
cultured with leukemic cells, was suppressed following treatment with PP242. These 
results were confirmed in mouse models, where PP242 inhibited mTOR signaling in 
leukemic cells with a greater anti-leukemia effect than rapamycin. Combined, studies 
with inhibitors targeting the PI3K-Akt-mTOR pathway show that disrupting mTOR-Akt 
signaling with selective kinase inhibitors could successfully target leukemic cells within 
the bone marrow microenvironment [163-165]. Additionally, the PI3K-Akt-mTOR 
signaling pathway has been found to play a central role in stromal cell-mediated 
resistance to FLT3 inhibition. Following combined treatment with selective PI3K 
inhibitor GDC-0941 and protein kinase inhibitor Sorafenib, a reversion of the protective 
effects of bone marrow stromal cells was found on FLT3-mutant AML cells in hypoxia. 
An association between the effect of this combined treatment and the downregulation of 
Pim-1 and Mcl-1 expression was noted [166]. Hence, PI3K-Akt-mTOR signaling is 
central for aging, adaptation, communication, differentiation, and proliferation in bone 
marrow MSCs and the inhibition of this pathway could affect and alter both MSC 
functional characteristics and AML cell microenvironments, including those of the stem 
cell niches. 
1.3.5 PI3K-Akt-mTOR and Ras-Raf-MEK-ERK pathway cross talk 
Together, the Ras- extracellular signal-regulated kinase (ERK) and PI3K-Akt-mTOR 
signaling pathways are the main mechanisms for regulating cell survival, differentiation, 
proliferation, metabolism, and motility in response to extracellular stimuli in the cell, 
and the pathways crosstalk to effect positive and negative regulation of each other [167, 
168]. Many mechanisms and methods of crosstalk between the two pathways have been 
identified, including cross-inhibition, cross-activation, negative feedback loops, and 





Figure 5. Main pathway components of Ras-MAPK and PI3K-Akt-mTOR and 
pathway crosstalk. Ras-MAPK and PI3K-Akt-mTOR pathways respond to 
extracellular and intracellular signals to control cell survival, proliferation, motility, 
and metabolism, and they are both activated by the binding of a growth factor to an 
RTK. In the Ras-MAPK pathway, this binding produces binding sites for the Src 
homology and collagen (SHC) and GRB2 adaptor molecules that recruit SOS to the 
membrane. SOS catalyzes the exchange of Ras GDP to Ras GTP, followed by the 
recruitment and activation of Raf. PKC is directly bound and activated by PMA 
through its mimicking of the natural ligand of PKC. The mechanism by which PKC 
activates ERK remains unclear. Following a Ras activation of MEK, ERK is activated 
through an activation loop phosphorylation. The pathway is further regulated by a 
negative feedback loop from ERK. Pathway crosstalk is regulated through cross-
inhibition (purple) and cross-activation (green) between the components of the Ras-
MAPK and PI3K-mTOR pathways. Each pathway has a mechanism to negatively feed 




phosphorylation of Raf. Components of the Ras-ERK pathway also exhibit positive 
regulation of the PI3K-Akt-mTORC1 pathway; TSC2 and mTORC1 are key 
integration sites that have several inputs from both the Ras-ERK and PI3K signaling. 
Positive regulation of the pathways are shown as arrows, and negative regulation of 
the pathways are represented as blunt-ended lines. PI3K-Akt (shaded in pink) and Ras-
ERK (shaded in blue) signaling network exhibit examples of crosstalk between 
intracellular networks. PI3K and ERK signaling meet on mTORC1, which is the 
master controller of protein translation. PTEN acts as a strong negative regulator of 
both pathways. The abbreviations shown in the figure can be found in the list of 
abbreviations. 
 
While some of the kinase, such as Raf, MEK, and mTORC1, that are involved in these 
pathways possess narrow substrate specificity, others such as ERK, RSK, Akt, and S6K, 
phosphorylate several members of the main signaling pathways in addition to several 
effector proteins. Consequently, a significant part of pathway integration occurs through 
these latter kinases.  
Mitogen-activated protein kinase (MAPK) is a Ser/Thr protein kinase that is broadly 
present in eukaryotic cells, and Ras-Raf-MEK-ERK is an important signaling pathway 
in MAPKs, with ERK as the key effector of the Ras oncoprotein [168]. Cell surface 
receptors activates the signal transduction and the production of the appropriate 
biological response. By conducting signals through the receptor, the Ras-Raf-MEK-
ERK pathway activates transcription factors and regulates gene expression [169]. The 
pathway is activated by growth factors, polypeptide hormones, neurotransmitters, 
chemokines, and phorbol esters (e.g. phorbol myristate acetate (PMA)), which signal 
through their related RTKs and GPCRs, or by the direct activation of protein kinase C 
(PKC). Ras recruits and activates the Ser/Thr protein kinase Raf, which promotes the 
MEK1/2 (MAPK/ERK kinase) dual-specificity protein kinase and the activation of 








Figure 6. Pathway Convergence. ERK and AGC kinases often regulate the same 
substrates to produce the same phenotypic effects. FOXO and GSK3 are examples of 
Ras-Raf-MEK-ERK and PI3K-Akt-mTOR convergence at different residues on the 
same substrate through ERK and AGC kinase inputs. The Myc-Mad1 and Myc-Max 
dimers are examples of two pathways converging on different members of the same 
complex. BAD and S6 are examples of AGC kinases regulating different motifs within 
the same substrate. YB1 and ERα are examples of AGC kinase promiscuity, in which 
several AGC kinases phosphorylate the same residue. The abbreviations shown in the 






The Ras-Raf-MEK-ERK pathway cross-activates PI3K-Akt-mTOR signaling by 
regulating three main substrates: PI3K, TSC2, and mTORC1. Ras-GTP can directly bind 
and allosterically activate PI3K [170-172]. Furthermore, strong activation of the Ras-
Raf-MEK-ERK pathway can activate mTORC1 indirectly through ERK and RSK 
signaling to the TSC complex. Constitutively active Ras mutants, phorbol esters, and 
EGF can phosphorylate TSC2 through ERK and RSK [167, 173]. The ERK and RSK 
sites functions to promote mTORC1 activity and tumorigenesis, but they are different 
from those phosphorylated by Akt [167] in that they induce a PI3K-independent 
mTORC1 phosphorylation of 4EBP1 [167, 174, 175].  In an active state, ERK and AGC 
kinases can act on the same substrate, often at the same time, to promote cell survival, 
proliferation, metabolism, and motility. Examples include the forkhead box O (FOXO) 
and c-Myc transcription factors, BAD (B-cell lymphoma (BCL) 2-associated agonist of 
cell death), and glycogen synthase kinase 3 (GSK3).  
Briefly, FOXOs are regulators of the expression of cell cycle components and apoptotic 
proteins that oversee cell survival and proliferation. c-Myc is an obligate heterodimer 
that, along with its activation partner Max, is responsible for the positive regulation of 
growth and survival transcriptional mechanisms. The related transcription factor Mad1 
competes with Max to bind to c-Myc, and the Myc/Mad heterodimer functions as a 
repressor of gene transcription of growth and survival genes [176]. BAD is a pro-
apoptotic BH3-only protein in the BCL-2 family. This protein positively regulates cell 
apoptosis by forming heterodimers with BCL-xL and BCL-2, reversing their death-
repressor activity. Different growth factors (e.g. Wnt, insulin) are known to deactivate 
GSK3 α/β Ser/Thr kinases. This deactivation releases the inhibitory effect of GSK3 of 
pro-survival, proliferation, and motility proteins, such as adhesion proteins and the β-
catenin transcription factor that drives the expression of cyclin D and MYC.  
1.3.6 PI3K-Akt-mTOR signaling pathway inhibition in AML 
It is commonly accepted that a disparity in the regulation of protein kinases may be one 
of the primary causes of genetic-based human diseases, and a major part of new drug 




kinase inhibitors. The PI3K-Akt-mTOR pathway has emerged as a possible therapeutic 
target in human malignancies, and several pharmacological inhibitors have been 
developed, including isoform-selective or pan-class I PI3K inhibitors, Akt inhibitors, 
rapamycin, and rapalogs as well as dual PI3K-mTOR inhibitors. The rapalogs 
everolimus and temsirolimus represent allosteric inhibitors directed towards mTORC1 
and are now in clinical use. Early studies indicated that PI3K inhibition has proapoptotic 
and antiproliferative effects in primary human AML cells through the 
dephosphorylation of Akt and BAD [145].  
The efficiency of several selective inhibitors towards the PI3K-Akt-mTOR pathway has 
been studied in AML cell lines and primary cells, and results have shown that Akt can 
be reactivated through negative feedback mechanisms subsequent to rapamycin-
mediated mTOR inhibition. Inhibitors targeting the catalytic domain of mTOR have also 
been developed [177], and pre-clinical studies of rapamycin combined with rapalogs 
targeted at mTOR showed inhibition of clonogenic AML cell proliferation without 
inhibition of normal CD34+ cells [148]. The antileukemic effects were further enhanced 
by combination with conventional cytotoxic drugs [158]. However, the relevant 
antileukemic activity of rapamycin and rapalogs has not been demonstrated in clinical 
trials [178-181].  
Both PI3K and mTOR are members of the PIKK superfamily and share structural 
domains, and some inhibitors therefore act on both kinases. An important consequence 
of inhibiting mTORC1/S6K by rapalogs has been the increased phosphorylation of Akt 
[177, 182]; this has been observed in both experimental and clinical studies. Dual 
inhibition of PI3K and mTOR blocks both the upstream and downstream pathways of 
Akt, consequently circumventing activation of Akt subsequent to the reduced mTORC1-
S6K-IRS1 mediated negative feedback loop [183]. Possible reasons for the failure to 
demonstrate clinically relevant antileukemic effects by pathway inhibitors include 
limited activity in human patients [184], intrinsic molecular defects [185], and dose-
limiting toxic effects [186]. Akt is important for a wide range of cellular functions and 
interacts with an immense number of substrates [122]. Only a few Akt inhibitors have 




Results from selected representative and relatively large clinical studies of PI3K-Akt-
mTOR inhibitors were recently reviewed by Herscbein-Liesveld and colleagues [189] 
and Table 3 represents the most relevant studies. These clinical studies justify the 
conclusions that (i) pathway inhibitors used alone have only modest antileukemic 
effects; (ii) pathway inhibition in combination with intensive chemotherapy have 
acceptable toxicity; (iii) the doses used in clinical studies can alter the activation of 
pathway mediators; and (iv) the most important toxicities revealed by clinical studies 
are hematological and gastrointestinal toxicity. However, while there is some evidence 
it may be more effective in certain subsets of patients, clinical experience with mTOR 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2 AIMS OF THE THESIS 
 
The PI3K-Akt-mTOR signaling network shows constitutive activation in human AML. 
This pathway is important for regulation of cell metabolism, cell cycle progression, gene 
transcription and translation, cell differentiation and apoptosis. However, AML is 
heterogenic disease and previous experimental studies suggest that the antileukemic 
effects of pathway inhibitors differ among patients.  
 The main aim of this thesis was to map patient heterogeneity based on cell signaling. 
This included mapping constitutive PI3K-Akt-mTOR signaling within a group of AML 
patients. The scientific and technological objectives were as follows: 
- Study constitutive PI3K-Akt-mTOR signaling with and without 
activation/stimulation 
- Evaluate the effects of pathway inhibitors among subgroups of patients 
- Study the metabolic regulation.  
 
3  SUMMARY OF THE RESULTS 
3.1 Article I  
Two acute myeloid leukemia patient subsets are identified based on the constitutive 
PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and 
transcriptomic comparison  
Authors: Ina Nepstad, Kimberley Joanne Hatfield, Elise Aasebø, Maria Hernandez-
Valladares, Annette K. Brenner, Sushma Bartaula-Brevik, Frode Berven, Frode 
Selheim, Jørn Skavland, Bjørn Tore Gjertsen, Håkon Reikvam, and Øystein Bruserud 
Background. The aim of this article was to study the constitutive PI3K-Akt-mTOR 
activation of primary AML cells for a large group of unselected patients.  
Methods. The expression and phosphorylation of 18 mediators in the PI3K-Akt-mTOR 




We compared global gene expression profiles, proteomic and transcriptomic profiles, 
and the difference in susceptibility to antileukemic agents among patients.  
Results. Patients were separated into one subset showing high constitutive activation 
and one subset showing low constitutive activation based on their constitutive pathway 
activation profiles. The high activation subset was characterized by reduced frequency 
of cells showing monocytic differentiation, increased frequency of adverse karyotypes, 
decreased constitutive cytokine release, and increased expression of certain integrins.  
Conclusion. The two subsets differed in their expression of genes encoding regulators 
of protein phosphorylation, whereas phosphoproteomic analyses showed differences 
related to transcriptional regulation. These variations are a part of complex phenotypic 
differences. 
3.2 Article II 
Insulin-initiated activation of the PI3K-Akt-mTOR pathway in acute myeloid 
leukemia cells; a study of patient heterogeneity and pathway inhibitors  
Authors: Ina Nepstad, Kimberley Joanne Hatfield, Elise Aasebø, Maria Hernandez-
Valladares, Karen Marie Hagen, Kristin Paulsen Rye, Frode Berven, Frode Selheim, 
Håkon Reikvam and Øystein Bruserud 
Background. Constitutive signaling through the PI3K-Akt-mTOR pathway is present 
in AML cells, and this pathway is considered a possible therapeutic target. Insulin can 
be a growth factor for AML cells, and we characterized the effect of insulin on PI3K-
Akt-mTOR activation.  
Methods. We investigated the phosphorylation level of 10 proteins involved in PI3K-
Akt-mTOR signaling by flow cytometry for AML cells derived from 76 unselected 
patients. Patient subsets were compared by global gene expression, and proteomic and 
phosphoproteomic profiling. 
Results. Patients were classified in two main subsets based on the constitutive activation 
of their AML cells; the overall results indicated insulin significantly increased the 




Strong insulin responders were characterized by a specific gene expression profile as 
well as proteomic and as phosphoproteomic differences with regard to regulators of 
transcription, RNA metabolism, and protein modification. Even though the overall 
effects of pathway inhibitors differed between patients, PI3K and Akt inhibition was 
characterized by a generally strong inhibition of AktpT308 and 4EBP1pT36pT45 
whereas mTOR inhibition caused a strong inhibition of mTORpS2448 and S6pS244. 
Conclusion. Insulin modulates PI3K-Akt-mTOR signaling in primary human AML 
cells, but the insulin effect differs between patient subsets, which can be identified 
through their mRNA or proteomic profiles. The effects of pathway inhibitors on 
activation differs between patients and depends on the molecular target of the inhibitor. 
3.3 Article III 
Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR Inhibition in 
primary human acute myeloid leukemia cells is associated with altered cell 
metabolism  
Authors: Ina Nepstad, Håkon Reikvam, Annette K. Brenner, Øystein Bruserud, 
Kimberley J. Hatfield 
Background. The PI3K-Akt-mTOR pathway plays a central role in the regulation of 
proliferation, differentiation, and survival of hematopoietic cells, and constitutive 
signaling through this pathway has been observed in AML cells. This pathway is a 
possible therapeutic target in human AML and we therefore investigated possible 
associations between cellular metabolism and sensitivity to PI3K-Akt-mTOR pathway 
inhibitors, in relation to heterogeneity of the disease.  
Methods. A non-targeted metabolite profiling was performed to compare the 
metabolome variances of primary human AML cells derived from patients susceptible 
or resistant to the in vitro antiproliferative effects of inhibitors to the pathway. 
Additionally, using flow cytometry, we investigated the phosphorylation profile of 18 
proteins involved in PI3K-Akt-mTOR signaling, together with the effect of the 




Results. Inhibitors of the PI3K-Akt-mTOR pathway have antiproliferative effects on 
leukemia cells for only a subset of patients. We compared the metabolite profiles of 
AML cells defined as either susceptible to or resistant to in vitro treatment with pathway 
inhibitors and found 627 metabolites could be detected. Non-responders showed 
increased levels of metabolites reflecting energy metabolism (citric acid, isocitric acid), 
amino acid metabolism (proline, aspartic acid, glutamine, taurine), and arachidonic acid 
metabolism (4,7,10,13-eicosateraenoic acid, 4,7,10,13,16-doocosapentaenoic acid). 
Decision tree analysis showed that the two patient groups could be identified based on 
the levels of cysteinyl-cysteine and threonic acid. Furthermore, the cyclooxygenase 
inhibitor indomethacin altered the phosphorylation of mTOR and its downstream 
mediators. 
Conclusion. Differences were found in leukemia cells that are susceptible or resistant 
to PI3K-Akt-mTOR inhibitors in energy, amino acid, and arachidonic acid metabolism. 
Results shows that modulation of arachidonic acid metabolism alters the activation of 
mTOR and its downstream mediators. 
3.4 Article IV 
Clonal heterogeneity reflected by PI3K-Akt-mTOR signaling in human acute 
myeloid leukemia cells and its association with adverse prognosis 
Authors: Ina Nepstad, Kimberley Joanne Hatfield, Tor Henrik Anderson Tvedt, Håkon 
Reikvam and Øystein Bruserud   
Background. Clonal heterogeneity is seen for a subset of AML patients, and detection 
of separate subclones based on karyotyping is associated with adverse prognoses. 
However, the use of another methodological strategy is required for a more general 
evaluation of the prognostic impact of clonal heterogeneity in human AML. Constitutive 
activation of the PI3K-Akt-mTOR pathway is present in AML cells, and this pathway 
is considered a possible therapeutic target in human AML. However, the degree of 
pathway activation varies between patients. In this study, we suggest that this pathway 




Methods and Results. We investigated constitutive PI3K-Akt-mTOR pathway 
activation in primary human AML cells derived from 114 patients, together with 18 
mediators central to the signaling in this pathway. The cohort included patients with 
normal karyotype or single karyotype abnormalities, with an expected heterogeneity 
regarding molecular genetic abnormalities. Clonal heterogeneity reflected as pathway 
mediator activation was detected for 39 patients, and the study shows that primary AML 
cells derived from patients with and without dual PI3K-Akt-mTOR cell copulations 
have differences in their global gene expression profiles. Finally, detection of AML 
subclones based on PI3K-Akt-mTOR signaling was associated with adverse prognosis 
for patients receiving intensive antileukemic treatment.  
Conclusion. Clonal heterogeneity, as shown in the activation status of selected 
mediators in the PI3K-Akt-mTOR pathway, was related to differences in gene 
expression profiles and had an independent prognostic impact. This biological 
heterogeneity reflected in the intracellular signaling status should be further investigated 
as a potential prognostic biomarker in human AML. 
 
4 METHODOLOGICAL CONSIDERATIONS 
 
The following section describes and elucidates the main methods and techniques used 
during the thesis. 
4.1 Selection of patients 
By definition, AML involves leukemic blast counts of 20% or more in the bone marrow 
or peripheral blood [13]. In addition, AML can be defined by the presence of an extra 
medullary tissue infiltrate or documented t(8;21), inv(16), or t(15;17) in the appropriate 
clinical setting, regardless of blast percentage [192]. In our studies, AML blasts derived 
from the peripheral blood of patients with high peripheral blood blast count was used. 
As will be discussed in detail below, our results may be relevant for AML in general 
despite this selection, but they should be interpreted carefully and may only be 




We investigated primary human AML cells derived from patients with high, relative, or 
absolute levels of circulating AML cells in the peripheral blood. This methodological 
approach was used to allow preparation of highly enriched AML cells by density 
gradient separation alone, thereby avoiding the induction of functional alterations in the 
leukemic cells - a potential problem that has been discussed in detail previously [32, 
193]. Furthermore, our previous studies showed that patient cohorts are reasonably 
representative for AML in general with regard to cytogenetic analysis and FLT3 
abnormalities, i.e. the most important genetic abnormalities related to prognostication 
and in vivo chemosensitivity [81]. Peripheral blood cells were also shown to be 
representative with regard to the corresponding bone marrow AML cells; even though 
quantitative differences may be seen, the major characteristics of the leukemic cells are 
maintained [194, 195]. Finally, the peripheral blood cell count is a weak prognostic 
parameter in human AML [196], and patients selected based on their peripheral blood 
extravasation are likely to be relevant for AML in general with regard to clinically 
relevant chemosensitivity.  
Even though remaining immature leukemic and pre-leukemic stem cells are thought to 
be responsible for AML relapse, several previous reports suggest that functional 
characteristics of the total AML cell population are important markers for 
chemosensitivity and thereby reflect fundamental common characteristics between the 
more immature minority of AML cells and the majority of the hierarchically organized 
AML cell population:  
 Genetic abnormalities are common for the cells within the hierarchically organized 
AML cell population genetics [1]. 
 Chemoresistant relapse is the most frequent cause of death in AML; treatment-
related mortality is usually low for younger patients receiving intensive 
chemotherapy alone, while non-relapse mortality is higher for patients treated with 
allogeneic stem cell transplantation [23, 197]. The prognostic impact of global 
mRNA profiles as well as selected mRNA profiles (e.g. leukemic stem cell profiles) 
[31, 198], epigenetic regulation [199], single molecular markers detected at the 




[202] has been demonstrated through analysis of the total AML cell population. 
These observations illustrate that the common biological characteristics of the 
overall AML cell populations are correlated with the chemosensitivity of the disease 
and the risk of chemoresistant relapse. In our opinion, studies using the total 
leukemia cell population should therefore be regarded as relevant. 
 In vivo evaluation through observation of bone marrow blast counts 17 days after the 
start of induction therapy, as well as the use of minimal residual disease (MRD) 
estimation by flow cytometry during consolidation therapy, is also based on 
evaluation of common AML cell characteristics [202].  
Taken together, these observations suggest that the biological characteristics of the total 
AML cell population reflect clinically relevant chemosensitivity in primary human 
AML cells. 
4.2  Cell preparation and cryopreservation 
Density gradient centrifugation was used for the isolation of AML cells for all patients, 
and highly enriched blast populations were prepared [32]. Most contaminating cells 
were small lymphocytes. In our opinion, this small degree of contamination was unlikely 
to have any major impact on our results; and in our experience, normal peripheral blood 
mononuclear cells cultured in medium alone without any specific activation signal do 
not show detectable proliferation or detectable cytokine release. 
Our methods for cryopreservation were highly standardized, and the same methodology 
was used for all samples in our biobank [203]. Even though more recent studies of 
mobilized stem cell grafts in human peripheral blood suggests that cells can be 
cryopreserved by using 5% dimethyl sulphoxide [204, 205], all our samples were 
preserved with 10% dimethyl sulphoxide and a standard concentration of inactivated 
fetal calf serum. 
The advantage of using cryopreserved cells instead of freshly prepared cells is the 
reduction in variations between analysis of different patients in different experiments 




parallel. The disadvantage is the reduction in the viability of the AML cell population 
though the freezing and thawing processes. 
4.3 Sample storage time  
We did not evaluate the possible influence of storage time on the protein levels and 
phosphorylation levels of the mediators in the PI3K-Akt-mTOR pathway. For this 
reason, we compared the relative storage times for samples with high and low pathway 
activation as identified in our study of constitutive pathway activation (Figure 1, article 
I). Patients with low constitutive PI3K-Akt-mTOR activation had an average storage 
time of 6.5 years whereas the patients with high activation had an average storage time 
of 6.0 years; this difference was not statistically significant. Thus, the storage time of 
cryopreserved samples is not considered to have any major impact on our analysis of 
constitutive pathway activation.  
4.4 Assay for the detection of apoptosis and the proliferation assays 
We used a standardized flow cytometric assay for the detection of apoptosis and the 
estimation of viable cells. Previous studies indicate that in vitro cultured AML cells 
undergo spontaneous in vitro apoptosis and the percentage of viable cells decreases 
during the first days of the culture until it reaches a low level [206]. We estimated the 
cell viability after one or two days, and our studies of cell viability thus reflect the 
characteristics of the major subset of more mature cells in the hierarchically organized 
AML cell population. 
For article I, II, and the pilot study of article III, we evaluated AML cell proliferation 
after seven days of in vitro culture using a 3H-thymidine assay. The isotope was added 
after six more days of culture, and 3H-thymidine incorporation was estimated on the 
following day. Thus, this proliferation analysis reflects the characteristics of a minor 
subset of cells that survive for at least six days and still are able to proliferate. The 
different time points for evaluation of apoptosis/viability and proliferation may thus 




4.5  Flow cytometry as a tool for the investigation of PI3K-Akt-mTOR 
signaling in AML 
We used flow cytometry, a laser-based analysis technique, for the study, 
characterization, and detection of the cells. A flow cytometer performs simultaneous 
and rapid quantitative measurements of numerous physical and chemical characteristics. 
The basic principle behind the method is the passage of particles in single file in front 
of a laser, which detects, counts, and sorts them. The cells are fluorescently labelled 
using antibodies and are excited by the laser though the emission of light at different 
wavelengths. The fluorescence can then be measured to determine the type and quantity 
of cells present in the given sample.  
Prior to measurement, particles in suspension are hydrodynamically focused to maintain 
proper alignment and separation of the cells within the fluid stream. The stream is run 
through one or more lasers, resulting in the detection of florescent and scattered light by 
photomultiplier tubes (PMT) (Figure 7). The signal is then amplified and converted to a 
voltage pulse and finally transformed to a digital value. While the run of each sample 
includes measurements of a large number of cells, the strength of the method is that each 
cell is measured by itself, allowing for the identification and grouping of individual cells. 
The technique uses fluorescent reagents, usually monoclonal antibodies, for the 
identification and stratification of cells.  
Fluorochromes are excited at a specific wavelength of light provided by the laser and 
emitted at a lower specific wavelength. Emitted light of a specific wavelength is 
distinguished by the use of suitable optical filters prior to the detection of the emitted 





Figure 7. Schematic of the basic steps of flow cytometry. A) A heterogeneous cell 
sample can be stimulated to prompt specific signaling cascades and phosphorylation 
of the proteins of interest. The cells are fixed, permeabilized, and stained with 
fluorophore-conjugated for identification of cell type and mediator of interest. The 
cells are then analyzed on a flow cytometer. B) A cell suspension is hydrodynamically 
focused to intersect with a laser. The signals from the laser are collected by a forward 
light scatter detector, a side light scatter detector, as well as various detectors for 
fluorescence emissions. Finally, the signals are amplified and transformed into digital 
data for further analysis. 
4.6 Intracellular flow cytometry 
The main method used in these studies is flow cytometric detection of total protein and 
protein phosphorylation, and all experiments (article I-IV) were performed on a FACS 
Verse flow cytometer. Flow cytometry offers several benefits for studies investigating 
cell signaling based on its ability to assemble data at the individual cell level. Detection 
of intracellular signaling responses mediated through protein phosphorylation for 
defined cell subsets within a complex cell population can be accomplished through the 
combined use of fluorescent subset-identifying antibodies (e.g. detection of specific cell 
surface molecules) and antibodies specific to protein phosphorylation sites.  
The processes that occurs within a cell are important for many aspects of cell biology 
and medicine. The understanding of the function of normal cell metabolism, cell 
response to environmental factors, and eventually, cell aging and cell death, can provide 




and when these normal processes malfunction is essential for the understanding of 
disease and the development of more effective treatments and cures. The ideal method 
of analysis would be to study and obtain information from living cells, without the need 
for labels. Instead, cell fixation is often used to allow a snapshot of a cell state to be 
measured. To detect specific phosphorylated proteins using flow cytometry, cells have 
to be fixed to preserve the phosphorylated state of the signaling proteins, and then the 
cell membrane must be permeabilized to allow antibodies to enter the cells and bind to 
their target epitopes.  
Aldehydes, including paraformaldehyde, function as cross-linking agents that react with 
proteins and nucleic acids within the cell, and are widely used in fixation. They provide 
good preservation of the cellular structure and their use does not appear to result in 
significant structural changes to the proteins.  
Following paraformaldehyde, methanol was used for permeabilization in all our studies 
(article I-IV); and cells were then stained with phosphospecific antibodies. Organic 
solvents, such as methanol, acetone, and ethanol preserve both cell morphology and 
nucleic acid content [207, 208]. Moreover, these fixatives have been shown to be more 
effective for the preservation of nucleic acid content in cells than aldehyde-based 
fixatives [208]. Methanol combined with low non-specific staining has the ability to 
increase the reactivity of antibodies to certain nuclear antigens [209], and cold methanol 
is often used as a permeabilization agent when flow cytometry is used to detect 
phosphorylated proteins and transcription factors. However, one of the potential 
problems with methanol is the denaturation of surface receptors [207, 208]. We tested 
our surface markers for studies I-IV before and after treatment with methanol and 
detected the same markers at both times.  
Protein phosphorylation is temporary and is regulated by protein phosphatases. Most 
methods for detection of protein phosphorylation require prompt inactivation of 
phosphatases immediately following stimulation. All cell samples were therefore swiftly 
fixed to sustain phosphorylation. In order to avoid unspecific antibodies binding to cells, 
the antibodies must be titrated. The degree to which this is a problem may differ between 




well-characterized antibodies throughout all of our studies to avoid the problem of 
variation in nonspecific binding between different experiments. During titration testing, 
we also found that the most effective concentration of antibodies for a staining mixture 
was essentially independent from the number of cells being stained but strongly 
dependent on stain volume. Hence, the same stain volume was used in all experiments. 
The normal level of cell fluorescence, referred to as autofluorescence, may present an 
issue for data analysis of flow cytometry. Mammalian cells contain many compounds 
that are excited by the 488 nm laser that is commonly used in flow cytometry. Hence, 
the signal to noise ratio is reduced resulting in a decreased sensitivity and more false-
positive cells. Spillover refers to the overlap among the emission spectra of certain 
commonly used fluorochromes, and spillover from one channel to another may mask 
low expressers. This can be corrected using unstained controls, and fluorophores that 
emit above 600 nm will have less autofluorescence interference. Fluorophore brightness 
is a relative indication of the intensity of a fluorophore, measured above the background 
(dim=1 to bright=5). The use of a bright fluorophore will diminish the effect of 
autofluorescence. In addition, we stained cells separately with each antibody as a 
compensation control.  
Cell signaling studies often investigate cellular responses to treatment with stimulatory 
or inhibitory molecules, making unstimulated or untreated cells the best controls for 
evaluation of background staining. In the past, isotype controls were widely used to 
correct for unspecific binding of antibodies. However, an unstimulated cell control 
considers the background characteristics of each antibody as well as the basal 
phosphoprotein expression levels within the cells of interest, which is different from an 
immunoglobulin isotype control. For this reason, we included three unstimulated cell 
controls for all flow cytometric assays in articles I-IV. For stimulation studies, we also 
included unstained controls with each stimulus or inhibitor, as well as stimulus plus 




4.7 Selection of antibodies 
All antibodies used during the course of the thesis were titrated to provide the best 
staining for phenotypic and phosphoantigens. For articles I-IV, antibodies to 
phosphoantigens were titrated using unstimulated samples, and for articles II-IV, we did 
an additional titration with stimulated samples to determine the concentration necessary 
to maximize fold change. Final concentrations were selected based on the point at which 
small changes in antibody concentrations caused little to no fold change. Additionally, 
during titration studies, we tested the effect of media conditions. We found that storage 
time of RPMI-1640 media affected the activation of some substrates. Hence, we always 
used fresh media for the studies to minimize unwanted effects, thereby minimizing 
irregularities in the results.  
We chose the fluorophores for this antibody panel based on the wavelength of available 
lasers and filters on the flow cytometer. The expression density of an antigen is also 
important in the selection of fluorophores. Some cellular antigens have a high expression 
density and can be combined with a variety of fluorophores with both high and low 
brightness, whereas others have a low expression density and should be combined with 
a bright fluorophore. We tested different fluorophores to determine which was best 
suited to differentiate between positive and negative populations. Selections were also 
based on the ability of the fluorophore to minimize spillover into central and sensitive 
channels to diminish the need for compensation and subsequent introduction of error. 
The selection of antibodies used for the identification of the correct cells was based on 
general knowledge of AML surface markers. Antibodies used in the analysis of 
intracellular cell signaling pathways were chosen to give the best coverage of the main 
track of the PI3K-Akt-mTOR signaling pathway. However, PI3K signaling is extremely 
complex, and there is a wide variety of available antibodies. For practical reasons, it was 
not possible to include all mediators that at some level influence or crosstalk with the 
main track PI3K-Akt-mTOR in this network. Our intention was to describe patient 
heterogeneity with regard to the activation status of the PI3K-Akt-mTOR pathway and 
to elucidate whether patient heterogeneity in this axis may be an explanation for why 




antileukemic activity in many patients. Due to the complexity of this signaling network, 
it will always be possible to criticize a selection and to suggest inclusion of additional 
mediators. However, for our purpose, we feel that the main substrates are included.  
4.8 Bioinformatic approaches 
Initial visualization and analysis of flow cytometry data was achieved with FlowJo (Tree 
Star) (articles I-IV). Identification of immune cell populations was based on light scatter 
properties or relative expression of CD markers. In articles I-IV, the mean fluorescence 
intensity (MFI) was recorded in channels used to measure phosphospecific antibodies. 
Unsupervised hierarchical clustering was used for identification of subgroups within 
patients in articles I-IV (not included in article IV). With hierarchical clustering analysis 
we aim to build a hierarchy of clusters where objects (in this thesis; AML patients) that 
are more similar cluster closer together, and more dissimilar objects are dispersed farther 
apart. Dissimilarities between clusters of objects can be defined in several ways: 
maximum dissimilarity (complete linkage), minimum dissimilarity (single linkage), or 
average dissimilarity (average linkage). Clustering categorizes big datasets into minor 
groups of similar or comparable entities, presenting data in a manageable format for 
further elucidation. However, hierarchical clustering analyses should be interpreted with 
care. The results for clustering analyses in articles I-III are dependent on the specific 
patients and mediators/effectors used in the study. The main differences that appear by 
changing the mediators and/or patients used for the cluster analysis, is that the order of 
patients in the cluster may be altered, while the trend with two signaling subsets is still 
present. One should therefor use at this type of analysis to generate an overview of the 
dataset and arrange objects into relatively homogeneous groups based on multivariate 
observations rather than for specific analysis at the patient level. For all articles, 
hierarchical clustering analysis was performed with the J-Express 2012 software 






5 GENERAL DISCUSSION  
AML is an aggressive malignancy characterized by a proliferation of immature myeloid 
leukemia cells [1, 2]. The main aim of this thesis was to describe the heterogeneity of 
AML patients by studying PI3K-Akt-mTOR signaling. We analyzed the same flow 
cytometric parameters in all four articles (I-IV) included in this thesis, and these 
mediators represent the main steps in the PI3K-Akt-mTOR pathway. The panel was 
selected to provide an overview of the signaling/phosphorylation status of this pathway, 
and by studying the same panel in all four articles, we were able to make an overview 
of the relationship between the pathway and AML patient heterogeneity, and thus 
evaluate if such signaling profiles could be correlated to clinical diagnosis or treatment. 
Due to the complexity of PI3K signaling, which is studied in all four articles, several 
key mediators should be included in this kind of study. For practical reasons, it was not 
possible to include all mediators that, at some level, influence or crosstalk with the main 
track PI3K-Akt-mTOR in this network. We selected a panel of 18 mediators (see article 
I-IV), and we do not argue that this selection is correct but rather that it is relevant; the 
identification of PTEN as total and as phosphorylated/inactive proteins (S380) is of 
fundamental importance because of its role in PI3K signaling regulation. However, as 
PTEN mutations have been shown to occur in less than 1% of AML patients, this 
mediator is less important in AML than in many other malignancies. As PDK1 is located 
between PI3K and Akt in the main track of the pathway, the activity of PTEN is reflected 
in the immediate downstream phosphorylation of PDK1 [210].  
In addition, GSK3 could constitute an important mediator, as analysis of GSK3 reveals 
whether PI3K signaling affects cell metabolism. In our opinion, for article I, this 
complex acts more like branch from the main track than an integral part of the main 
track.  
In retrospect, it would have been beneficial to include this or other mediators in our 
studies on insulin and metabolism. However, the effect of many of these mediators is 




5.1 Patients included in the various studies  
The various studies included patients with high peripheral blood cell counts or high 
percentages of leukemic blasts among circulating leukocytes. This was the only criteria 
for selection, and the patient populations consist of consecutive patients fulfilling this 
criterion, as discussed above. In a previous study, we compared patients with increased 
peripheral blood blasts with other AML patients without this degree of extravasation 
over a defined period of time [81]. This comparison showed negligible differences in 
the frequency of FLT3 mutations, with regard to cytogenetic abnormalities. Thus, the 
patients do not differ with regard to the most important biological characteristics 
associated with risk of relapse and clinical chemosensitivity. However, the degree of 
extravasation is also associated with an adverse prognosis [196], though this impact is 
much weaker. A final important prognostic parameter for chemosensitivity is whether 
complete hematological remission is achieved after the first induction cycle [196]. This 
parameter was not considered in our present studies because we included consecutive 
patients with a high median age, and as many of these patients did not receive intensive 
chemotherapy, this parameter is not available for these patients. Thus, in the present 
study we generally investigated associations with biological characteristics for which 
data were available for most or all patients: cytogenetics, FLT3 and NPM1 mutation, 
and differentiation. 
An extended mutational analysis was only available for a subset of patients; some of 
these mutations are now regarded as established prognostic parameters and should be 
included in routine clinical practice [1]. As a result, the prognostic classification of some 
of our patients might have changed had these data been available for all patients. 
However, as most of these mutations occur infrequently, additional mutational analyses 
might change the prognostic classification for only a relatively small number of patients. 
Because we included consecutive patients admitted to our hospital with diagnoses of 
AML, patients with both first diagnoses and relapsed leukemia are included in our 
studies. The median age at the time of first diagnosis of AML is 65-70 years, and this 




population included a relatively low percentage of patients with favorable cytogenetic 
abnormalities, compared to percentages typically seen in clinical studies of AML, 
because these abnormalities occur more frequently in younger AML patients; many 
clinical studies include intensive leukemic therapy, which requires the inclusion of 
patients below 60 or 65 years of age. Thus, our patient populations are representative 
for AML in general, but they should be interpreted carefully as they may not be 
representative for patients without extravasation or for subsets of younger patients.  
5.2 Strategies for therapeutic targeting of the PI3K-Akt-mTOR 
pathway 
In article I, the focus of our study was to characterize the activation profiles, which 
included the mediators of the main steps of the PI3K-Akt-mTOR signaling network, for 
a large group of AML patients. By investigating a large group of patients, we could 
describe patient heterogeneity. Results show that alterations in constitutive PI3K-Akt-
mTOR signaling are part of more complex genetic, as well as phenotypic, differences in 
AML cells, including constitutive cytokine release and proteomic and transcriptomic 
differences. In accordance with our clustering analysis, patients could be classified into 
two main subsets based on the described activation profile of the main track in this 
pathway/network. As this was our primary observation, we continued our study as a 
comparison of these two main subsets. Our initial intention was not to create a yes/no 
classification system, but as the analysis of our data showed that patients could be 
classified in this way, we regarded the comparison of these two subsets as important for 
the characterization of patient heterogeneity. In addition, the same findings were 
observed when examining other patient groups with the same antibody panel (article II-
IV). Simultaneously, the subsets also differed with regard to cell differentiation, but the 
association between differentiation and protein phosphorylation was relatively weak. In 
article I, the high phosphorylation group included an increased frequency of patients 
with adverse cytogenetic abnormalities, while frequencies of FLT3 or NPM1 mutations 
were not significantly different from those of the low phosphorylation group. However, 




abnormalities was found in the subsets with high phosphorylation. Studies have shown 
that isocitrate dehydrogenase (IDH) mutations can upregulate Akt-mTOR expression 
[212, 213]. However, only a minority of the patients included in our four articles show 
detectable levels of IDH mutations, and therefore this factor cannot explain the overall 
activation/expression pattern. 
5.3 Constitutive versus insulin-dependent pathway activation 
Insulin regulates cellular proliferation, survival, and metabolism by binding to its 
receptor, with PI3K-Akt-mTOR as one of many downstream pathways. PI3K-Akt-
mTOR is closely linked to insulin signaling through its insulin substrate receptor (IRS1), 
which can phosphorylate PI3K directly, thereby regulating the PI3K-Akt-mTOR 
pathway according to insulin levels. In contrast, constitutive activation of the pathway 
has been shown to inhibit the activity of IRS1 through a negative feedback loop caused 
by the activation of mTOR and p70S6K, resulting in phosphorylation of IRS1 [183]. 
PI3K, Akt and mTOR are important regulators of the PI3K-Akt-mTOR pathway and are 
able to sense both external and internal signals to control cellular growth and survival. 
For the adjustment of both uptake of glucose into muscle and fat, and gluconeogenesis 
in the liver, insulin serves as a main controller of blood glucose levels. Previous studies 
show that, for some subsets of patients, insulin has an enhancing effect of growth for 
primary human AML cells [214], and article III shows that the cellular metabolism 
differs between patients that are susceptible and unsusceptible to the antiproliferative 
effect of pathway inhibitors. In article IV, we characterized the heterogeneity of human 
AML based on the effects of insulin, both alone and combined with various pathway 
inhibitors (PI3K, Akt and mTOR inhibition), and the effect of PI3K-Akt-mTOR 
pathway activation in primary human AML cells. Results from articles II, III, and IV 
show that the heterogeneity found among AML patients is preserved after the activating 
effect of stimulation by insulin on PI3K-Akt-mTOR signaling in their leukemic cells as 
well as the effects of various inhibitors on the pathway activation. However, the general 
activation of the pathway increased significantly following insulin stimulation, and 




samples. The purpose of this study was not to investigate the inhibitors, but rather to 
study the heterogeneity of the patients in relation to the pathway. However, inhibitors 
that target mTOR will block the activity of mTORC2/Akt and hence further impair 
insulin insensitivity. Therefore, further targeting of mTOR complex could provide 
valuable information. 
5.4 Proline, energy, and arachidonic acid metabolism in malign 
cancers 
Previous experimental studies have proposed a large variation in the antileukemic 
effects of pathway inhibitors among patients. The aim of study III was to further 
characterize this patient heterogeneity in relation to the constitutive activation/signaling 
of the PI3K-Akt-mTOR pathway and study the effect of pathway inhibition and 
metabolic regulation. The observations described in article III suggest that primary 
AML cells derived from patients with high/low activation are heterogeneous with regard 
to their metabolic profile, and differences in the glutamine/proline/arachidonic acid 
metabolism are part of this heterogeneity.  
Proline and glutamine are nonessential amino acids that have a close metabolic 
association, but dissimilar physiologic purposes (See Figure 8) [215, 216]. Glutamine is 
a central signaling molecule, and like many other amino acids, it can activate mTOR 
[217]. In addition, it is the main source of endogenous proline, and during normal 
metabolic regulation, proline is incorporated into collagen [215, 216]. As collagen is the 
most abundant protein in the body, this stored pool of proline serves as an important 
source of amino acids and energy in conditions of metabolic stress.  
Arachidonic acid is a polyunsaturated fatty acid that is central to the processes of cell 
metabolism, especially the synthesis of prostanoids and leukotrienes, and the 
metabolism of arachidonic acid is important for the survival and proliferation of 
hematopoietic cells [218-220]. Our observations, described in article III, suggest that 
this may be true also for leukemic hematopoiesis. However, many questions remain with 
regard to our understanding of PI3K-Akt-mTOR signaling in malignant cells and its role 




studies are needed to further characterize AML cell metabolism, the metabolic 
heterogeneity of AML patients, and the possibility of metabolic targeting as a part of 
future AML therapies [221]. 
Amino acid metabolism is important for the energy metabolism of cells [215, 216]. 
However, previous studies show that oncogenic stimulation or activation of the PI3K-
Akt-mTOR signaling network stimulates post-translational regulation of glucose 
transporter movement to the plasma membrane; this represents an alternative 
mechanism for modulation of energy metabolism [222, 223]. This effect can be further 
strengthened through transcriptional upregulation of glucose transporter genes [224]. 
The combined effect of such mechanisms may provide strong stimulation of glucose 
uptake by cancer cells, thereby providing the amount of substrate necessary for aerobic 
glycolysis.  
Although the mechanisms that regulate metabolism through PI3K-Akt-mTOR signaling 
need to be studied in greater depth, our analysis suggest that the metabolic differences 
observed in cancer cells do not occur as isolated effects but as part of more complex 
biological phenotypes that are established by oncogenic signaling. The uptake and 
consumption of nutrition represent coordinated events that support the survival, growth, 
and proliferation of the malignant cells. The constitutive activation of PI3K-Akt-mTOR 
signaling may be caused by or may contribute to the metabolic signature of the AML 
cells.  
The proteomic studies in article II suggest that a subset of patients has a leukemic cell 
phenotype characterized by a general PI3K-Akt-mTOR activation/phosphorylation in 
response to insulin and a difference in several proteins that regulate cell metabolism; at 
the same time, these cells are characterized by low constitutive PI3K-Akt-mTOR 
activation and increased susceptibility to the antiproliferative effects of pathway 
inhibitors. Article III also describes different metabolomic profiles for AML cells that 
are susceptible to the antiproliferative effects of pathway inhibitors, and these two 




The interrelatedness of glutamine-glutamate-proline is well recognized [215, 216]. The 
free pool of proline is limited, but protein-bound proline can be released extracellularly, 
and collagen can then function as a proline reservoir [216]. Proline can be synthesized 
from glutamine/glutamate and from ornithine by ornithine aminotransferase [216]. 
Furthermore, the conversion of pyrroline-5-carboxylate (P5C) by P5C reductase to 




Figure 8. Proposed schematic of the proline metabolic pathway. Proline 
metabolism, or the proline cycle, is closely linked to the TCA cycle, the urea cycle, 
and the pentose phosphate pathway, and acts as a redox transport that transfers redox 
potential generated by the pentose phosphate pathway into the mitochondria for the 
production of ROS. The oxidation of proline to glutamate occurs in the mitochondria 
in two enzymatic steps, with the use of P5C which is the common intermediate for 
both biosynthesis and catabolism of proline. P5C is synthesized in mitochondria 
through the catabolism of proline by the enzyme PRODH. The abbreviations shown 
in the figure can be found in the list of abbreviations. Some of the pathways in this 




Recent studies have described the poor cell permeability of aspartate, and cancer cells 
may lack asparaginase, making them able to convert asparagine to aspartate [225]. 
Aspartate can function as an endogenous metabolic limitation for malignant cell 
proliferation; thus, cancers that express asparaginase may grow faster [225]. Aspartate 
has also been shown to support cellular redox homeostasis in addition to enhancing 
growth [226]. However, the importance of cytosolic aspartate in carcinogenesis may 
depend on the metabolic context because its antiapoptotic effect is most evident in low-
glutamine environments [226]. Though glutamine is a non-essential amino acid, 
malignant cells may consume glutamine in excess of other amino acids and thereby 
become dependent on extracellular glutamine for survival; malignant cells may also be 
dependent on serine [221]. Proline, glutamine, aspartate, and serine are functionally 
linked to one another, and they may serve as regulators of cellular proliferation and 
survival. Contribution to the cellular redox homeostasis is a characteristic they hold in 
common [221]. Furthermore, aspartate is linked to proline metabolism through the urea 
cycle and ornithine metabolism [221].  
It is not known whether the molecular mechanisms outlined above are operative in 
primary human AML cells or whether they are responsible for the 
resistance/susceptibility of primary AML cells to the antiproliferative effects of PI3K-
Akt-mTOR inhibitors. However, maintenance of NAD+ is important for protein 
deacetylation, ADP ribosylation, calcium signaling, generation of oxidized molecules 
necessary for biomass oxidation, support of anabolic reactions, and regulation of 
proliferation [227-231]. Thus, our hypothesis is that differences in proline/glutamine 
metabolism are important factors for chemosensitivity in AML through different 
mechanisms including their contribution in energy metabolism (i.e. the TCA cycle); 
their direct effects on redox homeostasis; and their indirect effects on the redox 
homeostasis, amino acid metabolism (aspartate, glutamine, serine) and ornithine 




5.5 Clonal heterogeneity in human AML – a prognostic parameter? 
 Clonal heterogeneity has been detected in several malignancies, and it is regarded as a 
driving mechanism of disease development and progression because a high degree of 
genetic variability is associated with an increased risk for development of subclones 
with a proliferative advantage, leading to clonal expansion [232, 233]. Clonal 
heterogeneity is also associated with disease that is more aggressive; this association is 
shown at the molecular level and is true for the pre-leukemic myelodysplastic syndrome 
[234]. Acute lymphoblastic leukemia (ALL) is also a hematological bone marrow 
disease characterized by infiltration of morphologically immature and undifferentiated 
hematopoietic cells; these characteristics are similar to those of AML. 
In pediatric ALL, the original clone often gives rise to several subclones, and some of 
these subclones lead to further subclonal diversification [235]. A recent publication 
investigating karyotypic clonal heterogeneity suggests that such heterogeneity is 
associated with adverse prognoses [236]. The authors concluded that the detection of 
subclones by karyotyping adds prognostic impact, especially in the cytogenetic adverse 
risk group. They could not detect any prognostic impact in patients with intermediate or 
core binding–factor AML, which, for this last group, is in line with previous 
observations that additional cytogenetic abnormalities do not have any additional 
negative prognostic impact [237]. The present study is too small to allow analysis of 
patient subsets, but only a minority of our patients had an adverse karyotype, and our 
results suggest that detection of clonal heterogeneity has a prognostic impact for other 
patient subsets, not only those with adverse cytogenetic abnormalities.  
5.6 Chemosensitivity in patients with different pathway activation 
The experience from AML patients treated with BCL-2 inhibitors suggest that high 
BCL-2 expression is associated with high susceptibility to BCL-2 inhibitors; this 
observation suggests that AML cells with high BCL-2 levels are highly dependent on 
this mediator and thereby have an increased susceptibility to and low expression of the 
half maximal inhibitory concentration (IC50) [238, 239]. However, there are exceptional 




BCL-2 levels; this may indicate that for these patients, the low levels allow effective 
inhibition at low drug concentrations. Taken together, these observations suggest that 
effective antileukemic activity at low concentrations is due to either high dependency 
on the targeted mediator or low expression levels that allow therapeutic effects at low 
drug concentrations. 
The antiproliferative in vitro effect of PI3K-Akt-mTOR inhibitors differs between 
patients; our in vitro studies suggest that low constitutive activity is associated with an 
increased antiproliferative effect, but several exceptional patients were seen (article II 
and III). Thus, both mechanisms for significant antileukemic effects may exist for these 
pathway inhibitors as they do for the BCL-2 inhibitors described previously. Low 
constitutive activation may facilitate pathway activation below a critical level, but 
exceptional patients clearly illustrate this is not the only factor that determines 
therapeutic effect.  
 
6 CONCLUDING REMARKS 
In all four articles, we were able to show that AML patients display different constitutive 
activation profiles for the PI3K-Akt-mTOR pathway. These dissimilarities are part of 
more complex phenotypic variations, including transcriptional regulation, cross 
signaling, and cell communication. We examined large groups of patients in each study 
and were able to generate an overview of the heterogeneity of AML patients based on 
the PI3K-Akt-mTOR signaling pathway. By stimulation of leukemic cells with insulin, 
we showed that AML patients are heterogeneous with regard to the effect of insulin on 
PI3K-Akt-mTOR pathway activation, as well as the effects of various inhibitors on 
pathway activation. In the metabolomic studies, we showed AML patient heterogeneity 
relative to PI3K-Akt-mTOR signaling by examining susceptibility or resistance to 
PI3K-Akt-mTOR inhibitors and showing that leukemic cells differ in energy, amino 
acid, and arachidonic acid metabolism. The results also showed that modulation of 
arachidonic acid metabolism alters the activation of mTOR and its downstream 




patients revealed by the activation status of selected components in the PI3K-Akt-
mTOR pathway and found that it was associated with different gene expression profiles 
and an independent prognostic impact. 
 
7 FUTURE PERSPECTIVES 
Our present studies support previous observations suggesting that the PI3K-Akt-mTOR 
pathway is important for disease development and chemosensitivity in AML. They also 
show that patients are heterogeneous with regard to pathway activation profiles. Though 
the results from the initial clinical studies using PI3K/mTOR inhibitors are regarded as 
disappointing by many clinicians [189], one should remember that results in 
relapsed/refractory patients may not be representative of effects in patients treated at the 
time of first diagnosis. Thus, our results suggest that biological identification of patient 
subsets should be evaluated in future clinical studies using this therapeutic strategy. 
Combined treatment, e.g. the combination of different pathway inhibitors (i.e. dual 
pathway inhibition) and the combination of pathway inhibitors with other targeted 
therapies or conventional chemotherapy should also be considered. 
Although the contributions of nearly all components of this pathway can now be 
described in mechanistic detail, there are issues that need to be addressed further, such 
as the signaling pathways may cooperate with other pathways. Thus, further analysis of 
the interrelations of this pathway with other signaling mediators, pathways, and/or 






1. Dohner, H.; Estey, E.; Grimwade, D.; Amadori, S.; Appelbaum, F. R.; Buchner, T.; 
Dombret, H.; Ebert, B. L.; Fenaux, P.; Larson, R. A.; Levine, R. L.; Lo-Coco, F.; Naoe, 
T.; Niederwieser, D.; Ossenkoppele, G. J.; Sanz, M.; Sierra, J.; Tallman, M. S.; Tien, 
H. F.; Wei, A. H.; Lowenberg, B.; Bloomfield, C. D., Diagnosis and management of 
AML in adults: 2017 ELN recommendations from an international expert panel. Blood 
2017, 129, (4), 424-447. 
2. Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; 
Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W., The 2016 revision to the World 
Health Organization classification of myeloid neoplasms and acute leukemia. Blood 
2016, 127, (20), 2391-405. 
3. Almond, L. M.; Charalampakis, M.; Ford, S. J.; Gourevitch, D.; Desai, A., Myeloid 
Sarcoma: Presentation, Diagnosis, and Treatment. Clin Lymphoma Myeloma Leuk 2017, 
17, (5), 263-267. 
4. Ganzel, C.; Douer, D., Extramedullary disease in APL: a real phenomenon to contend 
with or not? Best Pract Res Clin Haematol 2014, 27, (1), 63-8. 
5. Cicconi, L.; Lo-Coco, F., Current management of newly diagnosed acute promyelocytic 
leukemia. Ann Oncol 2016, 27, (8), 1474-81. 
6. Lo-Coco, F.; Cicconi, L., What is the standard regimen for patients with acute 
promyelocytic leukemia? Curr Hematol Malig Rep 2014, 9, (2), 138-43. 
7. Sanz, M. A.; Grimwade, D.; Tallman, M. S.; Lowenberg, B.; Fenaux, P.; Estey, E. H.; 
Naoe, T.; Lengfelder, E.; Buchner, T.; Dohner, H.; Burnett, A. K.; Lo-Coco, F., 
Management of acute promyelocytic leukemia: recommendations from an expert panel 
on behalf of the European LeukemiaNet. Blood 2009, 113, (9), 1875-91. 
8. Chen, W. L.; Wang, J. H.; Zhao, A. H.; Xu, X.; Wang, Y. H.; Chen, T. L.; Li, J. M.; Mi, 
J. Q.; Zhu, Y. M.; Liu, Y. F.; Wang, Y. Y.; Jin, J.; Huang, H.; Wu, D. P.; Li, Y.; Yan, 
X. J.; Yan, J. S.; Li, J. Y.; Wang, S.; Huang, X. J.; Wang, B. S.; Chen, Z.; Chen, S. J.; 
Jia, W., A distinct glucose metabolism signature of acute myeloid leukemia with 
prognostic value. Blood 2014, 124, (10), 1645-54. 
9. Kuo, T. C.; Tian, T. F.; Tseng, Y. J., 3Omics: a web-based systems biology tool for 
analysis, integration and visualization of human transcriptomic, proteomic and 
metabolomic data. BMC Syst Biol 2013, 7, 64. 
10. Roboz, J.; Roboz, G. J., Mass spectrometry in leukemia research and treatment. Expert 
Rev Hematol 2015, 8, (2), 225-35. 
11. Cancer Genome Atlas Research, N.; Ley, T. J.; Miller, C.; Ding, L.; Raphael, B. J.; 
Mungall, A. J.; Robertson, A.; Hoadley, K.; Triche, T. J., Jr.; Laird, P. W.; Baty, J. D.; 
Fulton, L. L.; Fulton, R.; Heath, S. E.; Kalicki-Veizer, J.; Kandoth, C.; Klco, J. M.; 
Koboldt, D. C.; Kanchi, K. L.; Kulkarni, S.; Lamprecht, T. L.; Larson, D. E.; Lin, L.; 
Lu, C.; McLellan, M. D.; McMichael, J. F.; Payton, J.; Schmidt, H.; Spencer, D. H.; 
Tomasson, M. H.; Wallis, J. W.; Wartman, L. D.; Watson, M. A.; Welch, J.; Wendl, M. 
C.; Ally, A.; Balasundaram, M.; Birol, I.; Butterfield, Y.; Chiu, R.; Chu, A.; Chuah, E.; 
Chun, H. J.; Corbett, R.; Dhalla, N.; Guin, R.; He, A.; Hirst, C.; Hirst, M.; Holt, R. A.; 
Jones, S.; Karsan, A.; Lee, D.; Li, H. I.; Marra, M. A.; Mayo, M.; Moore, R. A.; 
Mungall, K.; Parker, J.; Pleasance, E.; Plettner, P.; Schein, J.; Stoll, D.; Swanson, L.; 
Tam, A.; Thiessen, N.; Varhol, R.; Wye, N.; Zhao, Y.; Gabriel, S.; Getz, G.; Sougnez, 
C.; Zou, L.; Leiserson, M. D.; Vandin, F.; Wu, H. T.; Applebaum, F.; Baylin, S. B.; 




Zhang, N.; Ferguson, M. L.; Adams, C.; Black, A.; Bowen, J.; Gastier-Foster, J.; 
Grossman, T.; Lichtenberg, T.; Wise, L.; Davidsen, T.; Demchok, J. A.; Shaw, K. R.; 
Sheth, M.; Sofia, H. J.; Yang, L.; Downing, J. R.; Eley, G., Genomic and epigenomic 
landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368, (22), 
2059-74. 
12. Shivarov, V.; Dolnik, A.; Lang, K. M.; Kronke, J.; Kuchenbauer, F.; Paschka, P.; 
Gaidzik, V. I.; Dohner, H.; Schlenk, R. F.; Dohner, K.; Bullinger, L., MicroRNA 
expression-based outcome prediction in acute myeloid leukemia: novel insights through 
cross-platform integrative analyses. Haematologica 2016, 101, (11), E454-E456. 
13. Dohner, H.; Estey, E. H.; Amadori, S.; Appelbaum, F. R.; Buchner, T.; Burnett, A. K.; 
Dombret, H.; Fenaux, P.; Grimwade, D.; Larson, R. A.; Lo-Coco, F.; Naoe, T.; 
Niederwieser, D.; Ossenkoppele, G. J.; Sanz, M. A.; Sierra, J.; Tallman, M. S.; 
Lowenberg, B.; Bloomfield, C. D.; European, L., Diagnosis and management of acute 
myeloid leukemia in adults: recommendations from an international expert panel, on 
behalf of the European LeukemiaNet. Blood 2010, 115, (3), 453-74. 
14. Navada, S. C.; Steinmann, J.; Lubbert, M.; Silverman, L. R., Clinical development of 
demethylating agents in hematology. J Clin Invest 2014, 124, (1), 40-6. 
15. Szmigielska-Kaplon, A.; Robak, T., Hypomethylating agents in the treatment of 
myelodysplastic syndromes and myeloid leukemia. Curr Cancer Drug Targets 2011, 
11, (7), 837-48. 
16. Brandwein, J. M.; Zhu, N.; Kumar, R.; Leber, B.; Sabloff, M.; Sandhu, I.; Kassis, J.; 
Olney, H. J.; Elemary, M.; Schuh, A. C., Treatment of older patients with acute myeloid 
leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res 2017, 7, (4), 
30-40. 
17. Burnett, A. K.; Milligan, D.; Prentice, A. G.; Goldstone, A. H.; McMullin, M. F.; Hills, 
R. K.; Wheatley, K., A comparison of low-dose cytarabine and hydroxyurea with or 
without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic 
syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109, (6), 
1114-1124. 
18. Menzin, J.; Lang, K.; Earle, C. C.; Kerney, D.; Mallick, R., The outcomes and costs of 
acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162, (14), 1597-
1603. 
19. Fredly, H.; Ersvaer, E.; Kittang, A. O.; Tsykunova, G.; Gjertsen, B. T.; Bruserud, O., 
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as 
disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics 2013, 5. 
20. Fredly, H.; Gjertsen, B. T.; Bruserud, O., Histone deacetylase inhibition in the treatment 
of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the 
clinical and experimental evidence for combining valproic acid with other antileukemic 
agents. Clin Epigenetics 2013, 5, (1), 12. 
21. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Santini, V.; Gattermann, N.; Germing, 
U.; Sanz, G.; List, A. F.; Gore, S.; Seymour, J. F.; Dombret, H.; Backstrom, J.; 
Zimmerman, L.; McKenzie, D.; Beach, C. L.; Silverman, L. R., Azacitidine Prolongs 
Overall Survival Compared With Conventional Care Regimens in Elderly Patients With 
Low Bone Marrow Blast Count Acute Myeloid Leukemia. J Clin Oncol 2010, 28, (4), 
562-569. 
22. Garcia-Manero, G.; Jabbour, E.; Borthakur, G.; Faderl, S.; Estrov, Z.; Yang, H.; 
Maddipoti, S.; Godley, L. A.; Gabrail, N.; Berdeja, J. G.; Nadeem, A.; Kassalow, L.; 




Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol 2013, 31, (20), 
2548-+. 
23. Cornelissen, J. J.; Gratwohl, A.; Schlenk, R. F.; Sierra, J.; Bornhauser, M.; Juliusson, 
G.; Racil, Z.; Rowe, J. M.; Russell, N.; Mohty, M.; Lowenberg, B.; Socie, G.; 
Niederwieser, D.; Ossenkoppele, G. J., The European LeukemiaNet AML Working 
Party consensus statement on allogeneic HSCT for patients with AML in remission: an 
integrated-risk adapted approach. Nat Rev Clin Oncol 2012, 9, (10), 579-590. 
24. Canaani, J.; Labopin, M.; Socie, G.; Nihtinen, A.; Huynh, A.; Cornelissen, J.; 
Deconinck, E.; Gedde-Dahl, T.; Forcade, E.; Chevallier, P.; Bourhis, J. H.; Blaise, D.; 
Mohty, M.; Nagler, A., Long term impact of hyperleukocytosis in newly diagnosed 
acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An 
analysis from the acute leukemia working party of the EBMT. American Journal of 
Hematology 2017, 92, (7), 653-659. 
25. Smith, C., Hematopoietic stem cells and hematopoiesis. Cancer Control 2003, 10, (1), 
9-16. 
26. Majeti, R.; Park, C. Y.; Weissman, I. L., Identification of a hierarchy of multipotent 
hematopoietic progenitors in human cord blood. Cell Stem Cell 2007, 1, (6), 635-45. 
27. Manz, M. G.; Miyamoto, T.; Akashi, K.; Weissman, I. L., Prospective isolation of 
human clonogenic common myeloid progenitors. P Natl Acad Sci USA 2002, 99, (18), 
11872-11877. 
28. Edvardsson, L.; Dykes, J.; Olofsson, T., Isolation and characterization of human 
myeloid progenitor populations - TpoR as discriminator between common myeloid and 
megakaryocyte/erythroid progenitors. Exp Hematol 2006, 34, (5), 599-609. 
29. Hamburger, A. W.; Salmon, S. E., Primary bioassay of human tumor stem cells. Science 
1977, 197, (4302), 461-3. 
30. Wang, J. C.; Dick, J. E., Cancer stem cells: lessons from leukemia. Trends Cell Biol 
2005, 15, (9), 494-501. 
31. Eppert, K.; Takenaka, K.; Lechman, E. R.; Waldron, L.; Nilsson, B.; van Galen, P.; 
Metzeler, K. H.; Poeppl, A.; Ling, V.; Beyene, J.; Canty, A. J.; Danska, J. S.; Bohlander, 
S. K.; Buske, C.; Minden, M. D.; Golub, T. R.; Jurisica, I.; Ebert, B. L.; Dick, J. E., 
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat 
Med 2011, 17, (9), 1086-U91. 
32. Bruserud, O.; Gjertsen, B. T.; Foss, B.; Huang, T. S., New strategies in the treatment of 
acute myelogenous leukemia (AML): In vitro culture of AML cells - The present use in 
experimental studies and the possible importance for future therapeutic approaches. 
Stem Cells 2001, 19, (1), 1-11. 
33. Hanahan, D.; Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, (1), 57-70. 
34. Bruserud, O.; Aasebo, E.; Hernandez-Valladares, M.; Tsykunova, G.; Reikvam, H., 
Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological 
background for possible strategies. Expert Opin Drug Discov 2017, 12, (10), 1053-
1065. 
35. Mackillop, W. J.; Ciampi, A.; Till, J. E.; Buick, R. N., A stem cell model of human 
tumor growth: implications for tumor cell clonogenic assays. J Natl Cancer Inst 1983, 
70, (1), 9-16. 
36. Hope, K. J.; Jin, L.; Dick, J. E., Human acute myeloid leukemia stem cells. Arch Med 
Res 2003, 34, (6), 507-14. 
37. Miyamoto, T.; Weissman, I. L.; Akashi, K., AML1/ETO-expressing nonleukemic stem 
cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl 




38. Bonnet, D.; Dick, J. E., Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med 1997, 3, (7), 730-737. 
39. Reinisch, A.; Chan, S. M.; Thomas, D.; Majeti, R., Biology and Clinical Relevance of 
Acute Myeloid Leukemia Stem Cells. Semin Hematol 2015, 52, (3), 150-164. 
40. Taussig, D. C.; Vargaftig, J.; Miraki-Moud, F.; Griessinger, E.; Sharrock, K.; Luke, T.; 
Lillington, D.; Oakervee, H.; Cavenagh, J.; Agrawal, S. G.; Lister, T. A.; Gribben, J. 
G.; Bonnet, D., Leukemia-initiating cells from some acute myeloid leukemia patients 
with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010, 115, (10), 
1976-1984. 
41. Goardon, N.; Marchi, E.; Atzberger, A.; Quek, L.; Schuh, A.; Soneji, S.; Woll, P.; Mead, 
A.; Alford, K. A.; Rout, R.; Chaudhury, S.; Gilkes, A.; Knapper, S.; Beldjord, K.; 
Begum, S.; Rose, S.; Geddes, N.; Griffiths, M.; Standen, G.; Sternberg, A.; Cavenagh, 
J.; Hunter, H.; Bowen, D.; Killick, S.; Robinson, L.; Price, A.; Macintyre, E.; Virgo, P.; 
Burnett, A.; Craddock, C.; Enver, T.; Jacobsen, S. E.; Porcher, C.; Vyas, P., Coexistence 
of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer 
Cell 2011, 19, (1), 138-52. 
42. Saito, Y.; Kitamura, H.; Hijikata, A.; Tomizawa-Murasawa, M.; Tanaka, S.; Takagi, S.; 
Uchida, N.; Suzuki, N.; Sone, A.; Najima, Y.; Ozawa, H.; Wake, A.; Taniguchi, S.; 
Shultz, L. D.; Ohara, O.; Ishikawa, F., Identification of therapeutic targets for quiescent, 
chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010, 2, (17), 
17ra9. 
43. Jordan, C. T.; Upchurch, D.; Szilvassy, S. J.; Guzman, M. L.; Howard, D. S.; Pettigrew, 
A. L.; Meyerrose, T.; Rossi, R.; Grimes, B.; Rizzieri, D. A.; Luger, S. M.; Phillips, G. 
L., The interleukin-3 receptor alpha chain is a unique marker for human acute 
myelogenous leukemia stem cells. Leukemia 2000, 14, (10), 1777-1784. 
44. Majeti, R.; Chao, M. P.; Alizadeh, A. A.; Pang, W. W.; Jaiswal, S.; Gibbs, K. D.; van 
Rooijen, N.; Weissman, I. L., CD47 Is an Adverse Prognostic Factor and Therapeutic 
Antibody Target on Human Acute Myeloid Leukemia Stem Cells. Cell 2009, 138, (2), 
286-299. 
45. Bruserud, O., Effects of endogenous interleukin 1 on blast cells derived from acute 
myelogenous leukemia patients. Leukemia Res 1996, 20, (1), 65-73. 
46. van Rhenen, A.; van Dongen, G. A. M. S.; Kelder, A.; Rombouts, E. J.; Feller, N.; 
Moshaver, B.; Stigter-van Walsum, M.; Zweegman, S.; Ossenkoppele, G. J.; 
Schuurhuis, G. J., The novel AML stem cell-associated antigen CLL-1 aids in 
discrimination between normal and leukemic stem cells. Blood 2007, 110, (7), 2659-
2666. 
47. Hosen, N.; Park, C. Y.; Tatsumi, N.; Oji, Y.; Sugiyama, H.; Gramatzki, M.; Krensky, 
A. M.; Weissman, I. L., CD96 is a leukemic stem cell-specific marker in human acute 
myeloid leukemia. P Natl Acad Sci USA 2007, 104, (26), 11008-11013. 
48. Siveen, K. S.; Uddin, S.; Mohammad, R. M., Targeting acute myeloid leukemia stem 
cell signaling by natural products. Mol Cancer 2017, 16. 
49. Reikvam, H.; Oyan, A. M.; Kalland, K. H.; Hovland, R.; Hatfield, K. J.; Bruserud, O., 
Differences in proliferative capacity of primary human acute myelogenous leukaemia 
cells are associated with altered gene expression profiles and can be used for 
subclassification of patients. Cell Proliferat 2013, 46, (5), 554-562. 
50. Chan, S. M.; Majeti, R., Role of DNMT3A, TET2, and IDH1/2 mutations in pre-
leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013, 98, (6), 648-57. 
51. Majeti, R., Clonal evolution of pre-leukemic hematopoietic stem cells precedes human 




52. Mazumdar, C.; Shen, Y.; Xavy, S.; Zhao, F.; Reinisch, A.; Li, R.; Corces, M. R.; Flynn, 
R. A.; Buenrostro, J. D.; Chan, S. M.; Thomas, D.; Koenig, J. L.; Hong, W. J.; Chang, 
H. Y.; Majeti, R., Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem 
Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem 
Cell 2015, 17, (6), 675-88. 
53. Shlush, L. I.; Mitchell, A.; Heisler, L.; Abelson, S.; Ng, S. W. K.; Trotman-Grant, A.; 
Medeiros, J. J. F.; Rao-Bhatia, A.; Jaciw-Zurakowsky, I.; Marke, R.; McLeod, J. L.; 
Doedens, M.; Bader, G.; Voisin, V.; Xu, C.; McPherson, J. D.; Hudson, T. J.; Wang, J. 
C. Y.; Minden, M. D.; Dick, J. E., Tracing the origins of relapse in acute myeloid 
leukaemia to stem cells. Nature 2017, 547, (7661), 104-108. 
54. Sarkozy, C.; Gardin, C.; Gachard, N.; Merabet, F.; Turlure, P.; Malfuson, J. V.; Pautas, 
C.; Micol, J. B.; Thomas, X.; Quesnel, B.; Celli-Lebras, K.; Preudhomme, C.; Terre, C.; 
Fenaux, P.; Chevret, S.; Castaigne, S.; Dombret, H., Outcome of older patients with 
acute myeloid leukemia in first relapse. Am J Hematol 2013, 88, (9), 758-64. 
55. Schofield, R., Relationship between Spleen Colony-Forming Cell and Hematopoietic 
Stem-Cell - Hypothesis. Blood Cells 1978, 4, (1-2), 7-25. 
56. Anthony, B. A.; Link, D. C., Regulation of hematopoietic stem cells by bone marrow 
stromal cells. Trends Immunol 2014, 35, (1), 32-7. 
57. Nombela-Arrieta, C.; Isringhausen, S., The Role of the Bone Marrow Stromal 
Compartment in the Hematopoietic Response to Microbial Infections. Front Immunol 
2016, 7, 689. 
58. Baksh, D.; Song, L.; Tuan, R. S., Adult mesenchymal stem cells: characterization, 
differentiation, and application in cell and gene therapy. J Cell Mol Med 2004, 8, (3), 
301-16. 
59. Mendez-Ferrer, S.; Michurina, T. V.; Ferraro, F.; Mazloom, A. R.; MacArthur, B. D.; 
Lira, S. A.; Scadden, D. T.; Ma'ayan, A.; Enikolopov, G. N.; Frenette, P. S., 
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 
2010, 466, (7308), 829-U59. 
60. Morrison, S. J.; Scadden, D. T., The bone marrow niche for haematopoietic stem cells. 
Nature 2014, 505, (7483), 327-334. 
61. Ehninger, A.; Trumpp, A., The bone marrow stem cell niche grows up: mesenchymal 
stem cells and macrophages move in. The Journal of Experimental Medicine 2011, 208, 
(3), 421-8. 
62. Hanoun, M.; Frenette, P. S., This Niche Is a Maze; An Amazing Niche. Cell Stem Cell 
2013, 12, (4), 391-392. 
63. Ding, L.; Morrison, S. J., Haematopoietic stem cells and early lymphoid progenitors 
occupy distinct bone marrow niches. Nature 2013, 495, (7440), 231-235. 
64. Ding, L.; Saunders, T. L.; Enikolopov, G.; Morrison, S. J., Endothelial and perivascular 
cells maintain haematopoietic stem cells. Nature 2012, 481, (7382), 457-U65. 
65. Greenbaum, A.; Hsu, Y. M. S.; Day, R. B.; Schuettpelz, L. G.; Christopher, M. J.; 
Borgerding, J. N.; Nagasawa, T.; Link, D. C., CXCL12 in early mesenchymal 
progenitors is. required for haematopoietic stem-cell maintenance. Nature 2013, 495, 
(7440), 227-230. 
66. Rouault-Pierre, K.; Lopez-Onieva, L.; Foster, K.; Anjos-Afonso, F.; Lamrissi-Garcia, 
I.; Serrano-Sanchez, M.; Mitter, R.; Ivanovic, Z.; de Verneuil, H.; Gribben, J.; Taussig, 
D.; Rezvani, H. R.; Mazurier, F.; Bonnet, D., HIF-2alpha protects human hematopoietic 
stem/progenitors and acute myeloid leukemic cells from apoptosis induced by 




67. Glenjen, N.; Ersvaer, E.; Ryningen, A.; Bruserud, O., In vitro effects of native human 
acute myelogenous leukemia blasts on fibroblasts and osteoblasts. Int J Cancer 2004, 
111, (6), 858-67. 
68. Glenjen, N. I.; Hatfield, K.; Bruserud, O., Coculture of native human acute myelogenous 
leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular 
endothelial growth factor levels. Eur J Haematol 2005, 74, (1), 24-34. 
69. Bruserud, O.; Ryningen, A.; Wergeland, L.; Glenjen, N. I.; Gjertsen, B. T., Osteoblasts 
increase proliferation and release of pro-angiogenic interleukin 8 by native human acute 
myelogenous leukemia blasts. Haematologica 2004, 89, (4), 391-402. 
70. Hatfield, K.; Ryningen, A.; Corbascio, M.; Bruserud, O., Microvascular endothelial 
cells increase proliferation and inhibit apoptosis of native human acute myelogenous 
leukemia blasts. Int J Cancer 2006, 119, (10), 2313-21. 
71. Hatfield, K.; Oyan, A. M.; Ersvaer, E.; Kalland, K. H.; Lassalle, P.; Gjertsen, B. T.; 
Bruserud, O., Primary human acute myeloid leukaemia cells increase the proliferation 
of microvascular endothelial cells through the release of soluble mediators. Brit J 
Haematol 2009, 144, (1), 53-68. 
72. Hatfield, K. J.; Evensen, L.; Reikvam, H.; Lorens, J. B.; Bruserud, O., Soluble mediators 
released by acute myeloid leukemia cells increase capillary-like networks. European 
Journal of Haematology 2012, 89, (6), 478-490. 
73. Reikvam, H.; Brenner, A. K.; Hagen, K. M.; Liseth, K.; Skrede, S.; Hatfield, K. J.; 
Bruserud, O., The cytokine-mediated crosstalk between primary human acute myeloid 
cells and mesenchymal stem cells alters the local cytokine network and the global gene 
expression profile of the mesenchymal cells. Stem Cell Res 2015, 15, (3), 530-541. 
74. Ito, S.; Barrett, A. J.; Dutra, A.; Pak, E.; Miner, S.; Keyvanfar, K.; Hensel, N. F.; 
Rezvani, K.; Muranski, P.; Liu, P.; Melenhorst, J. J.; Larochelle, A., Long term 
maintenance of myeloid leukemic stem cells cultured with unrelated human 
mesenchymal stromal cells. Stem Cell Res 2015, 14, (1), 95-104. 
75. Brenner, A. K.; Nepstad, I.; Bruserud, O., Mesenchymal stem cells support survival and 
Proliferation of Primary human acute Myeloid leukemia cells through heterogeneous 
Molecular Mechanisms. Front Immunol 2017, 8. 
76. Mantovani, A.; Vecchi, A.; Allavena, P., Pharmacological modulation of monocytes 
and macrophages. Curr Opin Pharmacol 2014, 17, 38-44. 
77. Biswas, D.; Milne, T. A.; Basrur, V.; Kim, J.; Elenitoba-Johnson, K. S. J.; Allis, C. D.; 
Roeder, R. G., Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion 
proteins through distinct partner protein complexes. P Natl Acad Sci USA 2011, 108, 
(38), 15751-15756. 
78. Brenner, A. K.; Reikvam, H.; Bruserud, Ø., A Subset of Patients with Acute Myeloid 
Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and 
Altered Expression of Transcriptional as well as Angiogenic Regulators. Front Immunol 
2016, 7. 
79. Brenner, A.; Andersson Tvedt, T.; Bruserud, Ø., The Complexity of Targeting PI3K-
Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of 
Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and 
Immunocompetent Cells. Molecules 2016, 21, (11), 1512. 
80. Tvedt, T. H.; Nepstad, I.; Bruserud, O., Antileukemic effects of midostaurin in acute 
myeloid leukemia - the possible importance of multikinase inhibition in leukemic as 
well as nonleukemic stromal cells. Expert Opin Inv Drug 2017, 26, (3), 343-355. 
81. Bruserud, O.; Hovland, R.; Wergeland, L.; Huang, T. S.; Gjertsen, B. T., Flt3-mediated 




characterization of the effects of Flt3-ligand in AML cell populations with and without 
genetic Flt3 abnormalities. Haematologica 2003, 88, (4), 416-428. 
82. Reikvam, H.; Nepstad, I.; Bruserud, O.; Hatfield, K. J., Pharmacological targeting of 
the PI3K/mTOR pathway alters the release of angioregulatory mediators both from 
primary human acute myeloid leukemia cells and their neighboring stromal cells. 
Oncotarget 2013, 4, (6), 830-43. 
83. Bruserud, O.; Foss, B.; Petersen, H., Hematopoietic growth factors in patients receiving 
intensive chemotherapy for malignant disorders: studies of granulocyte-colony 
stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-
CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Eur Cytokine Netw 2001, 12, (2), 
231-8. 
84. Yi, H.; Zeng, D.; Shen, Z.; Liao, J.; Wang, X.; Liu, Y.; Zhang, X.; Kong, P., Integrin 
alphavbeta3 enhances beta-catenin signaling in acute myeloid leukemia harboring Fms-
like tyrosine kinase-3 internal tandem duplication mutations: implications for 
microenvironment influence on sorafenib sensitivity. Oncotarget 2016, 7, (26), 40387-
40397. 
85. Cordeiro-Spinetti, E.; Taichman, R. S.; Balduino, A., The bone marrow endosteal niche: 
how far from the surface? Journal of cellular biochemistry 2015, 116, (1), 6-11. 
86. Kunisaki, Y.; Bruns, I.; Scheiermann, C.; Ahmed, J.; Pinho, S.; Zhang, D. C.; 
Mizoguchi, T.; Wei, Q. Z.; Lucas, D.; Ito, K.; Mar, J. C.; Bergman, A.; Frenette, P. S., 
Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 2013, 502, 
(7473), 637-+. 
87. Orford, K. W.; Scadden, D. T., Deconstructing stem cell self-renewal: genetic insights 
into cell-cycle regulation. Nat Rev Genet 2008, 9, (2), 115-128. 
88. Pietras, E. M.; Warr, M. R.; Passegue, E., Cell cycle regulation in hematopoietic stem 
cells. J Cell Biol 2011, 195, (5), 709-20. 
89. Frenette, P. S.; Pinho, S.; Lucas, D.; Scheiermann, C., Mesenchymal stem cell: keystone 
of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. 
Annu Rev Immunol 2013, 31, 285-316. 
90. Schepers, K.; Campbell, T. B.; Passegue, E., Normal and leukemic stem cell niches: 
insights and therapeutic opportunities. Cell Stem Cell 2015, 16, (3), 254-67. 
91. Bonnet, D., Hematopoietic stem cell niche. First edition. ed.; Elsevier/Academic Press: 
Cambridge, MA, 2017; p ix, 175 pages. 
92. Haylock, D. N.; Nilsson, S. K., Osteopontin: a bridge between bone and blood. Brit J 
Haematol 2006, 134, (5), 467-474. 
93. Nilsson, S. K.; Johnston, H. M.; Whitty, G. A.; Williams, B.; Webb, R. J.; Denhardt, D. 
T.; Bertoncello, I.; Bendall, L. J.; Simmons, P. J.; Haylock, D. N., Osteopontin, a key 
component of the hematopoietic stem cell niche and regulator of primitive 
hematopoietic progenitor cells. Blood 2005, 106, (4), 1232-1239. 
94. Taichman, R. S., Blood and bone: two tissues whose fates are intertwined to create the 
hematopoietic stem-cell niche. Blood 2005, 105, (7), 2631-9. 
95. Liersch, R.; Gerss, J.; Schliemann, C.; Bayer, M.; Schwoppe, C.; Biermann, C.; 
Appelmann, I.; Kessler, T.; Lowenberg, B.; Buchner, T.; Hiddemann, W.; Muller-
Tidow, C.; Berdel, W. E.; Mesters, R., Osteopontin is a prognostic factor for survival of 
acute myeloid leukemia patients. Blood 2012, 119, (22), 5215-5220. 
96. Chen, Y. B.; Ren, S. M.; Li, S. D.; Du, Z., Prognostic significance of osteopontin in 




97. Brenner, A. K.; Aasebo, E.; Hernandez-Valladares, M.; Selheim, F.; Berven, F.; 
Bruserud, O., Rethinking the role of osteopontin in human acute myeloid leukemia. 
Leuk Lymphoma 2017, 58, (6), 1494-1497. 
98. Hatfield, K. J.; Bedringsaas, S. L.; Ryningen, A.; Gjertsen, B. T.; Bruserud, O., Hypoxia 
increases HIF-1alpha expression and constitutive cytokine release by primary human 
acute myeloid leukaemia cells. Eur Cytokine Netw 2010, 21, (3), 154-64. 
99. Saxton, R. A.; Sabatini, D. M., mTOR Signaling in Growth, Metabolism, and Disease. 
Cell 2017, 169, (2), 361-371. 
100. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B., Understanding the Warburg 
effect: the metabolic requirements of cell proliferation. Science 2009, 324, (5930), 
1029-33. 
101. Ward, P. S.; Thompson, C. B., Signaling in control of cell growth and metabolism. Cold 
Spring Harb Perspect Biol 2012, 4, (7), a006783. 
102. Braccini, L.; Ciraolo, E.; Martini, M.; Pirali, T.; Germena, G.; Rolfo, K.; Hirsch, E., 
PI3K keeps the balance between metabolism and cancer. Adv Biol Regul 2012, 52, (3), 
389-405. 
103. Farge, T.; Saland, E.; de Toni, F.; Aroua, N.; Hosseini, M.; Perry, R.; Bosc, C.; Sugita, 
M.; Stuani, L.; Fraisse, M.; Scotland, S.; Larrue, C.; Boutzen, H.; Féliu, V.; Nicolau-
Travers, M.-L.; Cassant-Sourdy, S.; Broin, N.; David, M.; Serhan, N.; Sarry, A.; 
Tavitian, S.; Kaoma, T.; Vallar, L.; Iacovoni, J.; Linares, L. K.; Montersino, C.; 
Castellano, R.; Griessinger, E.; Collette, Y.; Duchamp, O.; Barreira, Y.; Hirsch, P.; 
Palama, T.; Gales, L.; Delhommeau, F.; Garmy-Susini, B.; Portais, J.-C.; Vergez, F.; 
Selak, M. A.; Danet-Desnoyers, G.; Carroll, M.; Récher, C.; Sarry, J.-E., Chemotherapy 
Resistant Human Acute Myeloid Leukemia Cells are Not Enriched for Leukemic Stem 
Cells but Require Oxidative Metabolism. Cancer discovery 2017, 7, (7), 716-735. 
104. Hanahan, D.; Weinberg, R. A., Hallmarks of cancer: the next generation. Cell 2011, 
144, (5), 646-74. 
105. Herst, P. M.; Howman, R. A.; Neeson, P. J.; Berridge, M. V.; Ritchie, D. S., The level 
of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for 
clinical outcome. J Leukocyte Biol 2011, 89, (1), 51-55. 
106. Samudio, I.; Fiegl, M.; McQueen, T.; Clise-Dwyer, K.; Andreeff, M., The Warburg 
effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling 
associated with uncoupling protein 2 activation. Cancer Research 2008, 68, (13), 5198-
5205. 
107. Elstrom, R. L.; Bauer, D. E.; Buzzai, M.; Karnauskas, R.; Harris, M. H.; Plas, D. R.; 
Zhuang, H.; Cinalli, R. M.; Alavi, A.; Rudin, C. M.; Thompson, C. B., Akt stimulates 
aerobic glycolysis in cancer cells. Cancer Res 2004, 64, (11), 3892-9. 
108. Qin, L.; Tian, Y.; Yu, Z.; Shi, D.; Wang, J.; Zhang, C.; Peng, R.; Chen, X.; Liu, C.; 
Chen, Y.; Huang, W.; Deng, W., Targeting PDK1 with dichloroacetophenone to inhibit 
acute myeloid leukemia (AML) cell growth. Oncotarget 2016, 7, (2), 1395-407. 
109. Kim, J. W.; Tchernyshyov, I.; Semenza, G. L.; Dang, C. V., HIF-1-mediated expression 
of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation 
to hypoxia. Cell Metabolism 2006, 3, (3), 177-185. 
110. Duvel, K.; Yecies, J. L.; Menon, S.; Raman, P.; Lipovsky, A. I.; Souza, A. L.; 
Triantafellow, E.; Ma, Q.; Gorski, R.; Cleaver, S.; Vander Heiden, M. G.; MacKeigan, 
J. P.; Finan, P. M.; Clish, C. B.; Murphy, L. O.; Manning, B. D., Activation of a 
metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010, 




111. Poulain, L.; Sujobert, P.; Zylbersztejn, F.; Barreau, S.; Stuani, L.; Lambert, M.; Palama, 
T. L.; Chesnais, V.; Birsen, R.; Vergez, F.; Farge, T.; Chenevier-Gobeaux, C.; Fraisse, 
M.; Bouillaud, F.; Debeissat, C.; Herault, O.; Recher, C.; Lacombe, C.; Fontenay, M.; 
Mayeux, P.; Maciel, T. T.; Portais, J. C.; Sarry, J. E.; Tamburini, J.; Bouscary, D.; 
Chapuis, N., High mTORC1 activity drives glycolysis addiction and sensitivity to 
G6PD inhibition in acute myeloid leukemia cells. Leukemia 2017, 31, (11), 2326-2335. 
112. Uings, I. J.; Farrow, S. N., Cell receptors and cell signalling. Mol Pathol 2000, 53, (6), 
295-9. 
113. Kornblau, S. M.; Womble, M.; Qiu, Y. H.; Jackson, C. E.; Chen, W. J.; Konopleva, M.; 
Estey, E. H.; Andreeff, M., Simultaneous activation of multiple signal transduction 
pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108, (7), 
2358-2365. 
114. Reuter, C. W.; Morgan, M. A.; Bergmann, L., Targeting the Ras signaling pathway: a 
rational, mechanism-based treatment for hematologic malignancies? Blood 2000, 96, 
(5), 1655-69. 
115. Steelman, L. S.; Pohnert, S. C.; Shelton, J. G.; Franklin, R. A.; Bertrand, F. E.; 
McCubrey, J. A., JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle 
progression and leukemogenesis. Leukemia 2004, 18, (2), 189-218. 
116. Gilliland, D. G.; Tallman, M. S., Focus on acute leukemias. Cancer Cell 2002, 1, (5), 
417-20. 
117. Fruman, D. A.; Rommel, C., PI3K and cancer: lessons, challenges and opportunities. 
Nat Rev Drug Discov 2014, 13, (2), 140-56. 
118. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B., Exploiting the 
PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4, (12), 988-
1004. 
119. Sujobert, P.; Bardet, V.; Cornillet-Lefebvre, P.; Hayflick, J. S.; Prie, N.; Verdier, F.; 
Vanhaesebroeck, B.; Muller, O.; Pesce, F.; Ifrah, N.; Hunault-Berger, M.; Berthou, C.; 
Villemagne, B.; Jourdan, E.; Audhuy, B.; Solary, E.; Witz, B.; Harousseau, J. L.; 
Himberlin, C.; Lamy, T.; Lioure, B.; Cahn, J. Y.; Dreyfus, F.; Mayeux, P.; Lacombe, 
C.; Bouscary, D., Essential role for the p110delta isoform in phosphoinositide 3-kinase 
activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106, (3), 1063-
6. 
120. Piddock, R. E.; Bowles, K. M.; Rushworth, S. A., The Role of PI3K Isoforms in 
Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid 
Leukemia and Multiple Myeloma. Cancers 2017, 9, (4). 
121. Bellacosa, A.; Testa, J. R.; Moore, R.; Larue, L., A portrait of AKT kinases: human 
cancer and animal models depict a family with strong individualities. Cancer Biol Ther 
2004, 3, (3), 268-75. 
122. Manning, B. D.; Cantley, L. C., AKT/PKB signaling: Navigating downstream. Cell 
2007, 129, (7), 1261-1274. 
123. Burgering, B. M.; Coffer, P. J., Protein kinase B (c-Akt) in phosphatidylinositol-3-OH 
kinase signal transduction. Nature 1995, 376, (6541), 599-602. 
124. Schmitz, K. J.; Lang, H.; Wohlschlaeger, J.; Sotiropoulos, G. C.; Reis, H.; Schmid, K. 
W.; Baba, H. A., AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. 
World J Gastroenterol 2007, 13, (48), 6470-7. 
125. Kunz, J.; Henriquez, R.; Schneider, U.; Deuter-Reinhard, M.; Movva, N. R.; Hall, M. 
N., Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase 




126. Dowling, R. J. O.; Topisirovic, I.; Fonseca, B. D.; Sonenberg, N., Dissecting the role of 
mTOR: Lessons from mTOR inhibitors. Bba-Proteins Proteom 2010, 1804, (3), 433-
439. 
127. Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S. N.; Jung, S. Y.; Huang, Q. J.; Qin, 
J.; Su, B., SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt 
phosphorylation and substrate specificity. Cell 2006, 127, (1), 125-137. 
128. Kim, J. E.; Chen, J., Regulation of peroxisome proliferator-activated receptor-gamma 
activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 
2004, 53, (11), 2748-56. 
129. Peterson, T. R.; Laplante, M.; Thoreen, C. C.; Sancak, Y.; Kang, S. A.; Kuehl, W. M.; 
Gray, N. S.; Sabatini, D. M., DEPTOR Is an mTOR Inhibitor Frequently Overexpressed 
in Multiple Myeloma Cells and Required for Their Survival. Cell 2009, 137, (5), 873-
886. 
130. Frias, M. A.; Thoreen, C. C.; Jaffe, J. D.; Schroder, W.; Sculley, T.; Carr, S. A.; Sabatini, 
D. M., mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three 
distinct mTORC2s. Curr Biol 2006, 16, (18), 1865-1870. 
131. Richter, J. D.; Sonenberg, N., Regulation of cap-dependent translation by eIF4E 
inhibitory proteins. Nature 2005, 433, (7025), 477-480. 
132. Bai, X.; Ma, D.; Liu, A.; Shen, X.; Wang, Q. J.; Liu, Y.; Jiang, Y., Rheb activates mTOR 
by antagonizing its endogenous inhibitor, FKBP38. Science 2007, 318, (5852), 977-80. 
133. Proud, C. G., Cell signaling. mTOR, unleashed. Science 2007, 318, (5852), 926-7. 
134. Kandoth, C.; McLellan, M. D.; Vandin, F.; Ye, K.; Niu, B.; Lu, C.; Xie, M.; Zhang, Q.; 
McMichael, J. F.; Wyczalkowski, M. A.; Leiserson, M. D.; Miller, C. A.; Welch, J. S.; 
Walter, M. J.; Wendl, M. C.; Ley, T. J.; Wilson, R. K.; Raphael, B. J.; Ding, L., 
Mutational landscape and significance across 12 major cancer types. Nature 2013, 502, 
(7471), 333-9. 
135. Long, X.; Lin, Y.; Ortiz-Vega, S.; Yonezawa, K.; Avruch, J., Rheb binds and regulates 
the mTOR kinase. Curr Biol 2005, 15, (8), 702-713. 
136. Parmar, N.; Tamanoi, F., Rheb G-Proteins and the Activation of mTORC1. Enzymes 
2010, 27, 39-56. 
137. Kornblau, S. M.; Tibes, R.; Qiu, Y. H.; Chen, W.; Kantarjian, H. M.; Andreeff, M.; 
Coombes, K. R.; Mills, G. B., Functional proteomic profiling of AML predicts response 
and survival. Blood 2009, 113, (1), 154-64. 
138. Min, Y. H.; Eom, J. I.; Cheong, J. W.; Maeng, H. O.; Kim, J. Y.; Jeung, H. K.; Lee, S. 
T.; Lee, M. H.; Hahn, J. S.; Ko, Y. W., Constitutive phosphorylation of Akt/PKB protein 
in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003, 17, 
(5), 995-997. 
139. Chen, W. N.; Drakos, E.; Grammatikakis, I.; Schlette, E. J.; Li, J. A.; Leventaki, V.; 
Staikou-Drakopoulou, E.; Patsouris, E.; Panayiotidis, P.; Medeiros, L. J.; Rassidakis, G. 
Z., mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-
mutated acute myeloid leukemia cells. Mol Cancer 2010, 9. 
140. Brandts, C. H.; Sargin, B.; Rode, M.; Biermann, C.; Lindtner, B.; Schwable, J.; Buerger, 
H.; Muller-Tidow, C.; Choudhary, C.; McMahon, M.; Berdel, W. E.; Serve, H., 
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for 
increased survival, proliferation, and myeloid transformation. Cancer Res 2005, 65, 
(21), 9643-50. 
141. Levis, M., FLT3 mutations in acute myeloid leukemia: what is the best approach in 
2013? Hematology / the Education Program of the American Society of Hematology. 




142. Vanhaesebroeck, B.; Waterfield, M. D., Signaling by distinct classes of 
phosphoinositide 3-kinases. Exp Cell Res 1999, 253, (1), 239-54. 
143. Kubota, Y.; Ohnishi, H.; Kitanaka, A.; Ishida, T.; Tanaka, T., Constitutive activation of 
PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia 
cells: direct evidence of PI3K activation. Leukemia 2004, 18, (8), 1438-1440. 
144. Billottet, C.; Grandage, V. L.; Gale, R. E.; Quattropani, A.; Rommel, C.; 
Vanhaesebroeck, B.; Khwaja, A., A selective inhibitor of the p110delta isoform of PI 
3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects 
of VP16. Oncogene 2006, 25, (50), 6648-59. 
145. Xu, Q.; Simpson, S. E.; Scialla, T. J.; Bagg, A.; Carroll, M., Survival of acute myeloid 
leukemia cells requires PI3 kinase activation. Blood 2003, 102, (3), 972-80. 
146. Tamburini, J.; Elie, C.; Bardet, V.; Chapuis, N.; Park, S.; Broet, P.; Cornillet-Lefebvre, 
P.; Lioure, B.; Ugo, V.; Blanchet, O.; Ifrah, N.; Witz, F.; Dreyfus, F.; Mayeux, P.; 
Lacombe, C.; Bouscary, D., Constitutive phosphoinositide 3-kinase/Akt activation 
represents a favorable prognostic factor in de novo acute myelogenous leukemia 
patients. Blood 2007, 110, (3), 1025-8. 
147. Gallay, N.; Dos Santos, C.; Cuzin, L.; Bousquet, M.; Gouy, V. S.; Chaussade, C.; Attal, 
M.; Payrastre, B.; Demur, C.; Recher, C., The level of AKT phosphorylation on 
threonine 308 but not on serine 473 is associated with high-risk cytogenetics and 
predicts poor overall survival in acute myeloid leukaemia. Leukemia 2009, 23, (6), 
1029-1038. 
148. Recher, C.; Dos Santos, C.; Demur, C.; Payrastre, B., mTOR, a new therapeutic target 
in acute myeloid leukemia. Cell cycle 2005, 4, (11), 1540-9. 
149. Tamburini, J.; Chapuis, N.; Bardet, V.; Park, S.; Sujobert, P.; Willems, L.; Ifrah, N.; 
Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D., Mammalian target of rapamycin 
(mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating 
insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for 
therapeutic inhibition of both pathways. Blood 2008, 111, (1), 379-382. 
150. Chapuis, N.; Tamburini, J.; Cornillet-Lefebvre, P.; Gillot, L.; Bardet, V.; Willems, L.; 
Park, S.; Green, A. S.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D., 
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation 
in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. 
Haematol-Hematol J 2010, 95, (3), 415-423. 
151. Doepfner, K. T.; Spertini, O.; Arcaro, A., Autocrine insulin-like growth factor-I 
signaling promotes growth and survival of human acute myeloid leukemia cells via the 
phosphoinositide 3-kinase/Akt pathway. Leukemia 2007, 21, (9), 1921-1930. 
152. Liu, T. C.; Lin, P. M.; Chang, J. G.; Lee, J. P.; Chen, T. P.; Lin, S. F., Mutation analysis 
of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 2000, 63, (4), 170-5. 
153. Cheong, J. W.; Eom, J. I.; Maeng, H. Y.; Lee, S. T.; Hahn, J. S.; Ko, Y. W.; Min, Y. H., 
Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory 
domain is frequently observed in acute myeloid leukaemia and associated with poor 
clinical outcome. Brit J Haematol 2003, 122, (3), 454-456. 
154. Luo, J. M.; Yoshida, H.; Komura, S.; Ohishi, N.; Pan, L.; Shigeno, K.; Hanamura, I.; 
Miura, K.; Iida, S.; Ueda, R.; Naoe, T.; Akao, Y.; Ohno, R.; Ohnishi, K., Possible 
dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 
2003, 17, (1), 1-8. 
155. Bousquet, M.; Recher, C.; Queleen, C.; Demur, C.; Payrastre, B.; Brousset, P., 
Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human 




156. Cheng, A. M.; Rowley, B.; Pao, W.; Hayday, A.; Bolen, J. B.; Pawson, T., Syk tyrosine 
kinase required for mouse viability and B-cell development. Nature 1995, 378, (6554), 
303-6. 
157. Chen, L. F.; Monti, S.; Juszczynski, P.; Daley, J.; Chen, W.; Witzig, T. E.; Habermann, 
T. M.; Kutok, J. L.; Shipp, M. A., SYK-dependent tonic B-cell receptor signaling is a 
rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111, (4), 2230-
2237. 
158. Xu, Q.; Thompson, J. E.; Carroll, M., mTOR regulates cell survival after etoposide 
treatment in primary AML cells. Blood 2005, 106, (13), 4261-8. 
159. Carnevale, J.; Ross, L.; Puissant, A.; Banerji, V.; Stone, R. M.; DeAngelo, D. J.; Ross, 
K. N.; Stegmaier, K., SYK regulates mTOR signaling in AML. Leukemia 2013, 27, 
(11), 2118-28. 
160. Puissant, A.; Fenouille, N.; Alexe, G.; Pikman, Y.; Bassi, C. F.; Mehta, S.; Du, J. Y.; 
Kazi, J. U.; Luciano, F.; Ronnstrand, L.; Kung, A. L.; Aster, J. C.; Galinsky, I.; Stone, 
R. M.; DeAngelo, D. J.; Hemann, M. T.; Stegmaier, K., SYK Is a Critical Regulator of 
FLT3 in Acute Myeloid Leukemia. Cancer Cell 2014, 25, (2), 226-242. 
161. Krisenko, M. O.; Geahlen, R. L., Calling in SYK: SYK's dual role as a tumor promoter 
and tumor suppressor in cancer. Bba-Mol Cell Res 2015, 1853, (1), 254-263. 
162. Jacamo, R.; Chen, Y.; Wang, Z.; Ma, W.; Zhang, M.; Spaeth, E. L.; Wang, Y.; Battula, 
V. L.; Mak, P. Y.; Schallmoser, K.; Ruvolo, P.; Schober, W. D.; Shpall, E. J.; Nguyen, 
M. H.; Strunk, D.; Bueso-Ramos, C. E.; Konoplev, S.; Davis, R. E.; Konopleva, M.; 
Andreeff, M., Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of 
NF-κB mediates chemoresistance. Blood 2014, 123, (17), 2691-2702. 
163. Zeng, Z.; Shi, Y. X.; Tsao, T.; Qiu, Y.; Kornblau, S. M.; Baggerly, K. A.; Liu, W.; 
Jessen, K.; Liu, Y.; Kantarjian, H.; Rommel, C.; Fruman, D. A.; Andreeff, M.; 
Konopleva, M., Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces 
apoptosis in AML cells under conditions mimicking the bone marrow 
microenvironment. Blood 2012, 120, (13), 2679-89. 
164. Sandhofer, N.; Metzeler, K. H.; Rothenberg, M.; Herold, T.; Tiedt, S.; Groiss, V.; 
Carlet, M.; Walter, G.; Hinrichsen, T.; Wachter, O.; Grunert, M.; Schneider, S.; 
Subklewe, M.; Dufour, A.; Frohling, S.; Klein, H. G.; Hiddemann, W.; Jeremias, I.; 
Spiekermann, K., Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-
rearranged acute myeloid leukemia. Leukemia 2015, 29, (4), 828-838. 
165. Altman, J. K.; Sassano, A.; Platanias, L. C., Targeting mTOR for the treatment of AML. 
New agents and new directions. Oncotarget 2011, 2, (6), 510-7. 
166. Jin, L.; Tabe, Y.; Lu, H.; Borthakur, G.; Miida, T.; Kantarjian, H.; Andreeff, M.; 
Konopleva, M., Mechanisms of apoptosis induction by simultaneous inhibition of PI3K 
and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer 
Lett 2013, 329, (1), 45-58. 
167. Mendoza, M. C.; Er, E. E.; Blenis, J., The Ras-ERK and PI3K-mTOR pathways: cross-
talk and compensation. Trends Biochem Sci 2011, 36, (6), 320-328. 
168. Liu, F.; Yang, X.; Geng, M.; Huang, M., Targeting ERK, an Achilles' Heel of the MAPK 
pathway, in cancer therapy. Acta Pharmaceutica Sinica B 2018, 8, (4), 552-562. 
169. Chambard, J. C.; Lefloch, R.; Pouyssegur, J.; Lenormand, P., ERK implication in cell 
cycle regulation. Biochim Biophys Acta 2007, 1773, (8), 1299-310. 
170. Kodaki, T.; Woscholski, R.; Hallberg, B.; Rodriguez-Viciana, P.; Downward, J.; Parker, 





171. Rodriguez-Viciana, P.; Warne, P. H.; Dhand, R.; Vanhaesebroeck, B.; Gout, I.; Fry, M. 
J.; Waterfield, M. D.; Downward, J., Phosphatidylinositol-3-Oh Kinase as a Direct 
Target of Ras. Nature 1994, 370, (6490), 527-532. 
172. Suire, S.; Hawkins, P.; Stephens, L., Activation of phosphoinositide 3-kinase gamma 
by Ras. Curr Biol 2002, 12, (13), 1068-1075. 
173. Roux, P. P.; Ballif, B. A.; Anjum, R.; Gygi, S. P.; Blenis, J., Tumor-promoting phorbol 
esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via 
p90 ribosomal S6 kinase. P Natl Acad Sci USA 2004, 101, (37), 13489-13494. 
174. Pearce, L. R.; Komander, D.; Alessi, D. R., The nuts and bolts of AGC protein kinases. 
Nat Rev Mol Cell Bio 2010, 11, (1), 9-22. 
175. Carriere, A.; Romeo, Y.; Acosta-Jaquez, H. A.; Moreau, J.; Bonneil, E.; Thibault, P.; 
Fingar, D. C.; Roux, P. P., ERK1/2 Phosphorylate Raptor to Promote Ras-dependent 
Activation of mTOR Complex 1 (mTORC1). Journal of Biological Chemistry 2011, 
286, (1), 567-577. 
176. Grandori, C.; Cowley, S. M.; James, L. P.; Eisenman, R. N., The Myc/Max/Mad 
network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 
16, 653-99. 
177. O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; 
Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N., mTOR inhibition 
induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 
2006, 66, (3), 1500-8. 
178. Perl, A. E.; Kasner, M. T.; Tsai, D. E.; Vogl, D. T.; Loren, A. W.; Schuster, S. J.; Porter, 
D. L.; Stadtmauer, E. A.; Goldstein, S. C.; Frey, N. V.; Nasta, S. D.; Hexner, E. O.; 
Dierov, J. K.; Swider, C. R.; Bagg, A.; Gewirtz, A. M.; Carroll, M.; Luger, S. M., A 
phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC 
chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 
2009, 15, (21), 6732-9. 
179. Yee, K. W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; 
Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, 
F. J., Phase I/II study of the mammalian target of rapamycin inhibitor everolimus 
(RAD001) in patients with relapsed or refractory hematologic malignancies. Clin 
Cancer Res 2006, 12, (17), 5165-73. 
180. Rizzieri, D. A.; Feldman, E.; Dipersio, J. F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, 
V. M.; Albitar, M.; Bedrosian, C. L.; Giles, F. J., A phase 2 clinical trial of deforolimus 
(AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients 
with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008, 14, (9), 
2756-62. 
181. Boehm, A.; Mayerhofer, M.; Herndlhofer, S.; Knoebl, P.; Sillaber, C.; Sperr, W. R.; 
Jaeger, U.; Valent, P., Evaluation of in vivo antineoplastic effects of rapamycin in 
patients with chemotherapy-refractory AML. Eur J Intern Med 2009, 20, (8), 775-8. 
182. Lane, H. A.; Breuleux, M., Optimal targeting of the mTORC1 kinase in human cancer. 
Curr Opin Cell Biol 2009, 21, (2), 219-29. 
183. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P. J.; Valero, V.; Guzman, M.; Botero, 
M. L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, 
J. L.; Arribas, J.; Baselga, J., NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents 
PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. 
Cancer Res 2008, 68, (19), 8022-30. 
184. Wunderle, L.; Badura, S.; Lang, F.; Wolf, A.; Schleyer, E.; Serve, H.; Goekbuget, N.; 




Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute 
Leukemia: Results Of a Phase I Study. Blood 2013, 122, (21). 
185. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; 
Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; 
Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, 
T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P., 
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-
kinases. Cancer Res 2007, 67, (12), 5840-50. 
186. Pongas, G.; Fojo, T., BEZ235: When Promising Science Meets Clinical Reality. 
Oncologist 2016, 21, (9), 1033-1034. 
187. Gojo, I.; Perl, A.; Luger, S.; Baer, M. R.; Norsworthy, K. J.; Bauer, K. S.; Tidwell, M.; 
Fleckinger, S.; Carroll, M.; Sausville, E. A., Phase I study of UCN-01 and perifosine in 
patients with relapsed and refractory acute leukemias and high-risk myelodysplastic 
syndrome. Invest New Drugs 2013, 31, (5), 1217-27. 
188. Sampath, D.; Malik, A.; Plunkett, W.; Nowak, B.; Williams, B.; Burton, M.; 
Verstovsek, S.; Faderl, S.; Garcia-Manero, G.; List, A. F.; Sebti, S.; Kantarjian, H. M.; 
Ravandi, F.; Lancet, J. E., Phase I clinical, pharmacokinetic, and pharmacodynamic 
study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced 
hematologic malignancies. Leukemia Res 2013, 37, (11), 1461-1467. 
189. Herschbein, L.; Liesveld, J. L., Dueling for dual inhibition: Means to enhance 
effectiveness of PI3K/Akt/mTOR inhibitors in AML. Blood Rev 2017. 
190. Park, S.; Chapuis, N.; Saint Marcoux, F.; Recher, C.; Prebet, T.; Chevallier, P.; Cahn, 
J. Y.; Leguay, T.; Bories, P.; Witz, F.; Lamy, T.; Mayeux, P.; Lacombe, C.; Demur, C.; 
Tamburini, J.; Merlat, A.; Delepine, R.; Vey, N.; Dreyfus, F.; Bene, M. C.; Ifrah, N.; 
Bouscary, D.; Goelams, A phase Ib GOELAMS study of the mTOR inhibitor RAD001 
in association with chemotherapy for AML patients in first relapse. Leukemia 2013, 27, 
(7), 1479-86. 
191. Amadori, S.; Stasi, R.; Martelli, A. M.; Venditti, A.; Meloni, G.; Pane, F.; Martinelli, 
G.; Lunghi, M.; Pagano, L.; Cilloni, D.; Rossetti, E.; Di Raimondo, F.; Fozza, C.; 
Annino, L.; Chiarini, F.; Ricci, F.; Ammatuna, E.; La Sala, E.; Fazi, P.; Vignetti, M., 
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as 
salvage therapy for older patients with acute myeloid leukaemia: results of a phase II 
GIMEMA study (AML-1107). Brit J Haematol 2012, 156, (2), 205-212. 
192. Vardiman, J. W.; Thiele, J.; Arber, D. A.; Brunning, R. D.; Borowitz, M. J.; Porwit, A.; 
Harris, N. L.; Le Beau, M. M.; Hellstrom-Lindberg, E.; Tefferi, A.; Bloomfield, C. D., 
The 2008 revision of the World Health Organization (WHO) classification of myeloid 
neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114, (5), 
937-51. 
193. Gjertsen, B. T.; Oyan, A. M.; Marzolf, B.; Hovland, R.; Gausdal, G.; Doskeland, S. O.; 
Dimitrov, K.; Golden, A.; Kalland, K. H.; Hood, L.; Bruserud, O., Analysis of acute 
myelogenous leukemia: preparation of samples for genomic and proteomic analyses. J 
Hematother Stem Cell Res 2002, 11, (3), 469-81. 
194. Nepstad, I.; Reikvam, H.; Brenner, A. K.; Bruserud, O.; Hatfield, K. J., Resistance to 
the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human 
Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. Int J Mol 
Sci 2018, 19, (2). 
195. Reuss-Borst, M. A.; Klein, G.; Waller, H. D.; Muller, C. A., Differential Expression of 




196. Wheatley, K.; Burnett, A. K.; Goldstone, A. H.; Gray, R. G.; Hann, I. M.; Harrison, C. 
J.; Rees, J. K.; Stevens, R. F.; Walker, H., A simple, robust, validated and highly 
predictive index for the determination of risk-directed therapy in acute myeloid 
leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research 
Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107, 
(1), 69-79. 
197. Khwaja, A.; Bjorkholm, M.; Gale, R. E.; Levine, R. L.; Jordan, C. T.; Ehninger, G.; 
Bloomfield, C. D.; Estey, E.; Burnett, A.; Cornelissen, J. J.; Scheinberg, D. A.; 
Bouscary, D.; Linch, D. C., Acute myeloid leukaemia. Nat Rev Dis Primers 2016, 2, 
16010. 
198. Kern, W.; Kohlmann, A.; Schnittger, S.; Hiddemann, W.; Schoch, C.; Haferlach, T., 
Gene Expression Profiling as a Diagnostic Tool in Acute Myeloid Leukemia. American 
Journal of Pharmacogenomics 2004, 4, (4), 225-237. 
199. Yan, P.; Frankhouser, D.; Murphy, M.; Tam, H. H.; Rodriguez, B.; Curfman, J.; 
Trimarchi, M.; Geyer, S.; Wu, Y. Z.; Whitman, S. P.; Metzeler, K.; Walker, A.; 
Klisovic, R.; Jacob, S.; Grever, M. R.; Byrd, J. C.; Bloomfield, C. D.; Garzon, R.; Blum, 
W.; Caligiuri, M. A.; Bundschuh, R.; Marcucci, G., Genome-wide methylation profiling 
in decitabine-treated patients with acute myeloid leukemia. Blood 2012, 120, (12), 
2466-74. 
200. Astori, A.; Fredly, H.; Aloysius, T. A.; Bullinger, L.; Mansat-De Mas, V.; de la Grange, 
P.; Delhommeau, F.; Hagen, K. M.; Recher, C.; Dusanter-Fourt, I.; Knappskog, S.; 
Lillehaug, J. R.; Pendino, F.; Bruserud, O., CXXC5 (Retinoid-Inducible Nuclear Factor, 
RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia. 
Oncotarget 2013, 4, (9), 1438-1448. 
201. Alachkar, H.; Santhanam, R.; Maharry, K.; Metzeler, K. H.; Huang, X. M.; 
Kohlschmidt, J.; Mendler, J. H.; Benito, J. M.; Hickey, C.; Neviani, P.; Dorrance, A. 
M.; Anghelina, M.; Khalife, J.; Tarighat, S. S.; Volinia, S.; Whitman, S. P.; Paschka, P.; 
Hoellerbauer, P.; Wu, Y. Z.; Han, L.; Bolon, B. N.; Blum, W.; Mrozek, K.; Carroll, A. 
J.; Perrotti, D.; Andreeff, M.; Caligiuri, M. A.; Konopleva, M.; Garzon, R.; Bloomfield, 
C. D.; Marcucci, G., SPARC promotes leukemic cell growth and predicts acute myeloid 
leukemia outcome. Journal of Clinical Investigation 2014, 124, (4), 1512-1524. 
202. Brenner, A. K.; Tvedt, T. H. A.; Nepstad, I.; Rye, K. P.; Hagen, K. M.; Reikvam, H.; 
Bruserud, O., Patients with acute myeloid leukemia can be subclassified based on the 
constitutive cytokine release of the leukemic cells; the possible clinical relevance and 
the importance of cellular iron metabolism. Expert Opin Ther Tar 2017, 21, (4), 357-
369. 
203. Bruserud, Ø., Effect of dipyridamole, theophyllamine and verapamil on spontaneous in 
vitro proliferation of myelogenous leukaemia cells. Acta Oncol 1992, 31, (1), 53-8. 
204. Abrahamsen, J. F.; Rusten, L.; Bakken, A. M.; Bruserud, O., Better preservation of early 
hematopoietic progenitor cells when human peripheral blood progenitor cells are 
cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent 
dimethylsulfoxide. Transfusion 2004, 44, (5), 785-789. 
205. Abrahamsen, J. F.; Bakken, A.; Bruserud, O., No differences in colony formation of 
peripheral blood stem cells frozen with 5% or 10% DMSO. Blood 2000, 96, (11), 379a-
379a. 
206. Ryningen, A.; Ersvaer, E.; Oyan, A. M.; Kalland, K. H.; Vintermyr, O. K.; Gjertsen, B. 
T.; Bruserud, Ø., Stress-induced in vitro apoptosis of native human acute myelogenous 




low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Res 
2006, 30, (12), 1531-1540. 
207. Vielkind, U.; Swierenga, S. H., A Simple Fixation Procedure for Immunofluorescent 
Detection of Different Cytoskeletal Components within the Same Cell. Histochemistry 
1989, 91, (1), 81-88. 
208. Hobro, A. J.; Smith, N. I., An evaluation of fixation methods: Spatial and compositional 
cellular changes observed by Raman imaging. Vib Spectrosc 2017, 91, 31-45. 
209. Levitt, D.; King, M., Methanol Fixation Permits Flow Cytometric Analysis of 
Immunofluorescent Stained Intracellular Antigens. J Immunol Methods 1987, 96, (2), 
233-237. 
210. Martelli, A. M.; Evangelisti, C.; Chiarini, F.; McCubrey, J. A., The phosphatidylinositol 
3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous 
leukemia patients. Oncotarget 2010, 1, (2), 89-103. 
211. Beurel, E.; Grieco, S. F.; Jope, R. S., Glycogen synthase kinase-3 (GSK3): regulation, 
actions, and diseases. Pharmacol Ther 2015, 0, 114-31. 
212. Zhu, H. X.; Zhang, Y.; Chen, J. F.; Qiu, J. D.; Huang, K. T.; Wu, M. D.; Xia, C. L., 
IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling 
Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. 
Plos One 2017, 12, (1). 
213. Carbonneau, M.; Gagne, L. M.; Lalonde, M. E.; Germain, M. A.; Motorina, A.; Guiot, 
M. C.; Secco, B.; Vincent, E. E.; Tumber, A.; Hulea, L.; Bergeman, J.; Oppermann, U.; 
Jones, R. G.; Laplante, M.; Topisirovic, I.; Petrecca, K.; Huot, M. E.; Mallette, F. A., 
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nature 
Communications 2016, 7. 
214. Salem, M.; Delwel, R.; Touw, I.; Mahmoud, L.; Lowenberg, B., Human AML colony 
growth in serum-free culture. Leuk Res 1988, 12, (2), 157-65. 
215. Phang, J. M.; Liu, W.; Hancock, C. N.; Fischer, J. W., Proline metabolism and cancer: 
emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 2015, 18, 
(1), 71-7. 
216. Phang, J. M.; Liu, W.; Hancock, C.; Christian, K. J., The proline regulatory axis and 
cancer. Front Oncol 2012, 2, 60. 
217. Wyant, G. A.; Abu-Remaileh, M.; Wolfson, R. L.; Chen, W. W.; Freinkman, E.; Danai, 
L. V.; Heiden, M. G. V.; Sabatini, D. M., mTORC1 Activator SLC38A9 Is Required to 
Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient. Cell 
2017, 171, (3), 642-+. 
218. Karigane, D.; Takubo, K., Metabolic regulation of hematopoietic and leukemic 
stem/progenitor cells under homeostatic and stress conditions. Int J Hematol 2017, 106, 
(1), 18-26. 
219. Rizzo, M. T., The role of arachidonic acid in normal and malignant hematopoiesis. 
Prostaglandins Leukot Essent Fatty Acids 2002, 66, (1), 57-69. 
220. Hoggatt, J.; Pelus, L. M., Eicosanoid regulation of hematopoiesis and hematopoietic 
stem and progenitor trafficking. Leukemia 2010, 24, (12), 1993-2002. 
221. Luengo, A.; Gui, D. Y.; Vander Heiden, M. G., Targeting Metabolism for Cancer 
Therapy. Cell Chem Biol 2017, 24, (9), 1161-1180. 
222. Sommermann, T.; O’Neill, K.; Plas, D. R.; Cahir-McFarland, E., IKKβ and NFκB 
transcription govern lymphoma cell survival through AKT-induced plasma membrane 
trafficking of GLUT1. Cancer research 2011, 71, (23), 7291-7300. 
223. Fruman, D. A.; Chiu, H.; Hopkins, B. D.; Bagrodia, S.; Cantley, L. C.; Abraham, R. T., 




224. Fang, J.; Zhou, S. H.; Fan, J.; Yan, S. X., Roles of glucose transporter-1 and the 
phosphatidylinositol 3-kinase/protein kinase B pathway in cancer radioresistance. Mol 
Med Rep 2015, 11, (3), 1573-1581. 
225. Sullivan, L. B.; Luengo, A.; Danai, L. V.; Bush, L. N.; Diehl, F. F.; Hosios, A. M.; Lau, 
A. N.; Elmiligy, S.; Malstrom, S.; Lewis, C. A.; Vander Heiden, M. G., Aspartate is an 
endogenous metabolic limitation for tumour growth. Nat Cell Biol 2018, 20, (7), 782-
+. 
226. Alkan, H. F.; Walter, K. E.; Luengo, A.; Madreiter-Sokolowski, C. T.; Stryeck, S.; Lau, 
A. N.; Al-Zoughbi, W.; Lewis, C. A.; Thomas, C. J.; Hoefler, G.; Graier, W. F.; Madl, 
T.; Vander Heiden, M. G.; Bogner-Strauss, J. G., Cytosolic Aspartate Availability 
Determines Cell Survival When Glutamine Is Limiting. Cell Metabolism 2018. 
227. Chiarugi, A.; Dolle, C.; Felici, R.; Ziegler, M., The NAD metabolome - a key 
determinant of cancer cell biology. Nat Rev Cancer 2012, 12, (11), 741-752. 
228. Birsoy, K.; Wang, T.; Chen, W. W.; Freinkman, E.; Abu-Remaileh, M.; Sabatini, D. 
M., An Essential Role of the Mitochondrial Electron Transport Chain in Cell 
Proliferation Is to Enable Aspartate Synthesis. Cell 2015, 162, (3), 540-551. 
229. Sullivan, L. B.; Gui, D. Y.; Hosios, A. M.; Bush, L. N.; Freinkman, E.; Vander Heiden, 
M. G., Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in 
Proliferating Cells. Cell 2015, 162, (3), 552-563. 
230. Titov, D. V.; Cracan, V.; Goodman, R. P.; Peng, J.; Grabarek, Z.; Mootha, V. K., 
Complementation of mitochondrial electron transport chain by manipulation of the 
NAD(+)/NADH ratio. Science 2016, 352, (6282), 231-235. 
231. Gui, D. Y.; Sullivan, L. B.; Luengo, A.; Hosios, A. M.; Bush, L. N.; Gitego, N.; 
Davidson, S. M.; Freinkman, E.; Thomas, C. J.; Vander Heiden, M. G., Environment 
Dictates Dependence on Mitochondrial Complex I for NAD plus and Aspartate 
Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metabolism 
2016, 24, (5), 716-727. 
232. Campbell, P. J.; Yachida, S.; Mudie, L. J.; Stephens, P. J.; Pleasance, E. D.; Stebbings, 
L. A.; Morsberger, L. A.; Latimer, C.; McLaren, S.; Lin, M. L.; McBride, D. J.; Varela, 
I.; Nik-Zainal, S. A.; Leroy, C.; Jia, M.; Menzies, A.; Butler, A. P.; Teague, J. W.; 
Griffin, C. A.; Burton, J.; Swerdlow, H.; Quail, M. A.; Stratton, M. R.; Iacobuzio-
Donahue, C.; Futreal, P. A., The patterns and dynamics of genomic instability in 
metastatic pancreatic cancer. Nature 2010, 467, (7319), 1109-13. 
233. Maley, C. C.; Galipeau, P. C.; Finley, J. C.; Wongsurawat, V. J.; Li, X.; Sanchez, C. A.; 
Paulson, T. G.; Blount, P. L.; Risques, R. A.; Rabinovitch, P. S.; Reid, B. J., Genetic 
clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 
38, (4), 468-73. 
234. Jadersten, M.; Saft, L.; Smith, A.; Kulasekararaj, A.; Pomplun, S.; Gohring, G.; 
Hedlund, A.; Hast, R.; Schlegelberger, B.; Porwit, A.; Hellstrom-Lindberg, E.; Mufti, 
G. J., TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict 
disease progression. J Clin Oncol 2011, 29, (15), 1971-9. 
235. Mullighan, C. G.; Phillips, L. A.; Su, X.; Ma, J.; Miller, C. B.; Shurtleff, S. A.; Downing, 
J. R., Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. 
Science 2008, 322, (5906), 1377-80. 
236. Bochtler, T.; Stolzel, F.; Heilig, C. E.; Kunz, C.; Mohr, B.; Jauch, A.; Janssen, J. W. G.; 
Kramer, M.; Benner, A.; Bornhauser, M.; Ho, A. D.; Ehninger, G.; Schaich, M.; 
Kramer, A., Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an 





237. Schlenk, R. F.; Benner, A.; Krauter, J.; Buchner, T.; Sauerland, C.; Ehninger, G.; 
Schaich, M.; Mohr, B.; Niederwieser, D.; Krahl, R.; Pasold, R.; Dohner, K.; Ganser, A.; 
Dohner, H.; Heil, G., Individual patient data-based meta-analysis of patients aged 16 to 
60 years with core binding factor acute myeloid leukemia: a survey of the German Acute 
Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22, (18), 3741-50. 
238. Konopleva, M.; Pollyea, D. A.; Potluri, J.; Chyla, B.; Hogdal, L.; Busman, T.; 
McKeegan, E.; Salem, A. H.; Zhu, M.; Ricker, J. L.; Blum, W.; DiNardo, C. D.; Kadia, 
T.; Dunbar, M.; Kirby, R.; Falotico, N.; Leverson, J.; Humerickhouse, R.; Mabry, M.; 
Stone, R.; Kantarjian, H.; Letai, A., Efficacy and Biological Correlates of Response in 
a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous 
Leukemia. Cancer Discov 2016, 6, (10), 1106-1117. 
239. Pan, R.; Hogdal, L. J.; Benito, J. M.; Bucci, D.; Han, L.; Borthakur, G.; Cortes, J.; 
DeAngelo, D. J.; Debose, L.; Mu, H.; Dohner, H.; Gaidzik, V. I.; Galinsky, I.; Golfman, 
L. S.; Haferlach, T.; Harutyunyan, K. G.; Hu, J.; Leverson, J. D.; Marcucci, G.; 
Muschen, M.; Newman, R.; Park, E.; Ruvolo, P. P.; Ruvolo, V.; Ryan, J.; Schindela, S.; 
Zweidler-McKay, P.; Stone, R. M.; Kantarjian, H.; Andreeff, M.; Konopleva, M.; Letai, 
A. G., Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute 











 International Journal of 
Molecular Sciences
Article
Resistance to the Antiproliferative In Vitro Effect of
PI3K-Akt-mTOR Inhibition in Primary Human Acute
Myeloid Leukemia Cells Is Associated with Altered
Cell Metabolism
Ina Nepstad 1 ID , Håkon Reikvam 2, Annette K. Brenner 1,2, Øystein Bruserud 1,2
and Kimberley J. Hatfield 1,3,*
1 Department of Clinical Science, University of Bergen, 5021Bergen, Norway; ina.nepstad@uib.no (I.N.);
annette.brenner@uib.no (A.K.B.); Oystein.Bruserud@uib.no (Ø.B.)
2 Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway; Hakon.Reikvam@uib.no
3 Department of Immunology and Transfusion Medicine, Haukeland University Hospital,
5021 Bergen, Norway
* Correspondence: Kimberley.Hatfield@uib.no; Tel.: +47-55-973037
Received: 6 December 2017; Accepted: 23 January 2018; Published: 27 January 2018
Abstract: Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mechanistic target of
rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells. However,
AML is a heterogeneous disease, and we therefore investigated possible associations between cellular
metabolism and sensitivity to PI3K-Akt-mTOR pathway inhibitors. We performed non-targeted
metabolite profiling to compare the metabolome differences of primary human AML cells derived
from patients susceptible or resistant to the in vitro antiproliferative effects of mTOR and PI3K
inhibitors. In addition, the phosphorylation status of 18 proteins involved in PI3K-Akt-mTOR
signaling and the effect of the cyclooxygenase inhibitor indomethacin on their phosphorylation
status was investigated by flow cytometry. Strong antiproliferative effects by inhibitors were
observed only for a subset of patients. We compared the metabolite profiles for responders and
non-responders towards PI3K-mTOR inhibitors, and 627 metabolites could be detected. Of these
metabolites, 128 were annotated and 15 of the annotated metabolites differed significantly between
responders and non-responders, including metabolites involved in energy, amino acid, and lipid
metabolism. To conclude, leukemia cells that are susceptible or resistant to PI3K-Akt-mTOR inhibitors
differ in energy, amino acid, and arachidonic acid metabolism, and modulation of arachidonic acid
metabolism alters the activation of mTOR and its downstream mediators.
Keywords: acute myeloid leukemia; metabolism; mTOR; PI3K; phosphorylation
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by proliferating
myeloblasts in the bone marrow [1,2]. Abnormal constitutive signaling through intracellular pathways
is often observed in AML, including the phosphatidylinositol-3-kinase-Akt-mechanistic/mammalian
target of rapamycin (PI3K-Akt-mTOR) pathway that seems to be important both in normal and
leukemic hematopoiesis [3–5]. This pathway is important for regulation of proliferation, apoptosis,
differentiation, and metabolism [6,7].
Constitutive signaling through the PI3K-Akt-mTOR pathway is found in 50–80% of AML
patients and correlates with poor prognosis [4,8]. This abnormal signaling may be initiated by
various mechanisms, e.g., oncogenes or mutated receptor tyrosine kinases, cell adhesion molecules,
G-protein-coupled receptors, or other cytokine or hormonal receptors.
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When signaling is initiated in response to extracellular stimuli, scaffolding proteins are recruited
and bind to the regulatory subunit of PI3K. Sequentially, PI3K phosphorylates phosphatidylinositol
(4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which facilitates
recruitment and binding of proteins containing pleckstrin–homology domains, including Akt and
its upstream activator 3’phosphoinositide-dependent kinase 1 (PDK1) [9]. PDK1 phosphorylates
Akt at T308, leading to its partial activation. However, a subsequent phosphorylation at S473 is
required for full enzymatic activation of Akt [9,10], and this can be achieved by mTOR complex 2
(mTORC2) or DNA-dependent protein kinase (DNA-PK) [10,11]. The mTOR kinase is part of two
complexes, mTORC1 and mTORC2 with different biochemical structures and substrate specificity.
The interactions between Akt and mTORC1/2 are complex. Akt phosphorylates the inhibitor
of mTORC1 and proline-rich Akt-substrate-40 (PRAS40), preventing the suppression of mTORC1
signaling. Additionally, an Akt-driven inactivation of tuberous sclerosis complex (TSC) 1/2, leads
to activation of mTORC1 through Ras homolog enriched in brain (RHEB). mTORC1 is an important
regulator of cellular metabolism and protein synthesis through phosphorylation and activation of
both the S6 ribosomal protein kinase (S6PK) and the repressor of messenger RNA (mRNA) translation
initiation factor 4E-binding protein 1 (4EBP1) [6].
The PI3K-Akt-mTOR signaling pathway is one of the most frequently dysregulated pathways
in human malignancies, including AML [12,13]. Though PI3K-Akt-mTOR is rarely mutated in AML,
these patients harbor several mutations that may activate the pathway [12,14] and, hence, contribute
to chemoresistance [4,15]. Based on extensive experimental studies, this pathway has been regarded as
a possible therapeutic target in human AML [3,16]. However, despite this evidence, the initial clinical
studies suggest that the tested mTOR inhibitors have only a modest antileukemic effect [16]. However,
it should be emphasized that previous experimental studies also suggest that therapeutic targeting of
the PI3K-Akt-mTOR pathway will be effective only for a subset of patients [17], and pathway inhibition
may be more effective when using combined treatment strategies [18].
As discussed in a recent review, previous studies of resistance towards PI3K-Akt-mTOR inhibitors
have focused on the possible hyperactivation of upstream mediators through feedback loops (e.g., PI3K
and Akt) and compensatory activation of other pathways [16]. However, this cannot be the only
explanation because chemoresistance is also seen for inhibitors upstream to Akt [17]. Our present
study is to the best of our knowledge the first to suggest that metabolic alterations are a part of the
therapy-resistant AML cell phenotype, and the metabolic differences seem to involve pathways that
are involved in cellular energy and amino acid metabolism.
2. Results
2.1. Selection of Patients for the Metabolomics Comparison of Primary Human Acute Myeloid
Leukemia (AML) Cells
We investigated the antiproliferative effect of four PI3K-Akt-mTOR inhibitors on primary human
AML cell proliferation in the presence of exogenous cytokines [17]. The antiproliferative effects of
the inhibitors differed considerably between the 56 patient cell samples studied, and for a subset of
patients, even increased proliferation was seen in the presence of pathway inhibitors. In contrast,
these previous studies showed that pathway inhibitors had only minor effects on the spontaneous
stress-induced in vitro apoptosis that occurs during culture of primary human AML cells [19], and only
minor differences could then be detected between different patients [17]. Patient subsets could thus
be identified based solely on differences in our proliferation assay, i.e., these cells survived for 6 days
in the presence of the pathway inhibitors and could still proliferate and incorporate 3H-thymidine
during the period from day 6 to day 7 of the in vitro culture. This means that our subclassification was
based on the pharmacological effects on a cell subset within the hierarchically organized AML cell
population that were able to both survive and still be able to proliferate.
We also investigated the effects of pathway inhibitors on the in vitro proliferation of primary
human AML cells for a second and larger cohort including 76 additional consecutive patients; in these
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experiments, we only examined the effects of rapamycin and GDC-0941. The overall results are
presented in Figure 1. The studies of this second cohort confirmed that the antiproliferative effects
of PI3K-Akt-mTOR pathway inhibition varied among individual patients, and a variation of the
effect between the two drugs was observed. We also investigated the susceptibility to stress-induced
or spontaneous in vitro apoptosis for these 76 patients, but we could not observe any correlation
between this susceptibility to apoptosis and the antiproliferative effects of the two pathway inhibitors.
Taken together, our results from the two patient cohorts showed that neither the general regulation of
apoptosis, as reflected in the degree of spontaneous in vitro apoptosis, nor the viability of the AML cell
population after in vitro exposure to pathway inhibitors showed any significant association with the
variation in antiproliferative effects of pathway inhibitors that was detected in our proliferation assay.
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Figure 1. The effect of phosphatidylinositol-3-kinase-mechanistic target of rapamycin (PI3K-mTOR)
inhibitors on cytokine-dependent in vitro acute myeloid leukemia (AML) cell proliferation. Leukemic
cell proliferation was assayed as 3H-thymidine incorporation after six days of culture. We compared
the proliferation of primary human AML cells cultured in the presence of the PI3K-inhibitor GDC-0941
and the mTOR-inhibitor rapamycin. The results are presented as the ratio of proliferation, i.e., nuclear
incorporation of 3H-thymidine in drug-exposed cells relative to the incorporation in corresponding
drug-free control cultures. The patient cohort included 76 patients, but detectable proliferation was
only seen for the 68 AML patients whose results are presented in the figure. Each line represents the
results for one patient. The dashed line indicates a ratio of 1.0, i.e., no change in proliferation.
The data presented in Figure 1 clearly illustrate that pathway inhibitors can increase AML cell
proliferation for a subset of patients, whereas for other patients, a strong inhibition corresponding to
more than 50% inhibition could be detected for different mediator . For further analysis f the possible
association between metab lic haracteristics an the antip oliferative effects f pathway i hibitors on
primary human AML cells, we compared two contrasting groups of selected patients based on the
studies of the two patient cohorts. We then sele ted 15 patient samples with significantly d cre sed
proliferation after inhibition with both rapamycin and GDC-0941; these samples are referred to as
responders to the treatment. The other group included 15 patient samples showing no significant
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alteration of proliferation (corresponding to <10% inhibition) or even growth enhancement in the
presence of pathway inhibitors. These are referred to as non-responders to treatment.
2.2. Patient Samples with Different Drug Sensitivity towards PI3K-mTOR Inhibitors Also Differ in Energy,
Amino Acid and Arachidonic Acid Metabolism
Previous studies suggest that metabolic regulation of chronic myeloid leukemia cells is important
for their susceptibility towards targeted therapy with kinase inhibitors [20]. We compared the metabolic
profiles of the two contrasting patient groups that were sensitive and insensitive to PI3K-Akt-mTOR
inhibition in vitro. As described above, these groups were selected based on their susceptibility to the
antiproliferative effect of PI3K and mTOR inhibitors [17]. The metabolic analysis of the AML cells
detected a total of 627 metabolites, and 128 of these metabolites were annotated. A principal component
analysis was performed to illustrate the variance between the different sample groups. The responders
and non-responders showed a great overlap in the plot, though four of the non-responders clustered
separately from the rest (Figure 2). Thus, responders and non-responders could not be separated by an
analysis of the overall metabolic profile, and non-responder patients seem to be heterogeneous with
regard to their global metabolite profiles even though they show a similar resistance to PI3K-Akt-mTOR
pathway inhibition.
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Figure 2. Principal component analysis (PCA) comparing the metabolic profiles of responders and
non-responders to PI3K-mTOR inhibitors. The analysis was performed to generate an overview of the
metabolic variance among the entire set of samples. Prior to this analysis, primary AML cells from
30 patients were separated into two contrasting groups based on their susceptibility to the in vitro
antiproliferative effect of pathway inhibitors. The metabolic profiles for the primary AML cells derived
from patients being susceptible (15 responders; grey circle) or resistant (15 non-responders; black circle)
to PI3K-mTOR inhibitors were compared. The PCA depicts 71.2% (58.4 + 12.8% as indicated at the
X and Y axis) of all variances in the data set. A separation of four non-responders (indicated by the
asterisks *) from the rest of the sample was seen. Each circle represents the results for one patient.
Of the 627 detected metabolites, 23 metabolites differed significantly between the two contrasting
groups of responders and non-responders, and among these, 15 were annotated (Table 1). These
significantly altered metabolites are involved in energy (citric acid, isocitric acid, glutamine), amino acid
(proline, glutamine, taurine), and lipid metabolism (two phosphatidylinositols (PI), the arachidonic
acid metabolites 4,7,10,13-eicosatetraenoic acid, and 4,7,10,13,16-docosapentaenoic acid).
We did a metabolic pathway mapping based on the identified metabolites for further
characterization of differences between responders and non-responders based on the 80 top-ranked
metabolites. Purine metabolism (including the annotated metabolites glutamine, glutamic acid, glycine,
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and hypoxanthine) and Warburg effect (i.e., energy metabolism; including the annotated metabolites
NAD, glutamic acid, glutamine citric acid, and isocitric acid) were then the two highest-ranked
terms. This metabolic pathway mapping analysis further supports our conclusion that responders and
non-responders to PI3K-mTOR inhibitors show metabolic differences.
2.3. Responders and Non-Responders to PI3K-Akt-mTOR Inhibition Could Be Identified Based on
Metabolic Differences
No single metabolite could be used to identify responders and non-responders. However, a decision
tree analysis was performed showing that samples can be differentiated based on the levels of cysteinyl-
cysteine and threonic acid (Table 1). The patient subset sensitive to PI3K/mTOR inhibitors in vitro was then
characterized by low levels of both these metabolites (Figure 3). Cysteinyl-cysteine is a dipeptide composed
of two cysteine residues and an incomplete breakdown product of protein catabolism, whereas threonic
acid is probably derived from glycated proteins or degradation of ascorbic acid (Human Metabolome
Database). This additional and alternative analysis of our metabolomic data further illustrates that our
contrasting groups of responder and non-responder AML cells show metabolic differences.
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Figure 3. A decision tree analysis of the metabolic differences between 15 responders and 15 non-
responders to PI3K-Akt-mTOR inhibition. The levels of two metabolites, cysteinyl-cysteine and
threonic acid, allowed for discrimination between responders and non-responders. The 30 patients
(see the upper box) were first classified into two subsets based on their cysteinyl-cysteine levels (≤ or
>0.045). In the box with high cysteinyl-cysteine (>0.045; right box), there were 10 non-responders and
1 responder. The 19 patients (14 responders and 5 non-responders) with low levels of cysteinyl-cysteine
(≤0.045; left box) were further subclassified into two subsets based on the level of threonic acid (≤ or
>0.0145). Thirteen of the 14 responders with low levels of cysteinyl-cysteine also showed low levels of
threonic acid (≤0.0145; left box). Whereas four of five non-responders among the 19 patients with low
levels of cysteinyl-cysteine showed high levels of threonic acid (>0.0145; right box). Approximately
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2.4. Modulation of Arachidonic Acid Metabolism Alters PI3K-Akt-mTOR Signaling
In a previous study, we used Western blot to analyze phosphorylation mediators downstream
of mTOR in a small group of patients treated with PI3K-mTOR inhibitors [17]. Even though these
results have to be interpreted with great care as few patients were studied, the observations suggested
that (i) patients differed considerably with respect to the degree of constitutive signaling through the
PI3K-Akt-mTOR pathway; and (ii) the heterogeneous antiproliferative effects of PI3K-mTOR inhibitors
seen among patients could not be explained by differences in constitutive pathway activation.
Arachidonic acid metabolism seems to be important for survival and proliferation of various
cells, including myeloid cells [21,22]. Arachidonic acid can be metabolized by cyclooxygenase,
lipoxygenase, or the cytochrome P450 pathways into a number of metabolites, referred to as eicosanoids.
These arachidonic acid derived eicosanoids belong to a complex family of lipid signaling mediators
that control many important cellular processes, including cell proliferation, apoptosis, and cell
metabolism [21,23]. Therefore, we wanted to investigate whether modulation of the balance between
the various pathways of arachidonic acid metabolism would influence PI3K-Akt-mTOR signaling in
primary human AML cells.
In these experiments, we modulated the balance of arachidonic acid metabolism by incubating
the cells with indomethacin (a nonselective cyclooxygenase 1/2 inhibitor), and we investigated the
effects of this inhibitor on PI3K-Akt-mTOR signaling in primary AML cells derived from five patients
showing constitutive signaling throughout this pathway. These five patients showed a wide variation
in constitutive pathway activation; this activation was also observed in previous Western blot analyses
of the downstream mTOR mediators P70SK6 and p4E-BP1 (see above) [17]. Thus, a variation in the
degree of constitutive pathway activation can be detected by both Western blot and phospho-flow,
and, therefore, we selected five patient samples with a constitutive, though wide variation of signaling.
The variation between these five patients was, in addition, reproduced/documented in independent
analysis of cells derived from separate freezing ampullas.
Using a flow cytometry technique, we explored the effects of indomethacin of the PI3K-Akt-mTOR
pathway (10 µg/mL, 15-min incubation) for cells incubated in medium alone (i.e., constitutive signaling)
and medium supplemented with insulin 10 µg/mL (Figures 4 and 5). Insulin was studied because
PI3K-Akt-mTOR is an important pathway downstream of the insulin receptor [24,25], and in vitro
studies have shown that insulin is an important growth factor for primary AML cells for a major
subset of patients [26]. When performing an unsupervised hierarchical clustering of the overall results,
we observed that the four combinations tested (medium alone± indomethacin, insulin± indomethacin)
for each individual patient sample generally clustered together; showing that differences in pathway
signaling between patients were maintained even in the presence of cyclooxygenase inhibition.
An indomethacin-induced decrease of mTOR pS2448, S6 pS235 pS236, and S6 pS244 was seen for
all patients in insulin-free and/or insulin-supplemented cultures, and for four of the five patients
a decrease was seen for Akt pS473 and S6 pS240 (Figure 4).
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Figure 4. In vitro phospho-signaling analysis of primary AML cells derived from five patients to
explore the effects of indomethacin on the PI3K-Akt-mTOR pathway. AML cells were incubated in
medium alone, in medium supplemented with 10 µg/mL of either indomethacin or insulin, and in
medium supplemented with the combination of insulin and indomethacin. Phosphorylation status of
nine mediators were examined. An indomethacin-induced decrease of mTOR pS2448, S6 pS235 pS236,
and S6 pS244 was seen for all patients in insulin-free and/or insulin-supplemented cultures, and a
decrease of S6 pS240 and Akt pS473 was seen for four of the five patients. The X-axis is a log-scale for
fluorescence intensity; the Y-axis indicates the number of cells.
Based on our current observations, we conclude that modulation of arachidonic acid metabolism
by exposure to indomethacin has only minor effects on the phosphorylation of certain mediators
in the PI3K-Akt-mTOR pathway; a similar conclusion can be made also for insulin. Only minor
effects were observed on the overall pathway activation profile compared with the observed wide
variation in constitutive pathway activation between different patients. Accordingly, our results in
Figure 5 illustrate that the wide variation between patients in constitutive pathway activation seems
to be maintained also after exposure of the leukemic cells to insulin, as well as after drug-induced
modulation of arachidonic acid metabolism, i.e., samples from an individual patient cluster together
whereas samples from insulin/indomethacin exposed cells do not cluster together.
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Figure 5. The effect of indomethacin on the activation of PI3K-Akt-mTOR signaling. We investigated
the effects of indomethacin on PI3K-Akt-mTOR signaling in primary AML cells derived from five
patients. For each sample, we tested AML cells incubated in medium alone, with only indomethacin
10 µg/mL, in medium supplemented with 10 µg/mL insulin, and with the combination of insulin
and indomethacin. Phosphorylation status of nine mediators were examined. Red indicates high and
blue indicates low phosphorylation/expression of the mediators. All combinations tested for each
patient sample also clustered together in the same subclusters for all patients. All values from the flow
cytometric analyses were calculated using fold change on the Inverse hyperbolic sine (Arcsinh) scale.
3. Discussion
The PI3K-Akt-mTOR signaling network shows constitutive activation in human AML [12].
However, previous experimental studies [17] suggest that the antileukemic effects of pathway inhibitors
differ between patients, and the aim of the present study was to further characterize this patient
heterogeneity with regard to constitutive PI3K-Akt-mTOR activation/signaling, pathway inhibition,
and metabolic regulation.
For younger patients receiving the most intensive chemotherapy, the overall long-term AML-free
survival is only 40–50%. However, the large group of patients above 70–75 years of age are not able to
receive this intensive therapy, and are therefore, treated with AML-stabilizing treatment [27]. Many of
these elderly patients, as well as younger unfit patients, have an expected survival of only 1–3 months.
Thus, new therapeutic strategies are needed both for younger as well as for elderly and unfit patients
who can only receive AML-stabilizing treatment; combination therapy including PI3K-Akt-mTOR
inhibitors may then be an alternative therapeutic strategy [3,16,18]. However, due to the short survival
of many elderly and unfit patients [28,29], they may get only one chance of antileukemic therapy
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because of the rapid disease progression if this first treatment fails. For this reason, pretreatment
identification of patients with high risk of resistant disease will be important. Our present study
suggests that metabolic characterization should be further explored as a possible strategy to identify
patients with a high risk of resistance to PI3K-Akt-mTOR inhibition, and such patients should then try
an alternative strategy as their initial treatment.
In vitro cultured hierarchically organized AML cell populations show spontaneous apoptosis during
the first 4–5 days of culture; for most patients, this is an extensive process [19]. Our previous study
showed that PI3K-mTOR inhibitors only have weak influence on this spontaneous or stress-induced
in vitro apoptosis, and the variation between patients is limited so that it cannot be used for subset
classification [17]. However, a wide variation between patients can be detected when using our
3H-thymidine incorporation assay after six days of in vitro culture, i.e., an analysis of the AML cell
minority that has been able to survive the initial six days of in vitro culture and still are able to
proliferate. Inhibitors of the PI3K-Akt-mTOR pathway were added at the start of the cultures. Our patient
classification reflects a combined effect of pathway inhibitors on both survival and proliferation, i.e., the
presence of the drug during the initial six days characterized by spontaneous in vitro apoptosis and the
ability of the remaining viable cells to still show cytokine-dependent proliferation in the presence of the
pathway inhibitors when 3H-thymidine incorporation is assayed from day six to seven of in vitro culture.
We investigated the effect of insulin on phosphorylation of the PI3K-Akt-mTOR-pathway as this
pathway is important for insulin signaling [24,25], and insulin is also an important growth factor for
in vitro cultured primary human AML cells for a large subset of patients [26]. Our present studies
showed that insulin altered the activation/phosphorylation of several mediators; however, the effects
were minor and differed between patients. Also, the wide variation in PI3K-Akt-mTOR pathway
activation between patients was maintained in the presence of insulin (i.e., the samples exposed to
insulin did not cluster together with each other but rather together with the corresponding insulin-free
control (Figures 4 and 5)).
Even though constitutive activation of PI3K-Akt-mTOR signaling in the enriched leukemic cells is
seen for most AML patients, resistance to the antiproliferative effect of pathway inhibitors is relatively
common. In our present study, we show that resistant patient-derived leukemia cells differ with
regard to their metabolomic profile, including the metabolites involved in amino acid and arachidonic
acid metabolism. Similar abnormalities are also associated with chemoresistance in other myeloid
malignancies [30].
Arachidonic acid metabolism is important for survival and proliferation of hematopoietic
cells [21,23,31–33] and several of its metabolites can influence activation/signaling through
the PI3K-Akt-mTOR pathway, e.g., pathway-activating prostaglandins and eicosatetraenoic acid
derivatives [31–35]. Our comparison of the metabolite profiles of cell samples representing either
responders or non-responders to PI3K-Akt-mTOR inhibition supports the hypothesis that arachidonic
acid metabolism is important with regard to susceptibility to these inhibitors. This hypothesis was
also supported by our observed effects of modulated arachidonic acid metabolism by indomethacin
on mediator phosphorylation, and previous studies in both human chronic myeloid leukemia and in
animal models of leukemic stem cells indicating that arachidonic acid metabolism is important for
both leukemogenesis and chemosensitivity [20,36].
For other cell types, there are functional links between redox balance, purine metabolism,
NADH, proline, and glutamine metabolism, and the citric acid cycle [37–41]. Even though few
studies of myeloid cells are available, observations in other cell types suggest links between such
metabolic steps and PI3K-Akt-mTOR signaling. Firstly, arachidonic acid metabolites can function
as regulators of the PI3K-Akt-mTOR pathway [21,23,42,43], and our present results suggest that
this may also be true in human AML. Secondly, there are links between PI3K-Akt-mTOR signaling
via free oxygen radicals/redox homeostasis to the NAD/NADH/proline/glutamine/glutamate
system [44,45]. Thirdly, proline and glutamine are interconvertible, and glutamine is an important
substrate for the energy metabolism in many malignant cells; a link between arachidonic acid and
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energy metabolism/the citric acid cycle is therefore possible [37,39]. Finally, both arachidonic acid
metabolism and PI3K-Akt-mTOR signaling are important for regulation of the peroxisome proliferator
activated receptors, a group of transcription factors [21,40]. However, additional studies are needed to
clarify the possible contributions of these various steps in human AML.
Previous experimental studies suggest that altered proline metabolism can be important for the
development of cancer chemoresistance, and proline oxidase has been suggested as a possible target
in cancer treatment [37,39,41,46]. Our present study suggests that proline/glutamine metabolism
may also contribute to resistance of PI3K-mTOR inhibitors in human AML. Our observation of
increased levels of eicosatetraenoic acid and docosapentaenoic acid indicates that arachidonic acid
may be one of these interacting factors. However, an alternative explanation could be that effects on
proline/glutamine only reflect differences in energy metabolisms, and differences in arachidonic acid
metabolites may reflect the altered energy/lipid metabolism. This is further supported by previous
studies showing that arachidonic acid metabolism is important in murine leukemogenesis and for
chemoresistance in human chronic myeloid leukemia [20,36]. The PI3K-Akt-mTOR pathway may
represent a link between these two systems through the effect of arachidonic acid metabolites on this
pathway and the regulatory effect of mTOR on proline oxidase.
The role of arachidonic acid and its metabolites in normal and malignant hematopoiesis has
been reviewed previously [21]. Increased expression of lipoxygenase enzymes has been detected in
malignant myeloid cells, and products from this pathway of arachidonic acid metabolism often seem
to mediate growth-enhancing and antiapoptotic effects. Our present observations of increased levels
of eicosanoids in cells that are resistant to PI3K-Akt-mTOR inhibitors suggest that these metabolites
may have such a role in human AML. Furthermore, the effect of arachidonic acid itself seems to differ
between cell lines, but proapoptotic effects have been described. Finally, a previous study of primary
human AML cells showed that even low levels of indomethacin could reduce the AML cell levels of
prostaglandin E2, and in their model PGE2, could enhance both the spontaneous proliferation as well
as Toll like receptor mediated growth enhancement of primary human AML cells [47].
4. Materials and Methods
4.1. AML Patients
The study was approved by the Regional Ethics Committee (REK) (REK III 060.02, 10 June 2002;
REK Vest 215.03, 12 March 04; REK III 231.06, 15 March 2007; REK Vest 2013/634, 19 March 2013; REK
Vest 2015/1410, 19 June 2015), The Norwegian Data Protection Authority 02/1118-5, 22 October 2002,
and The Norwegian Ministry of Health 03/05340 HRA/ASD, 16 February 2004. All AML cell samples
were collected after written informed consent.
The clinical and biological characteristics of those 30 patients included in the metabolic studies
are summarized in Table 2. All patients had a high number and/or percentage of peripheral blood
blasts; leukemic peripheral blood mononuclear cells could, therefore, be isolated by density gradient
separation alone (Lymphoprep, Axis-Shield, Oslo, Norway) and generally contained at least 95%
leukemic blasts. The contaminating cells were small lymphocytes. These enriched AML cells were
stored in liquid nitrogen until used in the experiments [48]. All the 15 responder patients selected
for metabolic profiling had a strong inhibition (i.e., >50% inhibition) of cytokine-dependent AML
cell proliferation by both PI3K and mTOR inhibitors, whereas PI3K and mTOR inhibition either
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4.2. Drugs
Drugs used in this study included the mTOR inhibitor rapamycin (LC Laboratories, Woburn, MA,
USA), the PI3K class I specific inhibitor GDC-0941 (Axon Medchem BV, Groningen, The Netherlands),
human insulin (Sigma-Aldrich, St. Louis, MO, USA), and the nonselective cyclooxygenase 1/2 inhibitor
indomethacin (Sigma-Aldrich; dissolved in dimethyl sulfoxide (DMSO)). Stock solutions were sterile
filtered and stored at −20 ◦C until used in experiments, thawed only once, and diluted with their
respective solvents to obtain the desired final concentrations.
Indomethacin (Sigma-Aldrich) was tested at a final concentration of 10 µg/mL (corresponding to
28 µM). Previous studies in human as well as murine AML cells often used indomethacin concentrations
in the range of 10–50 µM (3.6–18 µg/mL) [49–51], and the conventional cyclooxygenase-blocking
concentration of indomethacin is considered to be 10–20 µM (for original reference see [50]). However,
even indomethacin concentrations as low as 1 µM (0.4 µg/mL) will decrease the in vitro prostaglandin
production by primary human acute leukemia cells [47]. Our use of indomethacin 10 µg/mL was
based on these previous studies. Finally, in pilot experiments we investigated pharmacological effects
after incubation for 7, 10, 15, 30, and 45 min before analyzing the PI3K-Akt-mTOR pathway activation.
We decided to incubate cells with the drugs for 15 min because additional effects could not be detected
when using longer incubations.
4.3. Analysis of PI3K-Akt-mTOR Activation
Flow cytometry was used to examine the basal expression of 18 mediators in the PI3K-Akt-mTOR
pathway/network in the AML cells. Cryopreserved and thawed primary leukemic cells were incubated
for 20 min in RPMI-1640 (Sigma-Aldrich) before being directly fixed in 1.5% paraformaldehyde (PFA)
and permeabilized with 100% methanol. The cells were subsequently rehydrated by adding 2 mL
phosphate-buffered saline (PBS), gently re-suspended, and then centrifuged. The cell pellet was washed
twice with 2 mL PBS and resuspended in 150 µL PBS supplemented with 0.1% bovine serum albumin
(BSA) (Sigma-Aldrich). Washed cells were blocked with immunoglobulin (Octagam; Octapharma,
Jessheim, Norway) and 1% BSA, and then split evenly into nineteen new tubes (1× 105 cells per sample)
before staining. All staining panels included the same live/dead discriminator, either FITC or Alexa
Fluor® 647 Mouse anti-Cleaved PARP (Asp214); an unstained sample was also included. Three directly
conjugated dyes were used: (i) Alexa Fluor® 647 was used for PTEN, PDPK1 pS241, PKCα, PKCα
pT497, Akt pS473, 4EBP1 pT36 pT45, elF4E pS209, S6 pS244, and mTOR; (ii) phycoerythrin (PE) for
Akt total, Akt pT308, mTOR pS2448, and S6 pS240; and (iii) V450 for S6 pS235 pS236. Antibodies were
purchased from BD Pharmingen (Franklin Lakes, NJ, USA), except for anti-mTOR that was purchased
from Cell Signal Technology (Danvers, MA, USA). Four of the antibodies were unconjugated (anti
Raptor, Tuberin, FKBP38, and RHEB; all from Abcam; Cambridge, UK) and required secondary
antibody-conjugated Alexa Fluor® 647 (BD Pharmingen). Together these mediators represent the main
steps in the PI3K-Akt-mTOR pathway and they were selected to provide an extended phosphorylation
profile of this pathway. Finally, in our pharmacological studies, AML cells were incubated with human
insulin 10 µg/mL (Sigma-Aldrich) and/or indomethacin 10 µg/mL (Sigma-Aldrich; dissolved in
DMSO); final concentration in the medium 0.5%) or a DMSO control solution for 15 min before flow
cytometric analysis as described above. Flow cytometry analysis was acquired on a BD FACS Verse
8-color flow cytometer (BD Biosciences, San Jose, CA, USA) and data analysis performed using FlowJo
10.0.7 software (Tree Star, Inc., Ashland, OR, USA).
4.4. Analysis of Cytokine-Dependent Proliferation in Presence of PI3K-mTOR Inhibitors
As described in detail previously [52,53]; AML cells (5 × 104 cells/well) were cultured in
flat-bottomed microtiter plates (150 µL/well) in Stem Span SFEMTM serum-free medium (Stem Cell
Technologies; Vancouver, BC, Canada) alone or in medium supplemented with granulocyte-macrophage
colony-stimulation factor (GM-CSF), stem cell factor (SCF) and Fms like tyrosine kinase 3 ligand
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(Flt3L) [54]. All cytokines were purchased from Peprotech (Rocky Hill, NJ, USA) and used at 20 ng/mL.
All drugs were added on the first day of culture, whereas 37 kBq/well of 3H-thymidine (Perkin Elmer;
Waltham, MA, USA) was added after 6 days, and nuclear incorporation was assayed after seven days
of culture. The mTOR inhibitor rapamycin and the PI3K inhibitor GDC-0941 were added at a final
concentration of 100 nM on the first day of culture [55].
4.5. Metabolomic Analysis
The metabolomic analyses and sample preparations were performed by Metabolomic Discoveries
GmbH (Potsdam, Germany) [56]. Briefly, non-targeted metabolite profiling of cells included analyses by
gas chromatography/mass spectrometry (GC-MS) and Liquid Chromatography Quadrupole-Time of
Flight (LC-QTOF)/MS; metabolites could then be analyzed in the range of 50–1700 Da with an accuracy
up to 1–2 ppm and a resolution of mass/∆mass = 40,000. Metabolites measured in the LC were
annotated according to their accurate mass and subsequent sum formula prediction. Metabolite profiles
were explored by the platforms of Metabolomic Discoveries and Small Molecule Pathway Database
(BioVariance, Munich, Germany). The lists of the 627 detected and the 128 annotated metabolites
are presented in the Supplementary Materials presenting the identity/accurate mass@retention time,
the p-value, and responder/non-responder ratio.
4.6. Bioinformatical and Statistical Analyses
Bioinformatic analyses were performed using the J-Express 2012 software (MolMine AS, Bergen,
Norway). For hierarchical clustering analysis, all values from cytometric analyses were calculated using
fold change on the Inverse hyperbolic sine (Arcsinh) scale. The median signal for each phospho-protein
was used as reference value for the calculation of basal phosphorylation. Complete linkage and Squared
Euclidean correlation were used as linkage method and distance measurement, respectively. Statistical
analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS) version 23
(Chicago, IL, USA), and p-values < 0.05 were regarded as statistically significant.
5. Conclusions
Despite the metabolic heterogeneity of the non-responders to PI3K-Akt-mTOR inhibitors, there
are distinct metabolic differences between responders and non-responders. Our present results are
consistent with the hypothesis that differences in arachidonic acid metabolism together with differences
in proline and/or energy metabolism are associated with differences in susceptibility to pathway
inhibitors. The possible importance of such differences should be considered when planning or
analyzing future clinical studies with PI3K-Akt-mTOR inhibitors and when designing combination
therapy for various AML patient subsets [57].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/2/
382/s1.
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Abbreviations
4EBP1 Translation initiation factor 4E-binding protein 1
AML Acute myeloid leukemia
DMSO Dimethyl sulfoxide
DNA-PK DNA-dependent protein kinase
FAB The French-American-British () classification system
Flt3 Fms like tyrosine kinase 3
Flt3L Flt3 ligand
GC-MS Gas chromatography-mass spectrometry
GM-CSF Granulocyte-macrophage colony-stimulation factor
ins Insertions
ITD Internal tandem duplications
LC-QTOF/MS Liquid Chromatography Quadrupole-Time of Flight MS
mRNA Messenger RNA




PCA Principal component analysis






RHEB Ras homolog enriched in brain
S6PK S6 ribosomal protein kinase
SCF Stem cell factor
SPSS Statistical Package for the Social Sciences
TSC Tuberous sclerosis complex
elF4E pS209 eukaryotic translation Initiation Factor 4E
PKCα Protein kinase C α
PTEN Phosphatase and tensin homolog
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Abstract: Clonal heterogeneity detected by karyotyping is a biomarker associated with adverse 
prognosis in acute myeloid leukemia (AML). Constitutive activation of the phosphatidylinositol-3-
kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in AML cells, 
and this pathway integrates signaling from several upstream receptors/mediators. We suggest that 
this pathway reflects biologically important clonal heterogeneity. We investigated constitutive 
PI3K-Akt-mTOR pathway activation in primary human AML cells derived from 114 patients, 
together with 18 pathway mediators. The cohort included patients with normal karyotype or single 
karyotype abnormalities and with an expected heterogeneity of molecular genetic abnormalities. 
Clonal heterogeneity reflected as pathway mediator heterogeneity was detected for 49 patients. 
Global gene expression profiles of AML cell populations with and without clonal heterogeneity 
differed with regard to expression of ectopic olfactory receptors (a subset of G-protein coupled 
receptors) and proteins involved in G-protein coupled receptor signaling. Finally, the presence of 
clonal heterogeneity was associated with adverse prognosis for patients receiving intensive 
antileukemic treatment. The clonal heterogeneity as reflected in the activation status of selected 
mediators in the PI3K-Akt-mTOR pathway was associated with a different gene expression profile 
and had an independent prognostic impact. Biological heterogeneity reflected in the intracellular 
signaling status should be further investigated as a prognostic biomarker in human AML. 
Keywords: acute myeloid leukemia; PI3K; Akt; mTOR; phosphorylation; clonal heterogeneity 
 
1. Introduction 
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by proliferating 
myeloblasts in the bone marrow [1–3]. Abnormal or constitutive signaling through intracellular 
pathways is often observed in the leukemic cells, including the phosphatidylinositol-3-kinase-Akt-
mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway that seems to be important both in 
normal and leukemic hematopoiesis [4–6]. Such abnormal signaling can be initiated by various 
mechanisms, e.g., various oncogenes or mutated receptor tyrosine kinases, cell adhesion molecules, 
G-protein-coupled receptors (GPCR) or other cytokine receptors. 
Primary AML cell populations may include various subclones at the time of diagnosis, and 
relapse can occur due to regrowth of the originally dominating clone, a subclone detectable at the 
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time of first diagnosis, or a new clone derived either from the original clone or from remaining 
preleukemic stem cells [7,8]. Detection of remaining leukemic cells with cytogenetic abnormalities at 
the time of allogeneic stem cell transplantation is associated with an adverse prognostic impact even 
when residual disease cannot be detected by flow cytometry, and morphological examination 
confirms that the patient is still in complete hematological remission [8]. One possible explanation 
for such a discrepancy may be the detection of a remaining minor subclone with a different 
immunophenotype compared with the dominating clone at the time of diagnosis [7]. The detection 
of subclones (i.e., clonal heterogeneity) based on karyotyping at the time of initial diagnosis is an 
independent adverse prognostic factor [9]. However, karyotyping for detection of clonal 
heterogeneity has several limitations as it is not a sensitive methodological approach and it cannot 
be used to detect heterogeneity for the majority of patients with normal karyotype or single 
cytogenetic abnormalities. 
Clonal heterogeneity of AML cell populations can also be detected by flow cytometric analysis 
of constitutively activated intracellular signaling pathways, and this may therefore be an alternative 
methodological strategy [10] that can be used also for evaluation of the large group of patients with 
normal karyotype. Such analyses may also reflect a functional heterogeneity caused by driving 
mutations and thereby reflect characteristics that are important for leukemogenesis and/or 
chemosensitivity. In our present study, we therefore investigated how clonal heterogeneity is 
reflected in the activation status of the PI3K-Akt-mTOR pathway. This pathway was chosen because 
(i) it is usually activated in primary human AML cells; (ii) integrates signaling from a wide range of 
upstream mediators/receptors; (iii) shows crosstalk with and thereby also reflects the activation status 
of parallel intracellular pathways; and (iv) targets a wide range of downstream mediators that are 
important for essential cellular processes e.g., regulation of energy metabolism, gene transcription, 
protein synthesis, induction of apoptosis, and cellular communication [4,6,11]. In this context, we 
have therefore investigated samples from a group of 114 unselected patients to clarify whether 
analysis of constitutive PI3K-Akt-mTOR signaling can be used to detect clonal heterogeneity, 
whether such heterogeneity is a biomarker associated with any clinical or biological patient 
characteristics, and whether clonal heterogeneity has an independent prognostic impact. 
2. Results 
2.1. Clonal AML Cell Heterogeneity Reflected by PI3K-Akt-mTOR Signaling Is Seen for a Subset of Patients 
In our flow cytometric analysis, we first identified the viable AML cells; this gating strategy is 
shown in Figure S1. The viable cell population was thereafter analyzed for expression levels of 
mediators and their phosphorylation. The viability of primary cells was analyzed both immediately 
after thawing and after the incubation steps by live dead gating. The viability did not differ 
significantly when comparing these two time points. The median frequency of dead cells after the 
incubation steps was 16.3% (range 0–48%). The viability of the AML cells did not differ when 
comparing AML cell samples with and without dual leukemic cell populations. 
We investigated the 18 mediators from the PI3K-Akt-mTOR pathway in leukemic cell samples 
from 114 unselected AML patients. Dual populations were detected in samples from 49 of patients 
and these overall results are summarized in Figure 1. The flow cytometric evidence for clonal 
heterogeneity is presented more in detail in Figure S1, and it can be seen that a minor population was 
clearly separated from the main AML cell population for all the 49 patients. 
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Figure 1. Clonal heterogeneity of primary human acute myeloid leukemia (AML) cell samples; an 
overview of the 49 patients showing dual populations when investigating activation of the 
phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway. The 
cells were incubated in medium alone (all patients), with insulin alone and with insulin and a 
pathway inhibitor (rapamycin, GDC-0941; only an unselected subset of patients). Dark grey means 
that dual populations were detected in all cultures with and without treatment, and light grey 
indicates detection only for some cultures. Patient samples analyzed for inhibition by mTOR inhibitor 
rapamycin and PI3K inhibitor GDC-0941 are indicated by an asterisk (*). 
For each of the 49 patients, clonal heterogeneity was detected only for some of the 18 mediators. 
Nineteen of the patients showed dual population for only one of any of the 18 mediators, 16 patients 
showed dual populations for two mediators, and dual populations for three mediators was found for 
seven patients. Thus, for the majority of these patients, dual AML cell populations were detected only 
by one or a few of the tested mediators, and dual populations for four to seven pathway mediators 
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Dual populations for mediators upstream to Akt were detected for 20 patients, whereas dual 
populations for Akt and mTOR were only detected for four of these 20 patients. Dual populations for 
mediators downstream to mTOR were detected for 10 patients. Furthermore, clonal heterogeneity 
reflected in constitutive Akt activation but not reflected by mediators upstream to Akt was found in 
17 patients. This heterogeneity reflects differences in activation alone because the total protein levels 
of Akt did not differ between cell subsets. Finally, it was uncommon for mTOR total protein level or 
phosphorylation/activation to reflect clonal heterogeneity. 
Taken together, the observations described above show that 49 out of 114 patients with clonal 
heterogeneity differ with regard to how the heterogeneity is reflected in the PI3K-Akt-mTOR 
expression/phosphorylation profile. 
The patient subsets with and without clonal heterogeneity were also compared with regard to 
their molecular genetics (i.e., analysis of 54 different mutations), morphological as well as molecular 
signs of differentiation and the overall PI3K-Akt-mTOR activation profile; though the two patient 
subsets did not show any significant differences with regard to these biological characteristics (see 
Table S1). 
2.2. Primary AML Cells Derived from Patients with and without dual PI3K-Akt-mTOR Cell Populations 
Differ in Their Global Gene Expression Profiles 
We compared the global gene expression profiles for 12 AML samples with and 27 samples 
without dual AML cell populations. A feature subset selection (FSS) analysis was performed for 
identification of the most discriminative genes between the two groups, and 1209 genes were then 
identified (i.e., p-value <0.05, see the complete gene list is included in Table S5 and Table S6). This 
criterion was chosen because AML is a highly heterogeneous disease with regard to differentiation, 
karyotype and molecular genetics [1–3]; and this can be seen from the characteristics of our present 
patient cohort (Tables 1 and 2 below, Table S1). For this reason, a relatively large number of 
differentially expressed genes will probably be needed to distinguish between patient subsets. The 
identified genes were used in a hierarchical clustering model (Pearson’s correlation distance measure 
with complete linkage; and this analysis identified two main patient subsets that corresponded to the 
patients with and without subpopulations. Furthermore, a correlation visualization with distance 
matrix displays the pairwise correlation between the 39 patients and the classification of patients into 
two main subsets corresponding to the subsets with and without subclones, respectively (Figure 2). 
Table 1. A comparison of overall survival for patients with and without dual populations based on 
the analysis of PI3K-Akt-mTOR activation. The table presents the results from univariate and adjusted 
or multivariate analyses (Cox Proportional Hazard Model). Significant p-values in the adjusted 
analysis are marked in bold. 
Covariate 
Crude Analysis Adjusted Analysis 
p-Value HR 95%-CI p-Value HR 95%-CI 
Age (per decade) <0.01 1.64 1.24–2.17 <0.01 1.69 1.22–2.36 
Subpopulation versus 
no subpopulation 
0.03 2.15 1,01–4,26 0.04 2.28 1.03–5.04 
Adverse cytogenetics 0.519 0.759 0.33–1.75 0.11 0.33 0.11–1.04 
NPM1-wt and Flt3-wt NA 1 (reference)  NA 1 (reference)  
NPM1-mutated and 
Flt3-wt 
0.92 1.62 0.58–4.56 0.693 1.24 0.42–3.75 
NPM1-wt and FLT3-
mutated 
0.21 1.86 0.71–4.92 0.03 3.88 1.18–12.71 
NPM1-mutated and 
FLT3-mutated 
0.05 2.33 1.00–5.34 0.48 1.44 0.57–3.61 
Abbreviations: CI, confidence interval; HR, hazard ratio. NPM1-wt: Nucleophosmin 1-wild type;  Flt3-wt: fms-
like tyrosine kinase 3-wild type.  
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Table 2. The biological and clinical characteristics of the 114 AML patients included in the study. 
Patient characteristics 
Age Secondary AML 
Median (years) 67 chemo 5 
Range (years) 18–87 CML 2 
  CML-RELAPSE 1 
Gender  CMML 4 
Females 49 de novo 81 
Males 65 LiFraum, chemo 1 
  MDS 8 
  MDS, AML relapse 1 
  MDS, CHEMO 1 
  Myelofibrosis 3 
  Polycytemia vera 1 
  Relapse 5 
Total 114 Relapse, chemo 1 
Cell Morphology 
FAB Classification CD34 Receptor 
M0 8 Negative (<20%) 30 
M1 28 Positive (>20%) 78 
M2 22 n.d. 6 
M4 27   
M5 21   
M7 1   










Favorable 11 Wild-type  62 
Intermediate 11 n.d. 17 
Normal 60   
n.d. 12 Flt3 mutations 
  ITD 41 
  Wild-type  55 
  n.d. 18 
The European Leukemia Net classification was used; n.d.: not determined; CML: Chronic myeloid 
leukemia; CMML:Chronic myelomonocytic leukemia; FAB: French-American-British. 
The differentially expressed genes were thereafter used to identify gene ontology terms that 
were overrepresented among the differentially expressed genes. We then selected Gene Ontology 
(GO) terms based on the criteria (i) False Discovery Rate (FDR) ad modum Benjamini <0.05 and (ii) 
p-values <0.05. Only two GO-terms were identified in each of the two analyses based on Biological 
processes or Molecular function, respectively. Based on Molecular function, the two groups G-protein 
coupled receptor signaling pathway (p = 0.0000078; 43 genes included) and Detection of chemical 
stimulus involved in sensory perception of smell (p = 0.000015; 26 genes included) were identified. 
Based on analysis of Biological processes we identified the two groups G-protein coupled receptor 
activity (p = 0.00002; 36 genes included) and Olfactory receptor activity (p = 0.000024; 26 genes 
included). The complete gene lists for each of these four GO terms are presented in Tables S2 and S3. 
None of the two patient subsets showed generally higher expression for all differentially expressed 
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2.3. Detection of AML Subclones Based upon PI3K-Akt-mTOR Signaling Is Associated with Decreased 
Patient Survival 
In a recent study, karyotyping could detect clonal heterogeneity for approximately 15% of 
patients, and this heterogeneity was then associated with an adverse prognosis in patients receiving 
intensive AML therapy [9]. We therefore investigated whether detection of subclones determined by 
analysis of constitutive PI3K-Akt-mTOR activation had a similar prognostic association. In our 
present study, we investigated a large group of unselected patients that included several elderly and 
unfit patients who could not receive intensive treatment [12]. However, 44 of our patients completed 
their planned intensive induction treatment followed by at least two consolidation cycles, autologous 
or allogeneic stem cell transplantation after their first diagnosis of AML. We compared the survival 
of 17 patients with and 27 patients without subpopulations; the overall survival was significantly 
higher for patients without subpopulations (Figure 3; p = 0.027). This association between prognosis 
and heterogeneity was significant both in crude (Table 1, Cox Proportional Hazard Model, p = 0.03) 
and adjusted analyses (p = 0.04). To summarize, the previous study [9] showed that detection of clonal 
heterogeneity in patients with abnormal karyotype had an adverse prognostic impact. In our present 
study we used an alternative methodological strategy for detection of subclones independent of the 
karyotype (i.e., also including patients with normal karyotype), and we could detect an association 
between clonal heterogeneity and adverse prognosis. 
We also did an adjusted analysis of the prognostic impact of age, clonal heterogeneity, 
cytogenetics, Flt3/NPM1 status (Table 1). After correcting for these adverse factors, clonal 
heterogeneity still had a significant association with survival. 
 
Figure 3. Overall survival of patients with (17 patients) and without (27 patients) clonal heterogeneity 
when investigating PI3K-Akt-mTOR pathway activation; an analysis of 44 patients who completed 
their intensive induction treatment followed by at least two consolidation cycles, autologous or 
allogeneic stem cell transplantation after their first diagnosis of AML. 
3. Discussion 
The PI3K-Akt-mTOR pathway shows constitutive activation in human AML and is therefore 
regarded as a possible therapeutic target, but despite this, the results from initial clinical studies 
suggest that pathway inhibitors have only modest antileukemic activity [13]. Possible explanations 
for this could be that patients are heterogeneous with regard to their susceptibility [14] due to 
differences in the crosstalk with other pathway [15], or there is clonal heterogeneity with variation in 
constitutive pathway activation between leukemic subclones for individual patients [7]. In the 
present study, we used flow cytometric analysis of PI3K-Akt-mTOR activation to detect clonal 
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heterogeneity. We investigated a large group of samples derived from unselected AML patients (i.e., 
the large majority of the patients had normal karyotype or only a single cytogenetic abnormality), 
and clonal heterogeneity was detected for the majority of these patient samples. However, for each 
of these patients the clonal heterogeneity was reflected in the basal expression of only one or a few of 
the 18 investigated pathway mediators, i.e., this heterogeneity was not associated with a difference 
in activation status throughout the pathway. A possible explanation for this limited pathway 
heterogeneity could be that the activation status of each mediator not only reflects the downstream 
signaling from receptor ligation, but also the crosstalk between specific mediators of the PI3K-Akt-
mTOR pathway and neighboring intracellular pathways. 
Most of our patients were elderly or unfit patients that could not receive intensive antileukemic 
treatment. Our patients are thus representative with regard to AML cell biology, but they are 
heterogeneous with regard to antileukemic treatment and the elderly/unfit patients usually received 
only disease-stabilizing or supportive treatment [12]. 
Aberrant expression of lymphoid markers is relatively common in AML, and according to the 
World Health Organization (WHO) classification an uncommon subset of acute leukemia patients 
also shows a mixed phenotype with both myeloid and lymphoid leukemic cell subpopulation [1]. 
However, among our heterogeneous AML cell populations neither patients with mixed leukemic 
phenotype nor aberrant expression of lymphoid markers (CD2, CD3, CD4, CD8, CD19, CD20) were 
detected. Furthermore, the presence of clonal heterogeneity in the PI3K-Akt-mTOR pathway showed 
no association with cytogenetic abnormalities, mutational status, morphological or molecular signs 
of differentiation. Thus, our identification of two patient subsets with and without clonal 
heterogeneity based on pathway activation seems independent of the conventional subclassification 
of AML patients. 
Clonal heterogeneity can be detected by various methodological strategies [7,9,10], including 
karyotyping which identified 15% of patients with clonal heterogeneity [9]. We observed clonal 
heterogeneity for 49 out of 114 patients (42%) using our flow cytometric approach and this higher 
frequency is most likely due to an additional molecular heterogeneity not reflected by karyotyping.  
We used flow cytometry to evaluate constitutive PI3K-Akt-mTOR activation and the criteria for 
detection of two AML cell subpopulations were (i) two distinct and clearly separated cell subsets for 
one or more of the 18 mediators; and (ii) the smallest subpopulation being at least 20% of the total 
viable cell population. Considering the limited number of metaphases analyzed by karyotyping, the 
study by Bochtler et al. [9] suggests that the clonal heterogeneity has to reach a certain (i.e., detectable) 
level to have a prognostic impact. By using 20% as our cutoff it was possible to identify distinct cell 
populations, and this cutoff has also been used to define positivity for differentiation markers by flow 
cytometry [16]. 
PI3K-Akt-mTOR is a part of a complex signaling network involving several single mediators 
and showing crosstalk with other pathways [13]. We selected 18 flow cytometric parameters that 
reflect the status of the main track of the pathway, including absolute levels and phosphorylation 
status of important upstream mediators, the key mediators Akt and mTOR and mediators 
downstream to mTOR (Table S1). It can be argued that for example phosphorylated PTEN should 
also be included, even though this mediator may be less important in AML than in many other 
malignancies at least with regard to PTEN mutations; PTEN seems to be mutated in less than 1% of 
AML patients. However, PDK1 is located between PI3K and Akt in the main pathway track, and the 
activity of PTEN will be reflected in the immediately downstream PDK1 phosphorylation [4]. 
The viability of the cryopreserved cells after thawing was determined for all patients and despite 
a variation between patients, all samples showed more than 50% viable cells. One would expect less 
than 100% viability for most patients when testing cryopreserved cells [17] and the viability did not 
differ between patients with and without detectable subclones. Thus, the detection of subclones is 
not associated with altered susceptibility of the AML cells to stress-induced or spontaneous in vitro 
apoptosis. 
The AML cell population from a single patient may consist of various subclones [7,9] that can be 
detected by single cell analyses (i.e., flow cytometry) of constitutive pathway activation [10]. We 
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never observed more than two subsets (dual populations) in a patient sample, independently of 
which mediator was analyzed. However, our methodological approach does not allow an accurate 
estimation of the total number of subpopulations when dual populations were detected for two or 
more pathway mediators because the same two subpopulations may be detected when analyzing 
various pathway mediators, or different subpopulations identified by different mediators. For this 
reason, we could classify our patients as either showing or not showing clonal heterogeneity, but we 
could not estimate the number of subclones in this assay. 
We compared the global gene expression profiles for AML cell samples with and without clonal 
heterogeneity; gene expression data were then available only for an unselected subset of our patients. 
We first investigated whether gene expression profiling could be used to identify patients with and 
without detectable clonal heterogeneity in the flow cytometric analysis. AML is a very heterogeneous 
disease [12], and as would be expected the patient heterogeneity is also illustrated by the clinical and 
biological characteristics (Tables 1 and 2, Table S2) of the patients included in our present study. We 
performed a clustering analysis (Figure 2) based on the differentially expressed genes and identified 
two patient subsets corresponding to the patient samples with and without dual subpopulations. 
Thus, despite the extensive heterogeneity of the AML disease, the patient subsets that are showing 
dual populations can be identified by analysis of gene expression profiles. 
To further investigate the biological differences between patients with and without clonal 
heterogeneity, we performed a GO term analysis, and we then identified the terms with FDR <0.05 
and statistical significance with p <0.05. This analysis was based on a correction for multiple 
hypothesis testing and ontologies including few genes were left out. We identified only two GO-
terms both when the analysis was based on Biological processes (G-protein receptor signaling, 
Detection of stimulus smell) and on Molecular function (G-protein receptor activity, Olfactory 
receptor activity). 
Our present studies showed that patients with and without clonal heterogeneity differed with 
regard to the expression of genes encoding olfactory receptor components and proteins involved in 
downstream signaling from G-protein coupled receptors (GPCRs) signaling. The olfactory receptors 
are a subset of the GPCRs [18–20]. Olfactory receptors are expressed in many tissues and by many 
different normal cells outside the olfactory system. This includes several normal leukocytes (e.g., 
monocytes, neutrophil granulocytes, erythrocytes, T and B cells, NK cells) [21] as well as adipose 
tissue, heart, skeletal muscles, kidney, prostate, gastrointestinal tract, liver, lung, several endocrine 
organs, ovary and testes [22]. It can also be expressed by various malignant cells [23–28], including 
human AML cells [29,30]. Thus, both normal and malignant myeloid cells are among the cells that 
show ectopic expression of olfactory receptors, but to the best of our knowledge, our present study 
is the first to describe an association between olfactory receptor expression and prognosis in a 
hematological malignancy. Furthermore, within these tissues certain olfactory receptors seem to have 
a more limited expression, whereas other receptors have a more widespread expression [22]. Limited 
data are available for the functional roles of ectopic olfactory receptors, but the overall data suggest 
that they can be involved in modulation and regulation of important cellular processes like cell 
survival/apoptosis induction, cell-cell recognition, proliferation and migration [22,28]. For cancer 
cells, these receptors seem to influence migration and development of metastases from solid tumors 
[31–34]. Our present study is one of the first to describe the broad olfactory receptor expression by 
primary human AML cells, and to the best of our knowledge, it is the first to suggest an association 
between chemosensitivity/survival in a hematological malignancy. 
Ectopically expressed olfactory receptors influence signaling through several signal 
transduction pathways, including the PI3K-Akt-mTOR pathway as well as NFκB, MEK-ERK1/2 and 
p42/44, and they seem to regulate calcium metabolism [22]. Several of these pathways are also 
important in AML [35]. The bone marrow ligands of these receptors are not known, but one 
possibility is binding of various metabolites [36]. Several metabolites and metabolic intermediates are 
ligands for olfactory receptors, including lactate, short- and medium-chain fatty acids, ketones and 
steroids [22,28,37]. Other metabolic intermediates share structural similarities with known ligands 
[22,28]. Our hypothesis is that the ectopic olfactory receptors function as metabolic sensors and the 
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metabolic/metabolite profile of the bone marrow microenvironment thereby becomes important for 
leukemogenesis and/or AML cell chemosensitivity. The local metabolic profile will probably also be 
influenced by the systemic metabolic profile, and this may explain why differences in the systemic 
(i.e., serum) metabolite profile has a prognostic impact in human AML [38]. Finally, these receptors 
can also be expressed by various stem cells [39], but their expression at the protein level has not been 
characterized, and it is not known whether they are expressed by leukemic or normal hematopoietic 
stem cells either. However, the observation that ectopic olfactory receptors are expressed at all stages 
of erythroid cell development [28,40] suggests that they have a more widespread expression at least 
in normal hematopoietic cells. 
Clonal heterogeneity detected by cytogenetic analysis has an adverse prognostic impact [9]. We 
used a methodological approach that enabled us to investigate all patients with respect to clonal 
heterogeneity, including the large group of patients with normal karyotype and the same single 
abnormality in all investigated AML cells. Our present analysis also showed an association between 
clonal heterogeneity and adverse prognosis, and clonal heterogeneity was an independent prognostic 
parameter in our present study of a patient cohort mainly including patients with normal karyotype 
or favorable genetic abnormalities and only a small subset of patients having a complex karyotype. 
Karyotyping is not suitable for rapid detection of clonal heterogeneity in routine clinical practice 
and this methodological strategy cannot be used for the majority of patients, e.g., patients with single 
abnormalities or normal karyotype, whereas our present strategy based on flow cytometry can detect 
clonal heterogeneity within a few hours. Our present study identifies detection of heterogeneity in 
PI3K-Akt-mTOR activation as a possible biomarker with prognostic impact in human AML. 
However, the activation status of this pathway may not only be used as a biomarker; the pathway is 
involved in several important cellular functions and therefore it may be a possible therapeutic target 
in human AML. 
4. Materials and Methods  
4.1. AML Patients  
The study was approved by the Regional Ethics Committee (REK) (REK III 060.02, 10 June 2002; 
REK Vest 215.03, 12 March 2004; REK III 231.06, 15 March 2007; REK Vest 2013/634, 19 March 2013; 
REK Vest 2015/1410, 19 June 2015), The Norwegian Data Protection Authority 02/1118-5, 22 October 
2002, and The Norwegian Ministry of Health 03/05340 HRA/ASD, 16 February 2004. All AML cell 
samples were collected after written informed consent. The clinical and biological characteristics of 
the 114 unselected patients included in the study are summarized in Table 2 (49 females and 65 males; 
median age 67 years with range 18–87 years). All patients had a high number and/or percentage of 
peripheral blood blasts; leukemic peripheral blood mononuclear cells could therefore be isolated by 
density gradient separation alone (Lymphoprep, Axis-Shield, Oslo, Norway) and generally contained 
at least 95% leukemic blasts. The contaminating cells were small lymphocytes. These enriched AML 
cells were stored in liquid nitrogen until used in the experiments [41]. 
4.2. Flow-Cytometric Analysis of PI3K-Akt-mTOR Activation 
Pathway-associated clonal heterogeneity was defined as flow-cytometric detection of at least 
one extra cell population including at least 20% of the leukemic cells and being detection by the 
analysis of at least one of the PI3K-Akt-mTOR mediators. 
Flow cytometry was used to examine the constitutive expression of 18 mediators in the PI3K-
Akt-mTOR pathway/network in the AML cells. Cryopreserved and thawed primary leukemic cells 
were incubated for 20 minutes in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) before being 
directly fixed in 1.5% paraformaldehyde (PFA) and permeabilized with 100% ice-cold methanol. The 
cells were thereafter rehydrated by adding 2 ml phosphate-buffered saline (PBS), gently re-
suspended and then centrifuged. The cell pellet was washed twice with 2 mL PBS and resuspended 
in 150 μL PBS supplemented with 0.1% bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA). 
Washed cells were blocked with immunoglobulin (Octagam; Octapharma, Jessheim, Norway) and 
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1% BSA, and thereafter split evenly into nineteen new tubes (1 × 105 cells per sample) before staining. 
All staining panels included the same live/dead discriminator, either FITC or Alexa Fluor® 647 Mouse 
anti-Cleaved PARP (Asp214); a blank sample was also included. Three directly conjugated dyes were 
used (Table S4): (i) Alexa Fluor® 647 was used for PTEN, PDPK1 (pS241), PKCα, PKCα (pT497), Akt 
(pS473), 4EBP1 (pT36/pT45), elF4E (pS209), S6 (pS244), and mTOR; (ii) phycoerythrin (PE) for Akt 
total, Akt (pT308), mTOR (pS2448), and S6 (pS240); and (iii) V450 for S6 (pS235/pS236). Antibodies 
were purchased from BD Pharmingen (Franklin Lakes, NJ, USA) except for anti-mTOR that was 
purchased from Cell Signal Technology (Danvers, MA, USA). Four of the antibodies were 
unconjugated (anti Raptor, Tuberin, FKBP38, and RHEB; all from Abcam; Cambridge, UK) and 
required secondary antibody-conjugated Alexa Fluor® 647 (Franklin Lakes, NJ, USA). Together all 
these mediators represent main steps in the PI3K-Akt-mTOR pathway and they were selected to 
provide an extended phosphorylation profile of this pathway. 
Viable leukemic cells were identified and analyzed in flow cytometric analysis based on 
live/dead staining, doublet discrimination, CD45 staining and forward/side scatter. Dead cells, 
doublets and the minor contaminating lymphocyte populations were excluded from further analyses. 
Our flow cytometric analyses were thus based on the analysis of viable leukemic cells, and the gating 
strategy used to identify the viable cell population is shown in Figure S2. 
AML cells were also incubated with human insulin 10 μg/mL (Sigma-Aldrich, St. Louis, MO, 
USA); the non-specific mTOR inhibitor rapamycin (LC Laboratories, Woburn, MA, USA) and the 
PI3K class I specific inhibitor GDC-0941 (Axon Medchem BV, Groningen, Netherlands) were added 
at a final concentration of 100 nM. Cells were incubated with these agents for 15 minutes before 
fixation/staining and flow cytometric analysis as described above. 
4.3. Analysis of Global Gene Expression Profiles and Mutation Analyses 
Our methods for RNA preparation, labelling and microarray hybridization have been described 
in detail previously [42]. All microarray experiments were performed using the Illumina iScan 
Reader, which is based upon fluorescence detection of biotin-labelled cRNA that was hybridized to 
the HumanHT-12 V4 Expression BeadChip according to the manufacturer’s instructions. The 
HumanHT-12 V4 BeadChip targets 47 231 probes that are mainly derived from genes in the NCBI 
RefSeq database (Release 38). Preprocessing, normalization and annotations of the microarray data 
has also been described in detail in this previous publication; the data from the array scanning were 
investigated in GenomeStudio and J-Express 2012 for quality control measures. 
Submicroscopic mutation profiling of 54 genes frequently mutated in myeloid leukemias was 
done using the Illuminas TruSight Myeloid Gene Panel and sequenced using the MiSeq system and 
reagent kit v3 (all from Illumina, San Diego, CA, USA) as described in detail previously [42]. The 
methods for fragment analysis of Flt3 exon 14–15 and NPM1 exon 12 and analysis of CEBPA 
mutations have also been described previously [42]. 
4.4. Data Collection, Bioinformatical and Statistical Analyses 
Flow cytometry analysis was acquired on a BD FACSVerse 8-color flow cytometer (BD 
Biosciences; Franklin Lakes, NJ, USA) and data analysis performed using FlowJo 10.0.7 software (Tree 
Star, Inc., Ashland, OR, USA). The J-Express software (J-Express 2012, MolMine AS, Bergen, Norway) 
was used for bioinformatical analyses. For unsupervised hierarchical clustering analysis, all values 
were calculated using fold change on the Inverse hyperbolic sine (Arcsinh) scale and with median 
values for each target group as control. Complete linkage (euclidean distance) and Pearson 
correlation were used as linkage method and distance measurement, respectively. Statistical analyses 
were performed using the IBM Statistical Package for the Social Sciences (SPSS) version 23 (IBM 
Corporation, Armonk, NY, USA). The Mann-Whitney U-test was used to compare different groups; 
the Chi square/Fischer’s exact test for analysis of categorized data and the Kendall’s tau-b correlation 
test for correlation analyses. The Cox Proportional Hazard Model was used for analysis of survival 
data. p-values <0.05 were regarded as statistically significant. The gene ontology enrichment analysis 
of differentially expressed genes was performed by using online bioinformatics tools of DAVID 
Cancers 2018, 10, 332 12 of 14 
 
Bioinformatics Resources 6.8, Laboratory of Human Retrovirology and Immunoinformatics (LHRI) 
[43,44]. 
5. Conclusions 
To conclude, clonal heterogeneity in human AML cell samples is reflected in the activation of 
mediator in the PI3K-Akt-mTOR pathway, and this heterogeneity had an independent prognostic 
impact in our patient cohort. Our present study suggests that that clonal heterogeneity as reflected 
in intracellular signaling pathways should be further investigated as a possible adverse prognostic 
biomarker in future clinical studies. 
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/9/332/s1. 
Figure S1: Detection of clonal heterogeneity for 49 AML patients; Figure S2. Cell preparation and gating strategy; 
Figure S3. A correlation visualization with distance matrix; Table S1. A comparison of patients with and without 
dual AML cell populations; studies of molecular genetics, differentiation and pathway activation profiles; Table 
S2. The GO-term showing significant differences when comparing AML cell populations for patients with and 
without clonal heterogeneity; the comparison being based on analysis of Molecular function; Table S3. The GO-
term showing significant differences when comparing AML cell populations for patients with and without clonal 
heterogeneity; Table S4. Monoclonal antibodies used in the flow-cytometric studies; Table S5. The complete gene 
list from patients with dual AML cell populations; Table S6. The complete gene list from patients without dual 
AML cell populations. 
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Figure S1. Detection of clonal heterogeneity for 49 acute myeloid leukemia (AML) patients; the results 
from representative flow cytometric analyses of phosphatidylinositol-3-kinase-Akt-mechanistic target of 
rapamycin (PI3K-Akt-mTOR) activation. For each patient clonal heterogeneity was detected by analysis 
Cancers 2018, 10, 332 S2 of S35 
of at least one mediator in the PI3K-Akt-mTOR pathway. Patient ID is shown in the upper right corner 
of each histogram. The figure documents the detection of dual populations for all patients, showing the 
results from one representative flow cytometric analysis for each of these 49 patients. The Y-axis 
represents the amount of cells, and the X-axis represents the fluorescence intensity. The stippled line 
shows the negative/unstained controls. 
 
Figure S2. Cell preparation and gating strategy. Flow cytometry was used for examination of the 
constitutive expression of the mediators in the PI3K-Akt-mTOR pathway/network in primary AML cells. 
Cryopreserved cells were thawed and washed before suspension cultures were prepared as described 
in Materials and methods. Briefly, cryopreserved and thawed primary leukemic cells were incubated for 
20 minutes in RPMI-1640 (Sigma-Aldrich) before being directly fixed in 1.5% paraformaldehyde (PFA) 
and permeabilized with 100% ice-cold methanol. The cells were thereafter rehydrated by adding 2 mL 
phosphate buffered saline (PBS), gently re-suspended and then centrifuged. The cell pellet was washed 
twice with 2 mL PBS and resuspended in 150 μL PBS supplemented with 0.1% bovine serum albumin 
(BSA) (Sigma, St. Louis, Missouri). Washed cells were blocked with immunoglobulin (Octagam; 
Octapharma, Jessheim, Norway) and 1% bovine serum albumin (BSA), and thereafter split evenly into 
nineteen new tubes (1 x 105 cells per sample) before staining. The first step in the gating was to 
distinguishing populations of cells based on their forward and side scatter properties. Doublet 
discrimination was performed based on both forward and side scatter, and elimination of dead cells was 
performed based on the live/dead discriminator, either FITC or Alexa Fluor®  647 Mouse anti-Cleaved 
PARP (Asp214). The identified viable cells were further analyzed based on each of the 
mediators/antibodies used in the study. The colors refer to the density of the cells relative to one another, 
where blue and green correspond to areas of lower cell density, yellow is mid-range, and red and orange 
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Figure S3. A correlation visualization with distance matrix displays the pairwise correlation between 
the 39 patients. Blue and green colors highlight the negative and positive correlation between samples. 
The genes found differently expressed were thereafter used to identify gene ontology terms (using the 
David Database for Gene Ontology) that were overrepresented among the genes differently expressed。 
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Table S1. A comparison of patients with and without dual AML cell populations; studies of molecular 
genetics, differentiation and pathway activation profiles. The two subsets do not differ with regard to 
frequencies of mutations, expression of differentiation Markers or level of PI3K-Akt-mTOR Activation. 
Additional Analysis of AML-Associated Mutations 
Classification of Mutations and Mutated Genes1 Dual Population Single Population 
NPM1 28 % 32 % 
Activated signaling 
Flt3-ITD, Flt3-TKD, NRAS, KRAS, JAK2, PTPN11 
67 % 64 % 
Tumor Suppressor 
TP53, WT1, CUX1, IKZF1, PHF6 
33 % 24% 
DNA methylation 
DNMT3A, TET2, IDH1, IDH2 
67 % 48 % 
Chromatin modifiers 
ASXL1, EZH2, GATA2 
22 % 24 % 
Myeloid transcription factors 
RUNX1, CEBPA 
28 % 24 % 
Spliceosome 
SRSF2, SF3B1, STAG2, RAD21, BCOR, BCORL1, CSF3R, 
ZRSR2 
39 % 24 % 
Cohesin 
SMC1A 




Molecular and Morphological Signs of Differentiation 
Expression of differentiation markers. According to the WHO classification a minor subset of acute leukemia 
patients show expression of both myeloid and lymphoid markers by their leukemic cells, either as expression of 
both myeloid and lymphoid markers by the same cells or as separate myeloid and lymphoid subpopulations 2. 
However, patients with and without dual populations in the PI3K-Akt-mTOR pathway activation analysis did 
not differ with regard to the expression of T cell (CD2, CD3, CD4, CD8) of B cell markers (CD19, CD20), and we 
could not detect any differences between the two patient subsets with regard to myeloid marker (DCD11b, 
CD11c, CD13, CD14, CD15, CD33), stem cell markers (CD34, CD117) or HLA-DR expression. 
Morphological signs of differentiation. The FAB classification did not differ between the two subsets. 
Activation Profile of The PI3K-AKT-mTor Pathway 
The constitutive activation of mediators within the PI3K-Akt-mTOR pathway varies between patients 3. Hence, 
we performed a clustering analysis to identify patients with similar pathway activation profiles, but the profiles 
did not differ between patients with and without detectable clonal heterogeneity. 
1 The percentages of various mutations for patients without and with dual acute myeloid leukemia (AML) 
cell populations are presented. A total of 54 AML-associated mutations were investigated. The table lists 
only those mutations that were detected in the 43 unselected patients that were investigated, i.e. 18 
patients with dual AML cell populations and 25 patients without clonal heterogeneity based on pathway 
activation analysis. 2 Referred in [1] 3 Referred in [2]. 
Table S2. The GO-term showing significant differences when comparing AML cell populations for 
patients with and without clonal heterogeneity; the comparison being based on analysis of Molecular 
function. The genes included in the analysis were identified by the comparison of 12 AML patient 
samples with and 27 samples without evidence for clonal heterogeneity when analyzing the PI3K-Akt-
mTOR pathway. Two GO-terms were then identified based; G-protein coupled receptor activity 
(GO:0004930; p-value 0.00002; 36 genes included) and Olfactory receptor activity (GO:0004984; p-value 
0.000024; 26 genes included). Several genes were included in both these terms; genes that did not overlap 
between these two terms are shaded in grey. Increased or decreased gene expression for patients with 
detectable subpopulations when analyzing constitutive PI3K-Akt-mTOR inhibition is indicated by 
upward arrows (↑) and downward arrows (↓), respectively. 
Molecular Function 
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GO:0004930 - G-protein coupled receptor 
activity; p-value 0.00002; 36 genes 
GO:0004984 - Olfactory receptor activity; p-
value 0.000024; 26 genes 
↑ G protein-coupled receptor 132(GPR132) ↓ 
olfactory receptor family 1 subfamily 
D member 4 
(gene/pseudogene)(OR1D4) 
↑ G protein-coupled receptor 139(GPR139) ↓ 
olfactory receptor family 1 subfamily J 
member 2(OR1J2) 
↓ G protein-coupled receptor 176(GPR176) ↓ 
olfactory receptor family 1 subfamily L 
member 8(OR1L8) 
↑ G protein-coupled receptor 183(GPR183) ↑ 
olfactory receptor family 10 subfamily 
G member 3(OR10G3) 
↑ G protein-coupled receptor 34(GPR34) ↓ 
olfactory receptor family 12 subfamily 
D member 3(OR12D3) 
↓ 
G protein-coupled receptor class C group 
5 member C(GPRC5C) 
↓ 
olfactory receptor family 2 subfamily 
A member 4(OR2A4) 
↓ 
G protein-coupled receptor class C group 
6 member A(GPRC6A) 
↓ 
olfactory receptor family 2 subfamily 
A member 42(OR2A42) 
↓ 
cadherin EGF LAG seven-pass G-type 
receptor 1(CELSR1) 
↓ 
olfactory receptor family 2 subfamily 
G member 3(OR2G3) 
↓ frizzled class receptor 7(FZD7) ↓ 
olfactory receptor family 2 subfamily 
M member 4(OR2M4) 
↓ 
olfactory receptor family 1 subfamily D 
member 4 (gene/pseudogene)(OR1D4) 
↓ 




olfactory receptor family 1 subfamily J 
member 2(OR1J2) 
↓ 
olfactory receptor family 2 subfamily T 
member 12(OR2T12) 
↓ 
olfactory receptor family 1 subfamily L 
member 8(OR1L8) 
↑ 
olfactory receptor family 3 subfamily 
A member 3(OR3A3) 
↑ 
olfactory receptor family 10 subfamily G 
member 3(OR10G3) 
↑ 
olfactory receptor family 4 subfamily 
C member 16 
(gene/pseudogene)(OR4C16) 
↓ 
olfactory receptor family 12 subfamily D 
member 3(OR12D3) 
↓ 
olfactory receptor family 4 subfamily 
C member 3(OR4C3) 
↓ 
olfactory receptor family 2 subfamily A 
member 4(OR2A4) 
↓ 
olfactory receptor family 4 subfamily 
C member 45(OR4C45) 
↓ 
olfactory receptor family 2 subfamily A 
member 42(OR2A42) 
↓ 
olfactory receptor family 4 subfamily F 
member 29(OR4F29) 
↓ 
olfactory receptor family 2 subfamily G 
member 3(OR2G3) 
↑ 
olfactory receptor family 5 subfamily 
AU member 1(OR5AU1) 
↓ 
olfactory receptor family 2 subfamily M 
member 4(OR2M4) 
↑ 
olfactory receptor family 5 subfamily 
H member 15(OR5H15) 
↓ 
olfactory receptor family 2 subfamily T 
member 11 (gene/pseudogene)(OR2T11) 
↑ 
olfactory receptor family 5 subfamily L 
member 1 (gene/pseudogene)(OR5L1) 
↓ 
olfactory receptor family 2 subfamily T 
member 12(OR2T12) 
↓ 
olfactory receptor family 51 subfamily 
G member 2(OR51G2) 
↑ 
olfactory receptor family 3 subfamily A 
member 3(OR3A3) 
↓ 
olfactory receptor family 52 subfamily 
L member 1(OR52L1) 
↑ 
olfactory receptor family 4 subfamily C 
member 16 (gene/pseudogene)(OR4C16) 
↑ 
olfactory receptor family 6 subfamily Y 
member 1(OR6Y1) 
↓ 
olfactory receptor family 4 subfamily C 
member 3(OR4C3) 
↓ 
olfactory receptor family 8 subfamily 
D member 4(OR8D4) 
↓ 
olfactory receptor family 4 subfamily C 
member 45(OR4C45) 
↓ 
olfactory receptor family 8 subfamily 
G member 2(OR8G2) 
↓ 
olfactory receptor family 4 subfamily F 
member 29(OR4F29) 
↑ 
olfactory receptor family 8 subfamily J 
member 1(OR8J1) 
↑ 
olfactory receptor family 5 subfamily AU 
member 1(OR5AU1) 
↑ 
olfactory receptor family 9 subfamily I 
member 1(OR9I1) 
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↑ 




olfactory receptor family 5 subfamily L 
member 1 (gene/pseudogene)(OR5L1) 
  
↓ 




























relaxin/insulin like family peptide receptor 
1(RXFP1) 
  
Table S3. The GO-term showing significant differences when comparing AML cell populations for 
patients with and without clonal heterogeneity; the comparison being based on analysis of Biological 
Processes. The genes included in the analysis were identified by the comparison of 12 AML patient 
samples with and 27 samples without evidence for clonal heterogeneity when analyzing the PI3K-Akt-
mTOR pathway. Two GO-terms were then identified based; G-protein coupled receptor signaling 
pathway (GO:0007186; p-value 0.0000078; 43 genes) and Detection of chemical stimulus involved in 
sensory perception of smell (GO:0050911; p-value 0.000015; 26 genes). Several genes were included in 
both these terms; genes that did not overlap between these two terms are shaded in grey. Increased or 
decreased gene expression for patients with detectable subpopulations when analyzing constitutive 
PI3K-Akt-mTOR inhibition is indicated by upward arrows (↑) and downward arrows (↓), respectively. 
Biological Processes 
GO:0007186 - G-protein coupled receptor 
signaling pathway; p-value 0.0000078; 43 
genes 
GO:0050911 - Detection of chemical stimulus 
involved in sensory perception of smell; p-value 
0,000015; 26 genes 
↓ C-C motif chemokine ligand 15(CCL15) ↓ 
olfactory receptor family 1 subfamily D member 
4 (gene/pseudogene)(OR1D4) 
↑ G protein-coupled receptor 132(GPR132) ↓ 
olfactory receptor family 1 subfamily J member 
2(OR1J2) 
↑ G protein-coupled receptor 139(GPR139) ↓ 
olfactory receptor family 1 subfamily L member 
8(OR1L8) 
↓ G protein-coupled receptor 176(GPR176) ↑ 
olfactory receptor family 10 subfamily G 
member 3(OR10G3) 
↑ G protein-coupled receptor 183(GPR183) ↓ 
olfactory receptor family 12 subfamily D 
member 3(OR12D3) 
↑ G protein-coupled receptor 34(GPR34) ↓ 
olfactory receptor family 2 subfamily A member 
4(OR2A4) 
↓ 
G protein-coupled receptor class C group 5 
member C(GPRC5C) 
↓ 
olfactory receptor family 2 subfamily A member 
42(OR2A42) 
↓ 
G protein-coupled receptor class C group 6 
member A(GPRC6A) 
↓ 
olfactory receptor family 2 subfamily G member 
3(OR2G3) 
 
NLR family pyrin domain containing 
6(NLRP6) 
↓ 
olfactory receptor family 2 subfamily M member 
4(OR2M4) 
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↓ apolipoprotein C3(APOC3) ↓ 
olfactory receptor family 2 subfamily T member 
11 (gene/pseudogene)(OR2T11) 
↓ 
cadherin EGF LAG seven-pass G-type 
receptor 1(CELSR1) 
↓ 
olfactory receptor family 2 subfamily T member 
12(OR2T12) 
↓ frizzled class receptor 7(FZD7) ↑ 
olfactory receptor family 3 subfamily A member 
3(OR3A3) 
↑ natriuretic peptide receptor 1(NPR1) ↑ 
olfactory receptor family 4 subfamily C member 
16 (gene/pseudogene)(OR4C16) 
↓ 
olfactory receptor family 1 subfamily D 
member 4 (gene/pseudogene)(OR1D4) 
↓ 
olfactory receptor family 4 subfamily C member 
3(OR4C3) 
↓ 
olfactory receptor family 1 subfamily J 
member 2(OR1J2) 
↓ 
olfactory receptor family 4 subfamily C member 
45(OR4C45) 
↓ 
olfactory receptor family 1 subfamily L 
member 8(OR1L8) 
↓ 
olfactory receptor family 4 subfamily F member 
29(OR4F29) 
↑ 
olfactory receptor family 10 subfamily G 
member 3(OR10G3) 
↑ 
olfactory receptor family 5 subfamily AU 
member 1(OR5AU1) 
↓ 
olfactory receptor family 12 subfamily D 
member 3(OR12D3) 
↑ 
olfactory receptor family 5 subfamily H member 
15(OR5H15) 
↓ 
olfactory receptor family 2 subfamily A 
member 4(OR2A4) 
↑ 
olfactory receptor family 5 subfamily L member 
1 (gene/pseudogene)(OR5L1) 
↓ 
olfactory receptor family 2 subfamily A 
member 42(OR2A42) 
↓ 
olfactory receptor family 51 subfamily G 
member 2(OR51G2) 
 
olfactory receptor family 2 subfamily G 
member 3(OR2G3) 
↓ 
olfactory receptor family 52 subfamily L 
member 1(OR52L1) 
↓ 
olfactory receptor family 2 subfamily M 
member 4(OR2M4) 
↑ 
olfactory receptor family 6 subfamily Y member 
1(OR6Y1) 
↓ 
olfactory receptor family 2 subfamily T 
member 11 (gene/pseudogene)(OR2T11) 
↓ 
olfactory receptor family 8 subfamily D member 
4(OR8D4) 
↓ 
olfactory receptor family 2 subfamily T 
member 12(OR2T12) 
↓ 
olfactory receptor family 8 subfamily G member 
2(OR8G2) 
↑ 
olfactory receptor family 3 subfamily A 
member 3(OR3A3) 
↑ 
olfactory receptor family 8 subfamily J member 
1(OR8J1) 
↑ 
olfactory receptor family 4 subfamily C 
member 16 (gene/pseudogene)(OR4C16) 
↑ 
olfactory receptor family 9 subfamily I member 
1(OR9I1) 
↓ 





















olfactory receptor family 5 subfamily L 
member 1 (gene/pseudogene)(OR5L1) 
  
↓ 








olfactory receptor family 6 subfamily Y 
member 1(OR6Y1) 
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↓ 
















platelet derived growth factor receptor 
like(PDGFRL) 
  
↑ prostaglandin E receptor 1(PTGER1)   
↓ regulator of G-protein signaling 13(RGS13)   
↑ 
vomeronasal 1 receptor 5 
(gene/pseudogene)(VN1R5) 
  
Table S4. Monoclonal antibodies used in the flow-cytometric studies. 
Antibody Manufacturer Specificity  
Alexa Fluor®  647 Mouse anti-PTEN BD Biosciences 
Recognizes PTEN, regardless of 
phosphorylation status 
Alexa Fluor®  647 Mouse anti-PDPK1 (pS241) BD Biosciences 
Recognizes the phosphorylated S241 in the 
activation loop of human PDPK1 
Alexa Fluor®  647 Mouse anti-PKCα BD Biosciences 
Recognizes PKCα , regardless of 
phosphorylation status 
Alexa Fluor®  647 Mouse anti-PKCα (pT497) BD Biosciences 
Recognizes the phosphorylated T497 in the 
kinase domain of human PKC a 
PE Mouse anti-Akt1  BD Biosciences 
Recognizes Akt1, regardless of 
phosphorylation status 
Alexa Fluor®  647 Mouse anti-Akt (pS473) BD Biosciences Recognizes Akt phosphorylated at S473 
PE Mouse Anti-Akt (pT308) BD Biosciences Recognizes Akt phosphorylated at T308 
Anti-RHEB antibody Abcam 
Specifically detects Rheb, regardless of 
phosphorylation status 
Anti-Tuberin antibody Abcam Specifically detects Tuberin/TSC2 




Detects endogenous levels of total mTOR 
protein 
PE Mouse Anti-mTOR (pS2448) BD Biosciences 
Recognizes mTOR that is phosphorylated at 
S2448 
Anti-Raptor antibody Abcam 
Specifically detects raptor, regardless of 
phosphorylation status 
Anti-FKBP38 antibody Abcam 
Specifically detects FKBP38, regardless of 
phosphorylation status 
Alexa Fluor®  647 Mouse anti-4EBP1 
(pT36/pT45) 
BD Biosciences 
Recognizes the phosphorylated T36 and T45 
of activated human 4EBP1 
Alexa Fluor®  647 Mouse anti-elF4E (pS209) BD Biosciences 
Recognizes the phosphorylated S209 
(pS209) of eIF4E 
Alexa Fluor®  647 Mouse anti-S6 (pS244) BD Biosciences 
Specifically detects the S6 ribosomal protein 
phosphorylated at S244 
PE Mouse anti-S6 (pS240) BD Biosciences 
Specifically detects the S6 ribosomal protein 
phosphorylated at S240 
V450 Mouse anti-S6 (pS235/pS236) BD Biosciences 
Specifically detects the S6 ribosomal protein 
phosphorylated at S235 and S236 
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Table S5. The complete gene list from patients with dual AML cell populations. We compared the global 
gene expression profiles for 12 AML samples with and 27 samples without dual AML cell populations. 
A feature subset selection (FSS) analysis was performed for identification of the most discriminative 
genes between the two groups, and 1209 genes were then identified (i.e., p-value <0.05). 




127099 LOC127099 XM_060328.1 LOC127099 5.4429588162369E-5 
100133469 LOC100133469 XM_001724642.1 LOC100133469 1.7669808120755886E-4 
70 ACTC1 NM_005159.3 ACTC1 1.8889853780927157E-4 
441762 LOC441762 XR_000268.2 LOC441762 1.9046862375469861E-4 
29798 C2orf27A NM_013310.3 C2ORF27A 2.295635289463627E-4 
256302 C17orf103 NM_152914.1 C17ORF103 2.488848990283393E-4 
100132215 LOC100132215 XM_001725462.1 LOC100132215 3.06887290218517E-4 
100134277 LOC100134277 XM_001715852.1 LOC100134277 5.030423315792432E-4 
402562 LOC402562 XM_939955.1 LOC402562 5.296271780355028E-4 
92293 TMEM132C XM_941994.1 TMEM132C 6.06081218427997E-4 
100134261 LOC100134261 XM_001720725.1 LOC100134261 8.150840426564979E-4 
125704 C18orf51 XM_945013.1 C18ORF51 8.157639850416456E-4 
    Hs.582068 HS.582068 0.0010039973861543901 
2857 GPR34 NM_001033513.1 GPR34 0.0011522345386179183 
5602 MAPK10 NM_138980.1 MAPK10 0.0012104478969770386 
1390 CREM NM_001881.2 CREM 0.0012766444909731805 
23213 SULF1 NM_015170.1 SULF1 0.0013817061034787775 
127845 GOLT1A NM_198447.1 GOLT1A 0.0014992835786023498 
4143 MAT1A NM_000429.2 MAT1A 0.00159068162706494 
766 CA7 NM_005182.2 CA7 0.001644218788577064 
647645 LOC647645 XM_942915.1 LOC647645 0.0019364782100578552 
54801 HAUS6 NM_017645.3 HAUS6 0.0021784295379641723 
64897 C12orf43 NM_022895.1 C12ORF43 0.0022888948062138475 
645333 LOC645333 XM_932822.1 LOC645333 0.002298417112688192 
100129122 LOC100129122 XM_001714405.1 LOC100129122 0.002358840674516944 
650686 LOC650686 XM_001714190.1 LOC650686 0.002402213696133287 
100130453 LOC100130453 XM_001717928.1 LOC100130453 0.0024686861240564824 
728534 LOC728534 XM_496481.2 LOC728534 0.0024810022011861103 
    Hs.544400 HS.544400 0.002570670446831798 
    Hs.90866 HS.90866 0.002622155947935263 
9578 CDC42BPB NM_006035.2 CDC42BPB 0.0026464265370225127 
390561 LOC390561 XM_931039.1 LOC390561 0.0030045102560638933 
126006 PCP2 NM_174895.1 PCP2 0.003152601601927658 
9994 CASP8AP2 NM_012115.2 CASP8AP2 0.003163468273950473 
2266 FGG NM_000509.4 FGG 0.003165510367807606 
647307 LOC647307 XR_039752.1 LOC647307 0.0031975215144755143 
100134549 LOC100134549 XM_001724842.1 LOC100134549 0.0032950797679523972 
6812 STXBP1 NM_001032221.1 STXBP1 0.003339918394712154 
643441 LOC643441 XM_933117.1 LOC643441 0.003445040137023792 
1004 CDH6 NM_004932.2 CDH6 0.003606641166778987 
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646201 LOC646201 XR_038827.1 LOC646201 0.003735695619295815 
124274 GPR139 NM_001002911.1 GPR139 0.0038673555386653483 
    Hs.541889 HS.541889 0.003928735303692297 
51557 LGSN NM_016571.1 LGSN 0.00396746217456975 
100129027 LOC100129027 XM_001726404.1 LOC100129027 0.004310105288322697 
64241 ABCG8 NM_022437.2 ABCG8 0.004340420679539069 
200576 PIP5K3 NM_152671.2 PIP5K3 0.004391969194981006 
284359 IZUMO1 NM_182575.1 IZUMO1 0.004395986667519091 
72 ACTG2 NM_001615.3 ACTG2 0.004571774525431297 
    Hs.308351 HS.308351 0.004593524046106714 
441873 LOC441873 XM_497653.2 LOC441873 0.004867506422327089 
9247 GCM2 NM_004752.1 GCM2 0.004942484701647254 
    Hs.564111 HS.564111 0.004988788091118323 
148203 LOC148203 XM_938387.1 LOC148203 0.005112562979819541 
441177 LOC441177 NM_001013720.1 LOC441177 0.0051398015983046535 
9217 VAPB NM_004738.3 VAPB 0.005175783078796158 
391112 OR6Y1 NM_001005189.1 OR6Y1 0.0052210678682481125 
338785 KRT79 NM_175834.2 KRT79 0.005267242199597024 
10675 CSPG5 NM_006574.2 CSPG5 0.005338716851169746 
4837 NNMT NM_006169.2 NNMT 0.005340018415067846 
731605 LOC731605 XM_001732887.1 LOC731605 0.0053742561572059306 
158062 LCN6 NM_198946.2 LCN6 0.00551050561678674 
    Hs.550619 HS.550619 0.005615448366994092 
5903 RANBP2 NM_006267.3 RANBP2 0.005944117799023746 
100134560 LOC100134560 XM_001718995.1 LOC100134560 0.00603271039077236 
81575 APOLD1 NM_030817.1 APOLD1 0.0061665469488665905 
55607 PPP1R9A XM_934519.1 PPP1R9A 0.006209093089838259 
51233 C22orf43 NM_016449.2 C22ORF43 0.006251254964463802 
729731 LOC729731 XM_001131140.1 LOC729731 0.006443489149451054 
641746 LOC641746 XR_036993.1 LOC641746 0.0064734119737271095 
401399 LOC401399 XM_938040.1 LOC401399 0.006503933510587002 
91445 RNF185 NM_152267.2 RNF185 0.006643879293476746 
343069 HNRNPCL1 NM_001013631.1 HNRNPCL1 0.00668848680455546 
653342 LOC653342 XM_926986.1 LOC653342 0.006704451522523867 
    Hs.130971 HS.130971 0.006835062263307346 
90326 THAP3 NM_138350.2 THAP3 0.006845201780484901 
406993 MIR211 NR_029624.1 MIR211 0.007000712087657615 
27253 PCDH17 NM_014459.2 PCDH17 0.007157587685755881 
317705 VN1R5 NM_173858.1 VN1R5 0.007308537801323615 
642698 LOC642698 XM_926147.1 LOC642698 0.007500827909900659 
647591 LOC647591 XM_936642.1 LOC647591 0.00768313187287398 
100129999 LOC100129999 XM_001723251.1 LOC100129999 0.007978078516773852 
652874 LOC652874 XM_942590.1 LOC652874 0.008058888114695309 
100133191 LOC100133191 XM_001720224.1 LOC100133191 0.008172412960470546 
6792 CDKL5 NM_003159.2 CDKL5 0.008262129917024259 
387267 KRTAP5-4 NM_001012709.1 KRTAP5-4 0.00833750183090909 
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400941 FLJ42418 NM_001001695.1 FLJ42418 0.008346757855315017 
57611 ISLR2 NM_020851.1 ISLR2 0.008393630774620991 
23269 MGA NM_001080541.1 MGA 0.008679894079816232 
85376 RIMBP3 NM_015672.1 RIMBP3 0.008898642569320844 
284323 ZNF780A NM_001010880.1 ZNF780A 0.008978682929154574 
653539 LOC653539 XM_934566.1 LOC653539 0.009019103245916179 
386681 KRTAP10-8 NM_198695.1 KRTAP10-8 0.009021269079951547 
3800 KIF5C NM_004522.1 KIF5C 0.009118444043063216 
652882 LOC652882 XM_942599.1 LOC652882 0.009171572198060862 
641955 LOC641955 XM_935721.1 LOC641955 0.0093460168089686 
3620 IDO1 NM_002164.4 IDO1 0.009363909447106255 
378884 NHLRC1 NM_198586.2 NHLRC1 0.0094580006051593 
652737 LOC652737 XM_001718112.1 LOC652737 0.009546427444424247 
54778 RNF111 NM_017610.6 RNF111 0.00968125336763508 
100129083 LOC100129083 XM_001724757.1 LOC100129083 0.009689938019977624 
51364 ZMYND10 NM_015896.2 ZMYND10 0.009907589492135787 
    Hs.542544 HS.542544 0.009956858921022441 
649909 LOC649909 XM_943982.1 LOC649909 0.010006376036609718 
1325 CORT NM_001302.3 CORT 0.010217548361631685 
    Hs.563373 HS.563373 0.010407261517864428 
59350 RXFP1 NM_021634.1 RXFP1 0.010545283382671588 
7321 UBE2D1 NM_003338.3 UBE2D1 0.010566544072874764 
84083 ZRANB3 NM_032143.2 ZRANB3 0.010841513823416579 
158763 FLJ30058 NM_144967.2 FLJ30058 0.010930058649637631 
10537 UBD NM_006398.2 UBD 0.011172926856343891 
54462 FAM190B NM_018999.2 FAM190B 0.011271251153973216 
650154 LOC650154 XM_944071.1 LOC650154 0.01129310117726207 
11218 DDX20 NM_007204.3 DDX20 0.011344211025161022 
644116 LOC644116 XM_933284.1 LOC644116 0.011369913354189182 
4103 MAGEA4 NM_001011550.1 MAGEA4 0.011459719768653004 
8085 MLL2 NM_003482.1 MLL2 0.011495307726533902 
3709 ITPR2 NM_002223.1 ITPR2 0.011520969086767587 
340481 ZDHHC21 NM_178566.2 ZDHHC21 0.011700678983183417 
441332 FAM90A12 XM_496961.2 FAM90A12 0.011926926139427045 
    Hs.27048 HS.27048 0.012139723893189567 
100132839 LOC100132839 XM_001725950.1 LOC100132839 0.012251193131297656 
643338 LOC643338 XM_927997.1 LOC643338 0.012309378127665593 
    Hs.522935 HS.522935 0.012366037463090873 
100313774 MIR302E NR_031683.1 MIR302E 0.012466799678927403 
    Hs.560698 HS.560698 0.012548076535386902 
131831 FAM194A NM_152394.2 FAM194A 0.012617196044206526 
30818 KCNIP3 NM_013434.3 KCNIP3 0.012677315030705984 
285311 C3orf56 NM_001007534.1 C3ORF56 0.01269820706499609 
402381 SOHLH1 NM_001012415.1 SOHLH1 0.012733956612552355 
643038 LOC643038 XM_926407.1 LOC643038 0.012838978911910548 
    Hs.542481 HS.542481 0.013035512837795495 
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100302274 MIR1178 NR_031589.1 MIR1178 0.01305870627028648 
    Hs.538176 HS.538176 0.013288378164829525 
728747 LOC728747 XM_928873.1 LOC728747 0.013678378485791646 
    Hs.565086 HS.565086 0.013681184497987222 
9249 DHRS3 NM_004753.4 DHRS3 0.013702070752348021 
100129808 LOC100129808 XR_039762.1 LOC100129808 0.013741295789919082 
100133577 LOC100133577 XM_001716788.1 LOC100133577 0.013790216364984282 
649991 LOC649991 XM_939078.1 LOC649991 0.01379355474644613 
  ERCC-00098 ERCC-00098 ERCC-00098 0.013910035983225006 
100134057 LOC100134057 XM_001718124.1 LOC100134057 0.01407780501664926 
283687 C15orf37 NM_175898.2 C15ORF37 0.014124185960867468 
3626 INHBC NM_005538.2 INHBC 0.014353200725974444 
644419 LOC644419 XM_932175.1 LOC644419 0.014357581612702485 
2255 FGF10 NM_004465.1 FGF10 0.014382194667132114 
100129583 FAM47E NM_001136570.1 FAM47E 0.014423022504089493 
    Hs.523127 HS.523127 0.01443578466046612 
441956 LOC441956 XM_498859.2 LOC441956 0.01450209839706341 
415 ARSE NM_000047.1 ARSE 0.014587512708243683 
406905 MIR1-2 NR_029662.1 MIR1-2 0.014600747058617292 
9366 RAB9P1 NR_000039.1 RAB9P1 0.014848160505048023 
6853 SYN1 NM_006950.2 SYN1 0.01507960250070801 
727944 LOC727944 Hs.444961 LOC727944 0.015091515444061319 
202459 LOC202459 NM_145303.1 LOC202459 0.015143355361588198 
150244 FLJ31568 NM_152509.1 FLJ31568 0.015402338394228391 
389633 LOC389633 XM_372030.4 LOC389633 0.015490223100747054 
100132117 LOC100132117 XM_001725240.1 LOC100132117 0.015580093268710318 
391670 LOC391670 XR_019025.1 LOC391670 0.015722796465197728 
400156 RPS26L NR_002225.2 RPS26L 0.01576965248812111 
266697 POM121L4P NR_024592.1 POM121L4P 0.01579271983878519 
    Hs.560984 HS.560984 0.015800344711278804 
254173 TTLL10 NM_153254.1 TTLL10 0.015812652787782506 
6326 SCN2A NM_021007.2 SCN2A 0.015940809007239015 
653275 LOC653275 XM_932990.1 LOC653275 0.016001770436982435 
    Hs.259386 HS.259386 0.016004345473892765 
650975 LOC650975 XM_940080.1 LOC650975 0.016029588990556298 
652258 LOC652258 XM_941668.1 LOC652258 0.01608013134347099 
63974 NEUROD6 NM_022728.2 NEUROD6 0.016150373017089045 
285643 KIF4B NM_001099293.1 KIF4B 0.016248333616922687 
    Hs.159049 HS.159049 0.016366558208216923 
653424 LOC653424 XM_932020.1 LOC653424 0.01637344608415435 
646269 LOC646269 XR_019325.2 LOC646269 0.016470839817159313 
    Hs.390407 HS.390407 0.016512944520498406 
8601 RGS20 NM_170587.1 RGS20 0.016542861227450488 
51430 C1orf9 NM_014283.2 C1ORF9 0.01685998003402229 
652798 LOC652798 XM_942459.1 LOC652798 0.016879126997924807 
164684 WBP2NL NM_152613.1 WBP2NL 0.016883078047378892 
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728603 FRMPD2L2 XM_931737.1 FRMPD2L2 0.016916786673588584 
644710 LOC644710 XM_932320.1 LOC644710 0.017266395442179817 
116966 WDR17 NM_170710.3 WDR17 0.017375785759740654 
22801 ITGA11 NM_012211.3 ITGA11 0.01749005821141641 
100133718 LOC100133718 XM_001713866.1 LOC100133718 0.01757902065841129 
64493 C16orf10 NR_024121.1 C16ORF10 0.017662612203510786 
653140 LOC653140 XM_931412.1 LOC653140 0.017685876567057807 
375567 VWC2 NM_198570.1 VWC2 0.017809725623884182 
100134592 LOC100134592 XR_039069.1 LOC100134592 0.01784849213198316 
100133431 LOC100133431 XM_001713711.1 LOC100133431 0.018033690902546494 
390507 LOC390507 XM_941221.1 LOC390507 0.018059490429512676 
791115 PWRN2 NR_026647.1 PWRN2 0.01809236729739171 
652128 LOC652128 XM_941465.1 LOC652128 0.018097957782505475 
100302139 MIR1537 NR_031718.1 MIR1537 0.01813555205320322 
    Hs.577082 HS.577082 0.018400209049827254 
5176 SERPINF1 NM_002615.4 SERPINF1 0.018577222684230937 
350 APOH NM_000042.1 APOH 0.018690631761723663 
10551 AGR2 NM_006408.3 AGR2 0.018848439149668654 
323 APBB2 NM_173075.3 APBB2 0.01892954217116504 
653419 LOC653419 XM_934475.1 LOC653419 0.018976474616645995 
147650 LOC147650 NM_207324.1 LOC147650 0.018986756554713668 
11096 ADAMTS5 NM_007038.2 ADAMTS5 0.01913768724155538 
150368 FAM109B NM_001002034.1 FAM109B 0.019167605385620224 
406887 MIRLET7E NR_029482.1 MIRLET7E 0.019214688371754666 
64506 CPEB1 NM_030594.3 CPEB1 0.01924155328879387 
    Hs.131656 HS.131656 0.01967564250413684 
644090 LOC644090 XM_945887.1 LOC644090 0.019790031059694815 
652071 LOC652071 XM_930113.1 LOC652071 0.019830966384617423 
641852 LOC641852 XM_935593.1 LOC641852 0.019928268073840807 
85360 SYDE1 NM_033025.4 SYDE1 0.020251423488305664 
401101 LOC401101 XM_379234.3 LOC401101 0.020290327540105495 
4008 LMO7 NM_005358.3 LMO7 0.02032681405922698 
246213 SLC17A8 NM_139319.1 SLC17A8 0.02040938433833191 
    Hs.450953 HS.450953 0.020425896992517793 
100133118 LOC100133118 XM_001719352.1 LOC100133118 0.020561847635159287 
3913 LAMB2 NM_002292.2 LAMB2 0.020727864885455943 
    Hs.523508 HS.523508 0.02072946020971049 
5345 SERPINF2 NM_000934.1 SERPINF2 0.02075928219921853 
22844 FRMPD1 NM_014907.1 FRMPD1 0.02094698274076949 
    Hs.577845 HS.577845 0.020961537623100948 
4666 NACA NM_005594.2 NACA 0.02100119453837278 
255426 RASGEF1C NM_001031799.1 RASGEF1C 0.021191749833611283 
255626 HIST1H2BA NM_170610.2 HIST1H2BA 0.021376189511903815 
650965 LOC650965 XM_944440.1 LOC650965 0.0214008969373685 
643534 LOC643534 XM_936822.2 LOC643534 0.021559336520668215 
140738 TMEM37 NM_183240.1 TMEM37 0.021599174420979573 
Cancers 2018, 10, 332 S14 of S35 
148170 CDC42EP5 NM_145057.2 CDC42EP5 0.021608582355112586 
8139 GAN NM_022041.2 GAN 0.02170980675855108 
642441 LOC642441 XM_930678.3 LOC642441 0.021736426354992913 
139189 DGKK NM_001013742.1 DGKK 0.021767396571142218 
650180 LOC650180 XM_939263.1 LOC650180 0.02182579988548141 
933 CD22 NM_001771.1 CD22 0.021869730561595586 
442251 LOC442251 XM_498135.2 LOC442251 0.02187831310995123 
644037 LOC644037 XR_017337.2 LOC644037 0.022220250277086427 
337967 KRTAP6-2 NM_181604.1 KRTAP6-2 0.02222310695794649 
644841 LOC644841 XM_927936.1 LOC644841 0.022422888467140092 
    Hs.578887 HS.578887 0.02243599378753856 
284541 CYP4A22 NM_001010969.2 CYP4A22 0.022461197895480303 
    Hs.544737 HS.544737 0.022511129189707275 
81555 YIPF5 NM_030799.6 YIPF5 0.022539229264113298 
649501 LOC649501 XM_938580.1 LOC649501 0.022567620190517213 
29933 GPR132 NM_013345.2 GPR132 0.022575922292977182 
729732 LOC729732 XM_932827.1 LOC729732 0.022685263572146966 
1946 EFNA5 NM_001962.1 EFNA5 0.022870521985390184 
9957 HS3ST1 NM_005114.2 HS3ST1 0.023096833903532978 
100131294 LOC100131294 XM_001718622.1 LOC100131294 0.02335883403484874 
219437 OR5L1 NM_001004738.1 OR5L1 0.023421551832223223 
728753 FAM90A19 XM_001129368.2 FAM90A19 0.02348762306281699 
83999 KREMEN1 NM_032045.3 KREMEN1 0.023749641111062317 
55871 CBWD1 NM_018491.3 CBWD1 0.0237621427097727 
81930 KIF18A NM_031217.2 KIF18A 0.023886877809522717 
730077 LOC730077 XM_929823.1 LOC730077 0.023982448377878662 
55554 KLK15 NM_017509.2 KLK15 0.0240493655076375 
27290 SPINK4 NM_014471.1 SPINK4 0.02408277086088165 
349114 LOC349114 XR_040229.1 LOC349114 0.024269512235205234 
100131223 LOC100131223 XR_039276.1 LOC100131223 0.02448826957591335 
79750 ZNF385D NM_024697.1 ZNF385D 0.02449260284148093 
652608 LOC652608 XM_942140.1 LOC652608 0.024538555779626832 
390445 OR5AU1 NM_001004731.1 OR5AU1 0.024666882109893585 
1446 CSN1S1 NM_001890.1 CSN1S1 0.0247003630519056 
574436 MIR485 NR_030160.1 MIR485 0.024719706991961146 
653453 LOC653453 XM_933338.1 LOC653453 0.02494463989225702 
85508 SCRT2 NM_033129.1 SCRT2 0.025139068866499865 
645649 LOC645649 XM_928663.1 LOC645649 0.025223184090347517 
171389 NLRP6 NM_138329.1 NLRP6 0.025317308419384465 
133482 SLCO6A1 NM_173488.2 SLCO6A1 0.025329794343735376 
    Hs.132448 HS.132448 0.02553378780006922 
80818 ZNF436 NM_030634.1 ZNF436 0.0255551614087837 
80031 SEMA6D NM_024966.2 SEMA6D 0.025558717309230792 
92340 C17orf72 NR_015354.2 C17ORF72 0.025633877058255945 
    Hs.399823 HS.399823 0.025670833890299852 
100133067 LOC100133067 XM_001725464.1 LOC100133067 0.02589841479039926 
Cancers 2018, 10, 332 S15 of S35 
23262 HISPPD1 NM_015216.2 HISPPD1 0.025898595112993666 
    Hs.537971 HS.537971 0.026063789227305127 
54822 TRPM7 NM_017672.2 TRPM7 0.0261330076463797 
100132088 LOC100132088 XR_037760.1 LOC100132088 0.026147330213606424 
10846 PDE10A NM_006661.1 PDE10A 0.02617993149900035 
    Hs.494628 HS.494628 0.026203085945303402 
100128328 LOC100128328 XM_001715053.1 LOC100128328 0.026391195653177747 
284912 LOC284912 NM_203375.1 LOC284912 0.02645942324817142 
100133959 LOC100133959 XM_001720421.1 LOC100133959 0.026649547761975846 
5205 ATP8B1 NM_005603.2 ATP8B1 0.026998467102858623 
    Hs.164254 HS.164254 0.02708058345318273 
645870 LOC645870 XM_930479.1 LOC645870 0.02708664365272622 
5681 PSKH1 NM_006742.1 PSKH1 0.027094411579846493 
644264 LOC644264 XM_927442.1 LOC644264 0.027203704934803792 
23414 ZFPM2 NM_012082.2 ZFPM2 0.027380423257296505 
219954 OR9I1 NM_001005211.1 OR9I1 0.027405531858696788 
100129461 LOC100129461 XM_001719437.1 LOC100129461 0.027424973554395375 
54477 PLEKHA5 NM_019012.2 PLEKHA5 0.027462476844466694 
29785 CYP2S1 NM_030622.5 CYP2S1 0.027469637841125567 
57045 TWSG1 NM_020648.3 TWSG1 0.027547802917928584 
10869 USP19 NM_006677.1 USP19 0.027715324591564602 
100133911 LOC100133911 XM_001714502.1 LOC100133911 0.02782298055874275 
100132029 LOC100132029 XM_001719312.1 LOC100132029 0.027832907304590242 
651125 LOC651125 XM_940255.1 LOC651125 0.02787994837746972 
257396 LOC257396 XM_001715443.1 LOC257396 0.027909105492990874 
730389 LOC730389 XM_001726418.1 LOC730389 0.02802181380683962 
649151 LOC649151 XM_944782.1 LOC649151 0.028035977164727922 
57084 SLC17A6 NM_020346.1 SLC17A6 0.02808767449264285 
10417 SPON2 NM_012445.1 SPON2 0.02809670267559562 
729826 LOC729826 XM_932003.1 LOC729826 0.02810333996192765 
138715 ARID3C NM_001017363.1 ARID3C 0.028113477207784367 
    Hs.543971 HS.543971 0.02817707262444036 
400844 FLJ42133 NM_001001690.1 FLJ42133 0.02820580226917168 
    Hs.444411 HS.444411 0.028238626580358715 
401648 LOC401648 XR_038983.1 LOC401648 0.028314991818208114 
650428 LOC650428 XM_939516.1 LOC650428 0.028702941205273995 
100133896 LOC100133896 XM_001723682.1 LOC100133896 0.028715684876214117 
401491 FLJ35024 NR_015375.1 FLJ35024 0.028811076040184593 
221468 TMEM217 XM_929843.1 TMEM217 0.029022603350601032 
11185 INMT NM_006774.4 INMT 0.0291037479385151 
100129159 LOC100129159 XM_001719666.1 LOC100129159 0.029374739907140807 
389671 LOC389671 XM_374275.2 LOC389671 0.029484891395720376 
154288 C6orf221 NM_001017361.2 C6ORF221 0.029593828182104785 
647154 LOC647154 XM_934436.1 LOC647154 0.029829653041726342 
386724 AMIGO3 NM_198722.1 AMIGO3 0.029951202277859936 
89796 NAV1 NM_020443.2 NAV1 0.02999043524271502 
Cancers 2018, 10, 332 S16 of S35 
56751 BARHL1 NM_020064.2 BARHL1 0.030022852681444435 
133619 PRRC1 NM_130809.2 PRRC1 0.030187721912594043 
64122 FN3K NM_022158.2 FN3K 0.03021107536473889 
56254 RNF20 NM_019592.5 RNF20 0.03033470528345383 
8771 TNFRSF6B NM_032945.2 TNFRSF6B 0.03035914723145836 
8392 OR3A3 NM_012373.1 OR3A3 0.03053809988231804 
    Hs.133261 HS.133261 0.030568099022101985 
100131124 LOC100131124 XR_038480.1 LOC100131124 0.03061359552459085 
655 BMP7 NM_001719.1 BMP7 0.030651295946450993 
145447 ABHD12B NM_181533.3 ABHD12B 0.030664450871831905 
114902 C1QTNF5 NM_015645.2 C1QTNF5 0.0307441372846035 
1272 CNTN1 NM_001843.2 CNTN1 0.030973923100136438 
100134397 LOC100134397 XM_001716222.1 LOC100134397 0.03102925073273608 
4747 NEFL NM_006158.1 NEFL 0.031244890324453 
51201 ZDHHC2 NM_016353.2 ZDHHC2 0.03130797889576718 
645038 LOC645038 XM_932599.1 LOC645038 0.03134188336365769 
100131507 LOC100131507 XR_038156.1 LOC100131507 0.031346082065930175 
    Hs.195035 HS.195035 0.031634632331781154 
654346 LGALS9C NM_001040078.2 LGALS9C 0.031764887661290764 
8563 THOC5 NM_001002878.1 THOC5 0.03191725864259395 
100132705 LOC100132705 XM_001715205.1 LOC100132705 0.03192907747211482 
55545 MSX2P1 NR_002307.1 MSX2P1 0.0319808871078602 
219428 OR4C16 NM_001004701.1 OR4C16 0.03203493369424288 
647247 LOC647247 XM_934568.1 LOC647247 0.032152819934808 
56849 TCEAL7 NM_152278.1 TCEAL7 0.03222680725793716 
57175 CORO1B NM_020441.2 CORO1B 0.03222783672970617 
641768 LOC641768 XM_935907.3 LOC641768 0.0322664317396529 
197407 ZNF48 NM_152652.1 ZNF48 0.03229426087776541 
100302163 MIR1278 NR_031691.1 MIR1278 0.032440391913297596 
55679 LIMS2 NM_017980.2 LIMS2 0.032517058083104546 
5834 PYGB NM_002862.3 PYGB 0.032539078867889336 
644934 LOC644934 XM_934677.1 LOC644934 0.0325617138291315 
1302 COL11A2 NM_080681.1 COL11A2 0.03256917573410545 
    Hs.156178 HS.156178 0.03263352286288794 
725 C4BPB NM_001017367.1 C4BPB 0.03290258407073522 
3741 KCNA5 NM_002234.2 KCNA5 0.033000791233888896 
441233 LOC441233 NM_001013724.1 LOC441233 0.03308686516536579 
651008 LOC651008 XM_940120.1 LOC651008 0.03331768852877934 
440243 LOC440243 XM_496041.3 LOC440243 0.033377254112434064 
653876 LOC653876 XM_936221.1 LOC653876 0.033379693490334726 
79677 SMC6 NM_024624.3 SMC6 0.03343033375558616 
401957 LOC401957 XM_496379.2 LOC401957 0.03343759911919372 
114815 SORCS1 NM_052918.3 SORCS1 0.03385617247917471 
100128404 LOC100128404 XM_001713786.1 LOC100128404 0.03386855319301855 
652286 LOC652286 XM_941705.1 LOC652286 0.033962860994464016 
399706 LOC399706 NM_001010910.1 LOC399706 0.034007211184900424 
Cancers 2018, 10, 332 S17 of S35 
1413 CRYBA4 NM_001886.1 CRYBA4 0.03401175055796066 
441502 RPS26P11 NR_002309.1 RPS26P11 0.03409019967664746 
    Hs.207074 HS.207074 0.034157092547502425 
11281 POU6F2 NM_007252.2 POU6F2 0.0342334160199717 
25903 OLFML2B NM_015441.1 OLFML2B 0.03426761739469739 
911 CD1C NM_001765.1 CD1C 0.03437678703029185 
201181 ZNF385C NM_001013624.1 ZNF385C 0.03442394727482257 
    Hs.61151 HS.61151 0.03450872404206222 
    Hs.572889 HS.572889 0.034602714666213466 
283824 LOC283824 XM_936476.1 LOC283824 0.03469855579099817 
389320 C5orf48 NM_207408.1 C5ORF48 0.03480603097892593 
643943 LOC643943 XM_934575.1 LOC643943 0.03492449423224515 
84140 FLJ13305 NM_032180.1 FLJ13305 0.034924817386345224 
653149 NBPF6 XM_926213.3 NBPF6 0.034948186249392776 
83755 KRTAP4-12 NM_031854.2 KRTAP4-12 0.03495961113206711 
644222 LOC644222 XM_932052.1 LOC644222 0.03502179995398587 
403274 OR5H15 NM_001005515.1 OR5H15 0.03528865792443498 
642302 LOC642302 XM_925847.1 LOC642302 0.03532679261216908 
5757 PTMA NM_002823.2 PTMA 0.03533048715758714 
85449 KIAA1755 NM_001029864.1 KIAA1755 0.03550092188291261 
280658 SSX7 NM_173358.2 SSX7 0.035527787941814014 
    Hs.559234 HS.559234 0.035570714704618304 
8894 EIF2S2 NM_003908.3 EIF2S2 0.03570589969817165 
647123 LOC647123 XM_930141.1 LOC647123 0.035816525085092685 
353140 LCE2C NM_178429.2 LCE2C 0.035934579863750746 
677801 SNORA14A NR_002955.1 SNORA14A 0.0361854163552442 
125058 TBC1D16 NM_019020.2 TBC1D16 0.03626812263100942 
652469 LOC652469 XM_941921.1 LOC652469 0.0362927530207742 
    Hs.66072 HS.66072 0.03637146426565126 
7128 TNFAIP3 NM_006290.2 TNFAIP3 0.03639524499582533 
84667 HES7 NM_032580.1 HES7 0.0364117990492306 
644928 LOC644928 NM_001093732.1 LOC644928 0.036419987574674156 
7809 BSND NM_057176.2 BSND 0.03653091396146062 
440792 LOC440792 XM_496493.2 LOC440792 0.03654208725894107 
492303 LOC492303 NR_002830.1 LOC492303 0.03660139461851856 
401281 FLJ27255 NM_207501.1 FLJ27255 0.03662507602211143 
391767 LOC391767 XM_936313.1 LOC391767 0.036632788973511736 
645141 LOC645141 XM_932673.1 LOC645141 0.036680323689545984 
375607 C7orf52 NM_198571.1 C7ORF52 0.03678010633215606 
400169 DKFZp451A211 NM_001003399.1 DKFZP451A211 0.037087843662292584 
441257 LOC441257 NM_001023562.1 LOC441257 0.03748984854102287 
5998 RGS3 NM_130795.2 RGS3 0.03750498381085232 
30845 EHD3 NM_014600.1 EHD3 0.03752440328750746 
128209 KLF17 NM_173484.2 KLF17 0.03753163799650583 
86614 HSFY1 NM_001001871.1 HSFY1 0.03756517173064518 
643717 LOC643717 XM_931762.1 LOC643717 0.03759956434879695 
Cancers 2018, 10, 332 S18 of S35 
3185 HNRNPF NM_004966.2 HNRNPF 0.03766736732960908 
60482 SLC5A7 NM_021815.2 SLC5A7 0.037777752067761614 
84775 ZNF607 NM_032689.3 ZNF607 0.037833110045205016 
646982 LOC646982 XM_929953.1 LOC646982 0.037858020157582745 
26533 OR10G3 NM_001005465.1 OR10G3 0.03787398889924781 
100132994 LOC100132994 XM_001716545.1 LOC100132994 0.0381880201170454 
51454 GULP1 NM_016315.2 GULP1 0.03823336785815221 
147670 LOC147670 XM_938354.1 LOC147670 0.038271133361022 
100133667 LOC100133667 XM_001716955.1 LOC100133667 0.038353586825590834 
441377 LOC441377 XM_938599.1 LOC441377 0.038425188952630224 
    Hs.576557 HS.576557 0.03845300174614561 
27190 IL17B NM_014443.2 IL17B 0.03851235934753757 
1612 DAPK1 NM_004938.1 DAPK1 0.038513267889527844 
406981 MIR19B2 NR_029491.1 MIR19B2 0.03865875848007942 
100129489 LOC100129489 XM_001725742.1 LOC100129489 0.0388785449116513 
389043 LOC389043 XM_374012.2 LOC389043 0.038894805019877444 
2326 FMO1 NM_002021.1 FMO1 0.0389169991967331 
643369 LOC643369 XM_926699.1 LOC643369 0.03894931459555177 
646688 LOC646688 XR_038043.1 LOC646688 0.03904764703794127 
407009 MIR224 NR_029638.1 MIR224 0.039111411385302795 
9991 ROD1 NM_005156.4 ROD1 0.03912009402141927 
55901 THSD1 NM_018676.2 THSD1 0.0391402794320996 
387742 FAM99A NM_001014374.1 FAM99A 0.039529403362823914 
504188 LOC504188 NM_001013404.1 LOC504188 0.03960475777464169 
55748 CNDP2 NM_018235.1 CNDP2 0.03969157665674203 
641515 LOC641515 XR_041510.1 LOC641515 0.0397689232251305 
80318 GKAP1 NM_025211.2 GKAP1 0.03986648588847759 
389376 SFTA2 NM_205854.1 SFTA2 0.03999423728853999 
648533 LOC648533 XM_937587.1 LOC648533 0.04031944639793983 
10694 CCT8 NM_006585.2 CCT8 0.0403292788968682 
6098 ROS1 NM_002944.2 ROS1 0.04033312843536948 
6670 SP3 NM_003111.3 SP3 0.04042713037654128 
1404 HAPLN1 NM_001884.2 HAPLN1 0.04048525841710001 
4881 NPR1 NM_000906.2 NPR1 0.040502565677173176 
649801 LOC649801 XM_938871.1 LOC649801 0.04050521442632797 
650144 LOC650144 XM_939226.1 LOC650144 0.04054045691347192 
4887 NPY2R NM_000910.2 NPY2R 0.04079826941342508 
60439 TTTY2 NR_001536.1 TTTY2 0.04092232641545795 
652517 LOC652517 XM_941993.1 LOC652517 0.041006153896141075 
    Hs.575322 HS.575322 0.04100760502736633 
644421 LOC644421 XM_932176.1 LOC644421 0.04115702923750378 
    Hs.567469 HS.567469 0.04119812979787987 
644150 LOC644150 XM_933686.1 LOC644150 0.04121231842909383 
26301 GBGT1 NM_021996.3 GBGT1 0.04133282944557231 
56947 MFF NM_020194.4 MFF 0.04134914870555508 
124790 HEXIM2 NM_144608.1 HEXIM2 0.0414099130711993 
Cancers 2018, 10, 332 S19 of S35 
4781 NFIB NM_005596.1 NFIB 0.04142927296674448 
652667 LOC652667 XM_942241.1 LOC652667 0.04145856823506089 
    Hs.550320 HS.550320 0.041472016762589686 
728353 LOC728353 XR_041035.1 LOC728353 0.04148634552345762 
    Hs.538064 HS.538064 0.041536830424488996 
100130648 LOC100130648 XM_001719568.1 LOC100130648 0.04156307760807585 
100302138 MIR1292 NR_031699.1 MIR1292 0.041597253865857386 
54842 MFSD6 NM_017694.2 MFSD6 0.04168319322226114 
100129722 LOC100129722 XM_001723078.1 LOC100129722 0.04178887578344652 
728897 LOC728897 XM_001714242.1 LOC728897 0.04179921046302966 
    Hs.570505 HS.570505 0.04186242156445938 
642828 LOC642828 XR_016385.2 LOC642828 0.04189952262354723 
128876 FAM83C NM_178468.2 FAM83C 0.0420309294383992 
7350 UCP1 NM_021833.3 UCP1 0.04209019401793435 
57703 CWC22 NM_020943.1 CWC22 0.042102050543425557 
2162 F13A1 NM_000129.2 F13A1 0.042112733355483295 
8463 TEAD2 NM_003598.1 TEAD2 0.04212361026047233 
123624 AGBL1 Hs.569517 AGBL1 0.042251663296841206 
51155 HN1 NM_016185.2 HN1 0.04254373110656518 
654085 LOC654085 XM_942123.1 LOC654085 0.04257358154415917 
    Hs.547985 HS.547985 0.04260022423480719 
4780 NFE2L2 NM_006164.2 NFE2L2 0.04267011054111266 
728612 LOC728612 XR_015601.1 LOC728612 0.0427617681836858 
100131909 LOC100131909 XM_001722362.1 LOC100131909 0.04290454348425088 
23284 LPHN3 NM_015236.3 LPHN3 0.04330834214616471 
85443 DCLK3 NM_033403.1 DCLK3 0.043353620219200605 
9840 KIAA0748 XM_934138.1 KIAA0748 0.04336354602898456 
650646 LOC650646 XM_930416.1 LOC650646 0.04349481866826087 
26168 SENP3 NM_015670.3 SENP3 0.043643046874244765 
441655 LOC441655 XM_497366.2 LOC441655 0.043662954044794984 
653051 LOC653051 XM_925795.1 LOC653051 0.04369705229509728 
651465 LOC651465 XM_944690.1 LOC651465 0.04376632172718305 
642712 LOC642712 XM_926777.1 LOC642712 0.043815420015324714 
9154 SLC28A1 NM_201651.1 SLC28A1 0.043841747366748285 
100128746 LOC100128746 XM_001726588.1 LOC100128746 0.043874905167078086 
646566 LOC646566 XM_933706.1 LOC646566 0.04390382362985182 
729356 LOC729356 XR_036863.1 LOC729356 0.04392491941625278 
169834 LOC169834 XM_936297.1 LOC169834 0.04406591788604947 
647836 LOC647836 XM_936893.1 LOC647836 0.044074300034243834 
79158 GNPTAB NM_024312.3 GNPTAB 0.044177209332562146 
    Hs.551358 HS.551358 0.04429590120343183 
55511 SAGE1 NM_018666.1 SAGE1 0.04454669580107023 
114088 TRIM9 NM_052978.3 TRIM9 0.044713601155745256 
1880 GPR183 NM_004951.4 GPR183 0.044766978044226774 
58525 WIZ NM_021241.2 WIZ 0.04487145485387742 
    Hs.570535 HS.570535 0.0448985342130216 
Cancers 2018, 10, 332 S20 of S35 
646040 LOC646040 XM_933354.1 LOC646040 0.044910321983449665 
100130663 LOC100130663 XM_001719837.1 LOC100130663 0.0449171581004836 
10156 RASA4 NM_006989.3 RASA4 0.0449172733642023 
100129412 LOC100129412 XM_001724449.1 LOC100129412 0.04509846942017952 
693142 MIR557 NR_030284.1 MIR557 0.04522478913460713 
83898 KRTAP4-8 XM_927495.1 KRTAP4-8 0.04533959100938478 
8440 NCK2 NM_003581.2 NCK2 0.045390805618902325 
26582 DUX3 NM_012148.2 DUX3 0.045444015891660465 
51338 MS4A4A NM_148975.1 MS4A4A 0.045824373203041946 
23090 ZNF423 NM_015069.2 ZNF423 0.0458380449604099 
112399 EGLN3 NM_022073.2 EGLN3 0.04586641476579686 
645450 LOC645450 XM_928482.1 LOC645450 0.04587792597520967 
    Hs.565704 HS.565704 0.04604524295035083 
727994 LOC727994 XM_001717645.1 LOC727994 0.04616846813419221 
5157 PDGFRL NM_006207.1 PDGFRL 0.046193739473114004 
282969 C10orf125 NM_198472.1 C10ORF125 0.04621714785670731 
647983 LOC647983 XM_937039.1 LOC647983 0.046354241561175194 
79031 PDCL3 XM_929879.1 PDCL3 0.04641754842007101 
100313938 MIR548G NR_031662.1 MIR548G 0.04655543373008615 
1611 DAP NM_004394.1 DAP 0.04656125580018756 
391241 LOC391241 XM_372864.3 LOC391241 0.046576699058196815 
150921 TCF23 NM_175769.1 TCF23 0.04661232178619408 
619554 MIR486 NR_030161.1 MIR486 0.046612985679481606 
100132979 LOC100132979 XM_001723476.1 LOC100132979 0.046630454056350454 
651362 LOC651362 XM_940505.1 LOC651362 0.04669258782808066 
8125 ANP32A NM_006305.2 ANP32A 0.046783736391782925 
2887 GRB10 NM_005311.3 GRB10 0.046952512945653696 
26235 FBXL4 NM_012160.3 FBXL4 0.04696753087023498 
644714 LOC644714 XM_934514.1 LOC644714 0.04703281511457221 
727910 LOC727910 XM_001718130.1 LOC727910 0.047078199178451074 
    Hs.571403 HS.571403 0.04708841921734624 
100134805 LOC100134805 XM_001719203.1 LOC100134805 0.04712513232533933 
745 C11orf9 NM_013279.1 C11ORF9 0.04715254550434623 
160492 IFLTD1 NM_152590.1 IFLTD1 0.04717322013598507 
7015 TERT NM_198253.2 TERT 0.04718613531279058 
    Hs.545952 HS.545952 0.04722315518419996 
8624 PSMG1 NM_203433.1 PSMG1 0.04737253754741517 
100129271 C1orf68 NM_001024679.2 C1ORF68 0.04737332589684549 
219477 OR8J1 NM_001005205.1 OR8J1 0.04737755389151637 
3872 KRT17 NM_000422.1 KRT17 0.047425982292438607 
643493 LOC643493 XM_931578.1 LOC643493 0.047431793499921646 
2710 GK NM_000167.3 GK 0.04747795359305717 
8528 DDO NM_003649.2 DDO 0.04759894764627622 
54868 TMEM104 NM_017728.2 TMEM104 0.04763931569476485 
64786 TBC1D15 NM_022771.3 TBC1D15 0.04776252741607036 
100302129 MIR1915 NR_031736.1 MIR1915 0.04780680859532939 
Cancers 2018, 10, 332 S21 of S35 
729475 RAD51AP2 Hs.515802 RAD51AP2 0.04782097794386552 
    Hs.544828 HS.544828 0.048024235371097825 
    Hs.580655 HS.580655 0.04817920321578044 
652845 LOC652845 XM_942543.1 LOC652845 0.04829554628170876 
  ERCC-00111 ERCC-00111 ERCC-00111 0.04833840947152641 
    Hs.260074 HS.260074 0.04835079602446493 
3231 HOXD1 NM_024501.1 HOXD1 0.048401910255265405 
64377 CHST8 NM_022467.3 CHST8 0.04858975405102501 
    Hs.560387 HS.560387 0.04860858415283664 
100134121 LOC100134121 XM_001714675.1 LOC100134121 0.04867882754541401 
10053 AP1M2 NM_005498.3 AP1M2 0.048839436915587696 
100132649 LOC100132649 XM_001718045.1 LOC100132649 0.04887013981366635 
6169 RPL38 NM_001035258.1 RPL38 0.04897774040010492 
652512 LOC652512 XM_941983.1 LOC652512 0.04917845930977059 
8819 SAP30 NM_003864.1 SAP30 0.04921232319667151 
57507 ZNF608 NM_020747.1 ZNF608 0.0493426107426408 
2658 GDF2 NM_016204.1 GDF2 0.04942968746423412 
Table S5. The complete gene list from patients without dual AML cell populations. We compared the 
global gene expression profiles for 12 AML samples with and 27 samples without dual AML cell 
populations. A feature subset selection (FSS) analysis was performed for identification of the most 
discriminative genes between the two groups, and 1209 genes were then identified (i.e., p-value <0.05). 
Gene ID Symbol Search Key 
Illumina (ILM)-
gene P-value 
642528 LOC642528 XM_926022.1 LOC642528 1.817595639495555E-4 
100130508 LOC100130508 XM_001716255.1 LOC100130508 4.447421112487998E-4 
    Hs.567094 HS.567094 6.800822576455169E-4 
643857 LOC643857 XM_927130.1 LOC643857 7.808779365329758E-4 
653111 LOC653111 XM_926073.2 LOC653111 8.070077698455909E-4 
401498 LOC401498 NM_212558.1 LOC401498 8.296802641247719E-4 
    Hs.313888 HS.313888 9.294829916806852E-4 
203414 CXorf24 XM_926772.1 CXORF24 9.756606904733263E-4 
    Hs.535372 HS.535372 0.001000817614127855 
23555 TSPAN15 NM_012339.3 TSPAN15 0.001079624881794884 
642553 LOC642553 XM_926041.1 LOC642553 0.0011128384035927249 
254225 RNF169 XM_940188.1 RNF169 0.0011286947961539869 
284293 HMSD NM_001123366.1 HMSD 0.0012888164659033512 
9182 RASSF9 NM_005447.2 RASSF9 0.0013483219634245417 
574446 MIR511-2 NR_030168.1 MIR511-2 0.0013825423617592363 
100134461 LOC100134461 XR_039702.1 LOC100134461 0.0013886851670043363 
643464 LOC643464 XM_931563.1 LOC643464 0.001403925102163556 
    Hs.561144 HS.561144 0.0014203934909458207 
127150 LOC127150 XM_497717.2 LOC127150 0.0014787996671713956 
100134368 LOC100134368 NR_024453.1 LOC100134368 0.0014831756022624565 
644451 LOC644451 XR_037207.1 LOC644451 0.0017513812633183805 
100133232 LOC100133232 XM_001720154.1 LOC100133232 0.0018682046476840581 
642608 LOC642608 XM_930949.1 LOC642608 0.0018893903351726647 
Cancers 2018, 10, 332 S22 of S35 
    Hs.563292 HS.563292 0.0019857574463121937 
649189 LOC649189 XM_943611.1 LOC649189 0.0020192891414445874 
388572 LOC388572 XM_001722169.1 LOC388572 0.0020738138287287465 
646334 LOC646334 XM_929268.1 LOC646334 0.0020862534372304044 
    Hs.232517 HS.232517 0.0021399762832749383 
654209 LOC654209 XM_941064.1 LOC654209 0.0022286393784698762 
288 ANK3 NM_020987.2 ANK3 0.0022312829691701246 
344148 NCKAP5 NM_207363.2 NCKAP5 0.002265105586918537 
653796 LOC653796 XM_929960.1 LOC653796 0.0023010467263336162 
84931 FLJ14816 XR_017947.2 FLJ14816 0.002610085693546829 
647219 LOC647219 XM_930260.1 LOC647219 0.0026196262039302792 
652355 LOC652355 XM_939668.1 LOC652355 0.00274036261086637 
1583 CYP11A1 NM_000781.1 CYP11A1 0.002750373015735045 
130 ADH6 NM_000672.2 ADH6 0.0028473581005427464 
693235 MIR92B NR_030281.1 MIR92B 0.0028723933716857998 
768239 PSAPL1 NM_001085382.1 PSAPL1 0.002904197951432086 
118425 GDEP NR_026555.1 GDEP 0.0029104742057124177 
    Hs.162932 HS.162932 0.0031252062777078807 
    Hs.559820 HS.559820 0.003222428963051623 
100133034 LOC100133034 XR_036886.1 LOC100133034 0.0032667673919331147 
    Hs.561960 HS.561960 0.003384888778334856 
642412 LOC642412 XM_925931.1 LOC642412 0.0035227020471639255 
100134821 LOC100134821 XM_001722581.1 LOC100134821 0.003624282268300971 
340970 LOC340970 XR_038494.1 LOC340970 0.003737685755019992 
    Hs.114286 HS.114286 0.003932674181302355 
768222 MIR770 NR_030528.1 MIR770 0.003986096141096122 
100131897 LOC100131897 XM_001725433.1 LOC100131897 0.004047894840157547 
158825 LOC158825 XM_944306.1 LOC158825 0.004123734367948094 
    Hs.541921 HS.541921 0.00413122853488739 
729291 LOC729291 XR_041493.1 LOC729291 0.0041748180800655005 
286310 LOC286310 XM_938575.1 LOC286310 0.004247249772839345 
649021 LOC649021 XM_938105.1 LOC649021 0.0043309613155418465 
6339 SCNN1D NM_002978.2 SCNN1D 0.004384104476889884 
9148 NEURL NM_004210.3 NEURL 0.004404169604086631 
100129272 LOC100129272 XR_038735.1 LOC100129272 0.004489042421780521 
646686 LOC646686 XM_929633.1 LOC646686 0.0045888199572226215 
100134245 LOC100134245 XM_001723619.1 LOC100134245 0.004651492454884095 
729759 OR4F29 NM_001005221.2 OR4F29 0.004687841476130208 
    Hs.579243 HS.579243 0.004778268630255688 
400804 LOC400804 NR_024236.1 LOC400804 0.004843756848718989 
  ERCC-00019 ERCC-00019 ERCC-00019 0.004868380227138507 
    Hs.555115 HS.555115 0.0048744360081739 
    Hs.545650 HS.545650 0.004878823751515827 
    Hs.560651 HS.560651 0.004922635228871089 
643195 LOC643195 XM_926563.1 LOC643195 0.004978023243253226 
647323 LOC647323 XM_930391.1 LOC647323 0.005000769305957843 
Cancers 2018, 10, 332 S23 of S35 
345 APOC3 NM_000040.1 APOC3 0.005101164742546303 
642384 LOC642384 XM_926149.1 LOC642384 0.005173983519467021 
56134 PCDHAC2 NM_031883.2 PCDHAC2 0.005303901459912222 
100132515 LOC100132515 XM_001719495.1 LOC100132515 0.0053358302717896695 
729623 LOC729623 XM_001716155.1 LOC729623 0.005393654110446185 
127077 OR2T11 NM_001001964.1 OR2T11 0.005415934852160404 
651007 LOC651007 XM_940119.1 LOC651007 0.005429676243793426 
81931 ZNF93 NM_031218.2 ZNF93 0.005455575321176081 
651481 LOC651481 XM_944705.1 LOC651481 0.0055417632881616195 
100133612 LOC100133612 NR_024455.1 LOC100133612 0.005662336973006867 
    Hs.129329 HS.129329 0.005768818496994594 
84141 FAM176A NM_001135032.1 FAM176A 0.005810056386037936 
652264 LOC652264 XM_941675.1 LOC652264 0.005858098708048516 
729459 LOC729459 XM_001720731.1 LOC729459 0.005911584917413475 
    Hs.290834 HS.290834 0.005924131281531853 
100132318 LOC100132318 XM_001718904.1 LOC100132318 0.0059987630165777885 
389730 FAM75A6 XR_041507.1 FAM75A6 0.006002113715609757 
    Hs.147725 HS.147725 0.006082745949588517 
402160 LOC402160 XM_938047.1 LOC402160 0.00618058117796696 
54550 NECAB2 NM_019065.2 NECAB2 0.006269455344883447 
401898 ZNF833 NM_001013691.1 ZNF833 0.006362520312844321 
10655 DMRT2 NM_181872.1 DMRT2 0.006384440067591239 
139542 LOC139542 XM_066752.1 LOC139542 0.0064241876819909885 
    Hs.505855 HS.505855 0.006434400433945601 
650439 LOC650439 XM_944199.1 LOC650439 0.006508297260284593 
1112 FOXN3 XM_929939.1 FOXN3 0.00660337190070171 
407021 MIR29A NR_029503.1 MIR29A 0.006642280164138524 
    Hs.540289 HS.540289 0.006958649946345595 
100134638 LOC100134638 XM_001719382.1 LOC100134638 0.0069592213315213935 
339906 PRSS42 NM_182702.1 PRSS42 0.007160306544423903 
121599 SPIC NM_152323.1 SPIC 0.007388445760845789 
649385 LOC649385 XM_938457.1 LOC649385 0.007497483289329452 
23443 SLC35A3 NM_012243.1 SLC35A3 0.007553044335781477 
442147 LOC442147 XM_498029.2 LOC442147 0.007648291765228071 
100130701 LOC100130701 XM_001717180.1 LOC100130701 0.007827397078180115 
653053 LOC653053 XM_925853.1 LOC653053 0.007900204294587978 
29986 SLC39A2 NM_014579.1 SLC39A2 0.007999477533355752 
8521 GCM1 NM_003643.2 GCM1 0.00812388029222538 
122183 FLJ40296 XM_939203.1 FLJ40296 0.008183868937692471 
    Hs.560728 HS.560728 0.008286770271927719 
9837 GINS1 NM_021067.2 GINS1 0.008296728324984135 
100131243 LOC100131243 XR_042510.1 LOC100131243 0.008446767342929243 
693219 MIR634 NR_030364.1 MIR634 0.008456173083631108 
100313772 MIR548M NR_031667.1 MIR548M 0.00849958265815995 
    Hs.551062 HS.551062 0.008645163460421596 
    Hs.516420 HS.516420 0.00889648558077197 
Cancers 2018, 10, 332 S24 of S35 
56834 GPR137 NM_020155.2 GPR137 0.008938805140316653 
199699 DAND5 NM_152654.2 DAND5 0.008942142967801789 
84467 FBN3 NM_032447.3 FBN3 0.00898446467340792 
652665 LOC652665 XM_001719814.1 LOC652665 0.009055477529238248 
728654 LOC728654 Hs.578787 LOC728654 0.00905675591396397 
654117 LOC654117 XM_939660.1 LOC654117 0.009082287421969534 
148738 HFE2 NM_213653.2 HFE2 0.0091178306291845 
6340 SCNN1G NM_001039.2 SCNN1G 0.00911900427873428 
5017 OVOL1 NM_004561.2 OVOL1 0.009159824466742588 
    Hs.582355 HS.582355 0.009196764808675737 
    Hs.581967 HS.581967 0.009287204096533039 
649094 LOC649094 XM_945141.1 LOC649094 0.009407504706926069 
5100 PCDH8 NM_002590.2 PCDH8 0.009772616370694803 
645039 LOC645039 XM_928095.1 LOC645039 0.009787421976979783 
2277 FIGF NM_004469.2 FIGF 0.009833563822276537 
9104 RGN XM_937211.1 RGN 0.009849569716599147 
113146 AHNAK2 NM_138420.2 AHNAK2 0.009922939294713589 
120227 CYP2R1 NM_024514.4 CYP2R1 0.01001708226445753 
652505 LOC652505 XM_941974.1 LOC652505 0.010040278019144642 
    Hs.540000 HS.540000 0.010058940716288397 
284618 C1orf104 NM_001039517.1 C1ORF104 0.010193965306880588 
130612 TMEM198 NM_001005209.1 TMEM198 0.010292867538476691 
    Hs.582338 HS.582338 0.010306764806367223 
114784 CSMD2 NM_052896.2 CSMD2 0.010320462285929569 
653623 LOC653623 XM_932876.1 LOC653623 0.010339962262382542 
648993 LOC648993 XM_932049.1 LOC648993 0.010645850219767923 
389400 GFRAL NM_207410.1 GFRAL 0.01069802979537872 
5651 PRSS7 NM_002772.1 PRSS7 0.01074816405737597 
401551 WDR38 XM_941914.1 WDR38 0.010901481221334513 
378948 RBMY1B NM_001006121.1 RBMY1B 0.010973341854028786 
27127 SMC1B NM_148674.3 SMC1B 0.01098107373278998 
100130808 LOC100130808 XM_001719331.1 LOC100130808 0.011022411175326036 
8324 FZD7 NM_003507.1 FZD7 0.011119660122521448 
100129055 LOC100129055 NR_024524.1 LOC100129055 0.011190951965361953 
644311 LOC644311 XM_933386.1 LOC644311 0.011245518853591773 
81469 OR2G3 NM_001001914.1 OR2G3 0.01125014975576129 
  ERCC-00112 ERCC-00112 ERCC-00112 0.011616489420920842 
642468 LOC642468 XM_931123.1 LOC642468 0.011628890636355619 
642273 FAM110C NM_001077710.1 FAM110C 0.01165792905924736 
    Hs.520328 HS.520328 0.011873977183376822 
    Hs.504674 HS.504674 0.011964393260100225 
645126 LOC645126 XM_928158.1 LOC645126 0.011969802328208998 
431704 RGS21 NM_001039152.2 RGS21 0.012066177424885915 
653799 LOC653799 XM_930003.1 LOC653799 0.012084751428363714 
    Hs.561963 HS.561963 0.01211700673958969 
    Hs.519022 HS.519022 0.012308192274700338 
Cancers 2018, 10, 332 S25 of S35 
2671 GFER NM_005262.2 GFER 0.012358644008364584 
27445 PCLO NM_033026.5 PCLO 0.012435428150906784 
374900 ZNF568 NM_198539.2 ZNF568 0.01251107186987248 
51666 ASB4 NM_145872.1 ASB4 0.012561012785904813 
728701 LOC728701 XM_001732848.1 LOC728701 0.01272238204011093 
26257 NKX2-8 NM_014360.2 NKX2-8 0.012760908430736332 
652148 LOC652148 XM_945224.1 LOC652148 0.012772870119896178 
100130592 LOC100130592 XM_001725751.1 LOC100130592 0.012811240982860801 
    Hs.539714 HS.539714 0.012840912412962124 
57569 ARHGAP20 NM_020809.2 ARHGAP20 0.013118470760808389 
653665 LOC653665 XM_928758.1 LOC653665 0.013128469298894354 
4710 NDUFB4 NM_004547.4 NDUFB4 0.013222649280353434 
401940 PRAMEF3 XM_001713666.1 PRAMEF3 0.013249479371121564 
654466 KGFLP2 NR_003670.1 KGFLP2 0.013290672798568059 
402217 LOC402217 XM_926343.1 LOC402217 0.013309286116595792 
    Hs.529442 HS.529442 0.013367123475068342 
84626 KIAA1862 NM_032534.1 KIAA1862 0.013422970670634833 
    Hs.222909 HS.222909 0.013500050558039321 
    Hs.278303 HS.278303 0.013528025823074474 
79541 OR2A4 NM_030908.1 OR2A4 0.013535774011872056 
23629 BRD7P3 NR_002730.2 BRD7P3 0.0136581493075215 
642655 LOC642655 XM_926114.1 LOC642655 0.01368705768083874 
222545 GPRC6A NM_148963.1 GPRC6A 0.013711233775200095 
401224 AACSL XM_376454.3 AACSL 0.01371367905687376 
6276 S100A5 NM_002962.1 S100A5 0.01379519022527498 
90987 ZNF251 XM_937814.1 ZNF251 0.013899350375122767 
285962 FLJ40852 NM_173677.1 FLJ40852 0.014060434770464255 
728181 LOC728181 Hs.577605 LOC728181 0.0141347940546377 
81543 LRRC3 NM_030891.3 LRRC3 0.014323459527928824 
26254 OPTC NM_014359.3 OPTC 0.014352304331036903 
    Hs.553088 HS.553088 0.014374538074530693 
406890 MIRLET7G NR_029660.1 MIRLET7G 0.01440899484424025 
646698 LOC646698 XM_929644.1 LOC646698 0.01483732667353354 
147687 ZNF417 NM_152475.1 ZNF417 0.01493098172105505 
574537 UGT2A2 NM_001105677.1 UGT2A2 0.01503029185309763 
644452 LOC644452 XM_927592.1 LOC644452 0.015181770414054904 
647527 LOC647527 XM_942881.1 LOC647527 0.015201527808483101 
440337 LOC440337 NM_001013705.1 LOC440337 0.015425289593572807 
768212 MIR758 NR_030406.1 MIR758 0.015508613507342983 
727894 LOC727894 XM_001720317.1 LOC727894 0.015543022881295037 
650433 LOC650433 XM_928063.1 LOC650433 0.015552972852532355 
3375 IAPP NM_000415.1 IAPP 0.015621056486094994 
648684 LOC648684 XM_937754.1 LOC648684 0.01565313143237827 
128239 IQGAP3 NM_178229.3 IQGAP3 0.015658724162056693 
8120 AP3B2 NM_004644.3 AP3B2 0.0156638685342592 
100127886 LOC100127886 XM_001721104.1 LOC100127886 0.01569002017637976 
Cancers 2018, 10, 332 S26 of S35 
100129520 LOC100129520 XM_001720546.1 LOC100129520 0.015726804775336712 
81797 OR12D3 NM_030959.2 OR12D3 0.015879234124184034 
442204 LOC442204 XM_941158.1 LOC442204 0.015897567172426633 
648879 LOC648879 XM_937958.1 LOC648879 0.01599569702802101 
653392 LOC653392 XM_929544.1 LOC653392 0.016044495811424156 
    Hs.454935 HS.454935 0.016147535401897353 
    Hs.169896 HS.169896 0.016207540339586237 
9469 CHST3 NM_004273.2 CHST3 0.016243901989474365 
    Hs.552917 HS.552917 0.0162697160542665 
653759 LOC653759 XM_933689.1 LOC653759 0.016371098321163312 
645769 LOC645769 XM_928769.1 LOC645769 0.016510185576198752 
7781 SLC30A3 NM_003459.4 SLC30A3 0.016511028193686883 
80144 FRAS1 NM_206841.1 FRAS1 0.016523873196868023 
664617 MIR542 NR_030399.1 MIR542 0.016613714909317213 
100302134 MIR1289-2 NR_031621.1 MIR1289-2 0.01662531022456159 
4134 MAP4 NM_002375.3 MAP4 0.016775584222864293 
677775 SCARNA5 NR_003008.2 SCARNA5 0.016785208842328966 
100133602 LOC100133602 XR_036856.1 LOC100133602 0.01683666670821988 
400352 LOC400352 XR_016578.2 LOC400352 0.017079739864692106 
653803 LOC653803 XM_376278.3 LOC653803 0.017127976599654482 
645643 LOC645643 XM_933022.1 LOC645643 0.017150239866511565 
441488 LOC441488 XM_929997.1 LOC441488 0.017215380981883834 
644076 GLYCAM1 XM_945144.1 GLYCAM1 0.01722458438549089 
646399 LOC646399 XM_929326.1 LOC646399 0.01754998407582004 
652760 LOC652760 XM_942393.1 LOC652760 0.017582158167762218 
100133056 LOC100133056 XM_001723741.1 LOC100133056 0.017614278666529242 
653513 LOC653513 XM_927826.1 LOC653513 0.01764358092608569 
100133638 LOC100133638 XM_001714231.1 LOC100133638 0.01773533627268364 
29113 C6orf15 NM_014070.1 C6ORF15 0.017803645740275556 
653149 LOC653149 XM_926213.1 LOC653149 0.01787715309412106 
653941 LOC653941 XM_943151.1 LOC653941 0.018263229409780438 
8385 OR1D4 NM_003552.2 OR1D4 0.018307855268222265 
649280 LOC649280 XM_941486.1 LOC649280 0.018391792044690356 
83856 FSD1L NM_031919.1 FSD1L 0.01846573577669781 
    Hs.579259 HS.579259 0.018467485733116545 
    Hs.581657 HS.581657 0.018606211149496413 
    Hs.133257 HS.133257 0.018767528532055853 
100048912 ANRIL Hs.556821 ANRIL 0.01879524479320668 
692200 SNORD85 NR_003066.1 SNORD85 0.018976701195394474 
    Hs.581645 HS.581645 0.01899843200332198 
79710 MORC4 NM_024657.2 MORC4 0.01910590570428638 
122038 LOC122038 XM_062912.1 LOC122038 0.019196424317865713 
100128838 LOC100128838 XM_001724524.1 LOC100128838 0.01922384593465647 
    Hs.242159 HS.242159 0.019287226676571085 
729528 PRAMEF14 NM_001099854.1 PRAMEF14 0.019416555497664207 
406902 MIR10A NR_029608.1 MIR10A 0.019425208689276614 
Cancers 2018, 10, 332 S27 of S35 
650977 LOC650977 XM_935578.1 LOC650977 0.01956314166256176 
    Hs.541600 HS.541600 0.019629559223353542 
2525 FUT3 NM_000149.1 FUT3 0.019700089768871422 
729393 LOC729393 XM_935556.1 LOC729393 0.019865272887790345 
100132209 LOC100132209 XM_001714087.1 LOC100132209 0.020221726568477035 
652575 LOC652575 XM_942082.1 LOC652575 0.02028866877821377 
100313884 MIR548H4 NR_031680.1 MIR548H4 0.020330775601036345 
653806 LOC653806 XM_930050.1 LOC653806 0.020337837904343084 
    Hs.563518 HS.563518 0.020396989331975476 
10060 ABCC9 NM_020298.2 ABCC9 0.02040799559747524 
646574 LOC646574 XM_933715.1 LOC646574 0.02062140321117068 
730196 LOC730196 XM_930127.1 LOC730196 0.020624550982535607 
650721 LOC650721 XM_944342.1 LOC650721 0.02062949543418754 
642692 LOC642692 XM_926143.1 LOC642692 0.020863646281524408 
    Hs.571515 HS.571515 0.020882015379294242 
55908 LOC55908 NM_018687.3 LOC55908 0.02090164536976935 
    Hs.534913 HS.534913 0.021066473132055688 
643922 LOC643922 XM_927182.1 LOC643922 0.02111492999640619 
441795 LOC441795 XM_937553.1 LOC441795 0.02113572373628669 
    Hs.550218 HS.550218 0.02113799599016684 
649041 LOC649041 XM_938124.1 LOC649041 0.021141231059488303 
284417 TMEM150B XM_209187.5 TMEM150B 0.02123943361465546 
462 SERPINC1 NM_000488.2 SERPINC1 0.021275751939699005 
441016 LOC441016 XM_936464.1 LOC441016 0.021327771230071232 
56675 NRIP3 NM_020645.1 NRIP3 0.021359967827102422 
    Hs.409403 HS.409403 0.021368339724236827 
10512 SEMA3C NM_006379.2 SEMA3C 0.021410594450011266 
65082 VPS33A NM_022916.3 VPS33A 0.021667463211417614 
344558 SH3MD4 XM_293090.5 SH3MD4 0.02171773623940785 
219557 MGC26647 NM_152706.2 MGC26647 0.02173921534576355 
92105 INTS4 XM_941208.1 INTS4 0.02174200017972866 
286557 RBMY1A3P NR_001547.1 RBMY1A3P 0.02176637253887792 
729240 PRR20C NM_001130405.1 PRR20C 0.021780497537751933 
158852 CT45-2 NM_152582.3 CT45-2 0.02184468944229154 
646823 LOC646823 XM_933959.1 LOC646823 0.021954614523768918 
51804 SIX4 NM_017420.2 SIX4 0.02196686864294639 
100131696 LOC100131696 XM_001719335.1 LOC100131696 0.021973367354500152 
    Hs.576474 HS.576474 0.021982121554966757 
643937 LOC643937 XM_927195.1 LOC643937 0.02199470986446304 
100131999 LOC100131999 XM_001714361.1 LOC100131999 0.02210884720074493 
    Hs.543340 HS.543340 0.02221949537497687 
728022 LOC728022 XM_001720082.1 LOC728022 0.022536695804648364 
100134292 LOC100134292 XM_001717524.1 LOC100134292 0.022562678768112604 
85302 FBF1 XM_946190.1 FBF1 0.02267592886449689 
643062 LOC643062 XM_926433.1 LOC643062 0.02270477174650738 
256144 OR4C3 NM_001004702.1 OR4C3 0.02274452747329593 
Cancers 2018, 10, 332 S28 of S35 
388468 POTEC NM_001137671.1 POTEC 0.022857498615990433 
284467 FAM19A3 NM_001004440.1 FAM19A3 0.022993737812894953 
5549 PRELP NM_002725.3 PRELP 0.023129210919753312 
643365 FLJ44054 NR_024609.1 FLJ44054 0.023168962721932574 
51090 PLLP NM_015993.1 PLLP 0.023229776752251536 
55025 FLJ20712 XM_929740.1 FLJ20712 0.02332271643085656 
55890 GPRC5C NM_022036.2 GPRC5C 0.023339187030995644 
5731 PTGER1 NM_000955.2 PTGER1 0.02334109658809124 
100134687 LOC100134687 XM_001725648.1 LOC100134687 0.023364433029817847 
6534 SLC6A7 NM_014228.2 SLC6A7 0.02351409087980999 
153218 SPINK5L3 XM_376433.2 SPINK5L3 0.023561990750792117 
389396 C6orf140 XM_001717222.1 C6ORF140 0.02380808919026948 
148766 LOC148766 XM_944043.1 LOC148766 0.023814290697377855 
161357 MDGA2 NM_182830.2 MDGA2 0.0239783457626738 
100128074 LOC100128074 XM_001716711.1 LOC100128074 0.024034324339671117 
389888 LOC389888 XM_372248.3 LOC389888 0.02420778796700878 
3854 KRT6B NM_005554.2 KRT6B 0.024242414229249387 
253650 FLJ35740 NM_147195.1 FLJ35740 0.024248226617046308 
9620 CELSR1 NM_014246.1 CELSR1 0.02442422597179391 
650689 LOC650689 XM_944331.1 LOC650689 0.024620891735010586 
650851 LOC650851 XM_939939.1 LOC650851 0.02470620850525972 
    Hs.445179 HS.445179 0.024783874247643473 
100131060 LOC100131060 XM_001726569.1 LOC100131060 0.024789556725427153 
79837 PIP4K2C NM_024779.3 PIP4K2C 0.024790272965445812 
643431 LOC643431 XM_928128.1 LOC643431 0.0248750546433254 
389365 LOC389365 XM_371797.2 LOC389365 0.02499211911817448 
727884 LOC727884 XR_037459.1 LOC727884 0.02512510114659658 
149708 WFDC5 NM_145652.2 WFDC5 0.025211307697428416 
644054 FAM25C NM_001137548.1 FAM25C 0.025286841884306046 
206338 FLJ90650 NM_173800.3 FLJ90650 0.025331849080773603 
345274 SLC10A6 NM_197965.1 SLC10A6 0.025539266030957946 
574508 MIR505 NR_030230.1 MIR505 0.025542229322075727 
677830 SNORA50 NR_002980.1 SNORA50 0.025648115404393816 
    Hs.538367 HS.538367 0.0258033480835266 
644316 LOC644316 XM_927484.1 LOC644316 0.0258203783413274 
100128717 LOC100128717 XR_037607.1 LOC100128717 0.02594124537372537 
93659 CGB5 NM_033043.1 CGB5 0.02604889505318224 
    Hs.548213 HS.548213 0.026209602842411143 
643402 LOC643402 XM_926737.1 LOC643402 0.02622565874116249 
117531 TMC1 NM_138691.2 TMC1 0.026310984504829084 
5303 PIN4 NM_006223.2 PIN4 0.026349367250758066 
767610 SNORD114-29 NR_003222.1 SNORD114-29 0.02636118469746321 
393076 LOC393076 XM_935699.1 LOC393076 0.02642569718895187 
644098 LOC644098 XM_931998.1 LOC644098 0.026472465676084144 
391819 KRT18P42 XR_039234.1 KRT18P42 0.02653184971257089 
100129376 LOC100129376 XM_001714929.1 LOC100129376 0.026682345819321992 
Cancers 2018, 10, 332 S29 of S35 
157724 SLC7A13 NM_138817.2 SLC7A13 0.026698560476787658 
29931 LOH3CR2A NM_013343.1 LOH3CR2A 0.026792621726054573 
56122 PCDHB14 NM_018934.2 PCDHB14 0.026817705068609882 
100131183 LOC100131183 XR_039203.1 LOC100131183 0.02688306877348543 
    Hs.353831 HS.353831 0.026919042069835364 
5080 PAX6 NM_000280.2 PAX6 0.027014121380323875 
144402 CPNE8 NM_153634.2 CPNE8 0.027083771991721642 
    Hs.580251 HS.580251 0.027115028419016078 
728656 LOC728656 XM_932849.1 LOC728656 0.02719021068000494 
652326 LOC652326 XM_941750.1 LOC652326 0.027209804441805464 
648064 LOC648064 XM_937115.1 LOC648064 0.027538570723816908 
    Hs.564082 HS.564082 0.02763550270793093 
245973 ATP6V1C2 NM_144583.3 ATP6V1C2 0.027694136772679557 
130120 REG3G NM_001008387.1 REG3G 0.027932711689056387 
340561 MGC42638 XM_926284.1 MGC42638 0.028277961439309544 
3714 JAG2 NM_145159.1 JAG2 0.02841786844924962 
    Hs.542618 HS.542618 0.028503835503501194 
26492 OR8G2 NM_001007249.1 OR8G2 0.0285351290547875 
    Hs.221951 HS.221951 0.028565419239745177 
    Hs.538525 HS.538525 0.028632798570462893 
574493 MIR520H NR_030215.1 MIR520H 0.02865016994231157 
9180 OSMR NM_003999.1 OSMR 0.029033257307868314 
    Hs.529590 HS.529590 0.029095528736048856 
100129264 LOC100129264 XM_001725448.1 LOC100129264 0.029164465075395617 
    Hs.232520 HS.232520 0.02932739677614784 
79823 C2orf34 NM_024766.1 C2ORF34 0.02943581684894508 
84530 SRRM4 NM_194286.2 SRRM4 0.029557850541321092 
390880 LOC390880 XM_372707.3 LOC390880 0.029577098030507207 
    Hs.544707 HS.544707 0.029829129270451688 
348801 LNP1 XM_379203.2 LNP1 0.02985157069630891 
    Hs.571245 HS.571245 0.029888463512216464 
403257 OR4C45 NM_001005513.1 OR4C45 0.029893456666116217 
100131573 LOC100131573 XM_001716335.1 LOC100131573 0.029921462243786185 
642867 LOC642867 XM_931130.1 LOC642867 0.02995179201679189 
574460 MIR498 NR_030182.1 MIR498 0.02999828744136964 
5130 PCYT1A NM_005017.2 PCYT1A 0.03001622031954481 
6359 CCL15 NM_004167.3 CCL15 0.030086532136797735 
693191 MIR606 NR_030337.1 MIR606 0.030092216058631844 
130951 C2orf65 NM_138804.2 C2ORF65 0.030141646111764182 
8542 APOL1 NM_145344.1 APOL1 0.03014373088034522 
114038 C21orf84 NM_153752.1 C21ORF84 0.030270306908501375 
    Hs.576698 HS.576698 0.030320096011271686 
402066 LOC402066 XM_377725.3 LOC402066 0.030385264422877218 
220032 GDPD4 NM_182833.1 GDPD4 0.030427690838538468 
11245 GPR176 NM_007223.1 GPR176 0.030603100342009137 
389442 LOC389442 XM_945400.1 LOC389442 0.030698112698738667 
Cancers 2018, 10, 332 S30 of S35 
148811 PM20D1 NM_152491.3 PM20D1 0.030930813297524267 
    Hs.568434 HS.568434 0.031003115105758768 
391002 PRAMEF8 NM_001012276.1 PRAMEF8 0.031078148393666006 
647954 LOC647954 XM_938141.1 LOC647954 0.03115141005922734 
6003 RGS13 NM_144766.1 RGS13 0.03115524736341413 
390616 ANKRD34C XM_930512.1 ANKRD34C 0.03126601674428487 
283585 LOC283585 XM_375099.2 LOC283585 0.03126958784080985 
651787 LOC651787 XM_944941.1 LOC651787 0.03128112310360932 
    Hs.46693 HS.46693 0.03129196190008781 
    Hs.537983 HS.537983 0.03139569345078746 
645848 LOC645848 XM_933202.1 LOC645848 0.03145673574418213 
645201 LOC645201 XM_928236.1 LOC645201 0.031545488210135406 
643446 LOC643446 XM_932755.1 LOC643446 0.0315889226603109 
1014 CDH16 NM_004062.2 CDH16 0.0317473861882028 
100129536 LOC100129536 XR_038075.1 LOC100129536 0.031820383098682216 
441250 TYW1B XR_015176.2 TYW1B 0.03183031116099876 
644669 LOC644669 XM_927774.1 LOC644669 0.0318303814739753 
    Hs.546079 HS.546079 0.03191419153433756 
643799 LOC643799 XM_929213.1 LOC643799 0.031949486116225896 
340895 C10orf112 XM_001716843.1 C10ORF112 0.032093992948235735 
651923 LOC651923 XM_945017.1 LOC651923 0.0321414742003836 
650632 LOC650632 XM_939721.1 LOC650632 0.03219295571905057 
100302229 MIR1250 NR_031652.1 MIR1250 0.03222536563546908 
648898 LOC648898 XM_944772.1 LOC648898 0.03224153084769567 
677840 SNORA71D NR_003018.2 SNORA71D 0.03228973382905253 
    Hs.566864 HS.566864 0.032351696758506805 
387755 INSC NM_001031853.2 INSC 0.032364003360592905 
127064 OR2T12 NM_001004692.1 OR2T12 0.032808211355858825 
114771 PGLYRP3 NM_052891.1 PGLYRP3 0.032837605539625184 
    Hs.581365 HS.581365 0.032875995067218604 
11260 XPOT NM_007235.3 XPOT 0.03293121754836928 
440026 TMEM41B NM_015012.1 TMEM41B 0.033056690688610224 
400958 LOC400958 XM_379100.3 LOC400958 0.03307097076308331 
100129000 LOC100129000 XM_001719583.1 LOC100129000 0.033091916558510376 
652833 LOC652833 XM_942519.1 LOC652833 0.03321298535418646 
149775 GNASAS NR_002785.2 GNASAS 0.03344199943180014 
653781 LOC653781 XM_929706.1 LOC653781 0.03347996462830669 
222183 FLJ37078 NM_153043.3 FLJ37078 0.03354247547865309 
100134372 LOC100134372 XM_001714877.1 LOC100134372 0.03355176427687743 
643435 LOC643435 XM_931545.1 LOC643435 0.03357003327282396 
5874 RAB27B NM_004163.3 RAB27B 0.033575194307435996 
79954 NOL10 NM_024894.1 NOL10 0.0335990779953308 
84793 MGC12982 NR_026878.1 MGC12982 0.03361970373140142 
286075 ZNF707 NM_173831.2 ZNF707 0.03371320701560756 
100131320 LOC100131320 XM_001723688.1 LOC100131320 0.03385445543039937 
283025 C10orf40 NR_024340.1 C10ORF40 0.03394751501046586 
Cancers 2018, 10, 332 S31 of S35 
5599 MAPK8 NM_002750.2 MAPK8 0.03399866452797381 
644079 LOC644079 XM_001720206.1 LOC644079 0.0341912882375524 
368 ABCC6 NM_001079528.1 ABCC6 0.03431493026050804 
100132767 LOC100132767 XM_001720251.1 LOC100132767 0.03440080915221909 
138881 OR1L8 NM_001004454.1 OR1L8 0.03456597396989249 
6584 SLC22A5 NM_003060.2 SLC22A5 0.03460459391804023 
677829 SNORA49 NR_002979.2 SNORA49 0.03463335854931575 
    Hs.574252 HS.574252 0.03477897443857523 
728876 LOC728876 Hs.207162 LOC728876 0.03482274997843915 
119467 CLRN3 NM_152311.1 CLRN3 0.035018728475164886 
79822 ARHGAP28 NM_030672.2 ARHGAP28 0.03505231068410014 
    Hs.562032 HS.562032 0.03508937672895057 
7767 ZNF224 NM_013398.1 ZNF224 0.03512398245050982 
5916 RARG NM_000966.3 RARG 0.035124813290261965 
100128537 LOC100128537 XM_001714326.1 LOC100128537 0.03517421150909691 
    Hs.542875 HS.542875 0.03517734679208625 
    Hs.18849 HS.18849 0.03527114019290617 
100132972 LOC100132972 XR_039130.1 LOC100132972 0.035333362585726155 
    Hs.549487 HS.549487 0.0354015803965153 
93986 FOXP2 NM_148898.1 FOXP2 0.03550743036656206 
284697 BTBD8 NM_183242.1 BTBD8 0.03557651653273978 
81629 TSSK3 NM_052841.3 TSSK3 0.03559026459232305 
728193 LOC728193 XR_001254.1 LOC728193 0.03560005450194582 
55214 LEPREL1 NM_018192.2 LEPREL1 0.03561315135191362 
100132963 LOC100132963 XM_001714657.1 LOC100132963 0.035694192240537256 
  ERCC-00017 ERCC-00017 ERCC-00017 0.035822810531763706 
10143 CLEC3A NM_005752.2 CLEC3A 0.0358258784540761 
100131673 LOC100131673 XM_001723856.1 LOC100131673 0.03586836841115992 
692108 SNORD67 NR_003056.1 SNORD67 0.035873412006882904 
643927 LOC643927 XM_927188.1 LOC643927 0.03590837992065841 
729643 LOC729643 XM_001130893.1 LOC729643 0.03611177583217427 
654101 LOC654101 XM_939354.1 LOC654101 0.03611818282844728 
641311 RPL31P11 XR_000997.1 RPL31P11 0.03615679052967315 
    Hs.545364 HS.545364 0.036224827502454135 
646764 LOC646764 XM_929715.1 LOC646764 0.036249539928655795 
727997 LOC727997 XM_001127849.1 LOC727997 0.03635395411914439 
    Hs.542667 HS.542667 0.03639857127404468 
    Hs.541092 HS.541092 0.03644836231965023 
728924 LOC728924 XM_001132979.1 LOC728924 0.036626538623253165 
652335 LOC652335 XM_941764.1 LOC652335 0.03689505668917005 
26583 DUX2 NM_012147.2 DUX2 0.03698973758707169 
344382 LOC344382 XM_293026.5 LOC344382 0.03700152462800427 
100133053 LOC100133053 XM_001720766.1 LOC100133053 0.037011044365361706 
642018 LOC642018 XM_936088.1 LOC642018 0.037069802753291296 
643549 FLJ40606 XR_041973.1 FLJ40606 0.03716768958347956 
401317 LOC401317 XM_938320.1 LOC401317 0.037207267570032204 
Cancers 2018, 10, 332 S32 of S35 
100128485 LOC100128485 XM_001715311.1 LOC100128485 0.037552837763810396 
    Hs.545648 HS.545648 0.03783155531545804 
642194 LOC642194 XM_942778.1 LOC642194 0.03789201700212872 
654032 LOC654032 XM_939494.1 LOC654032 0.03813728856527247 
643414 LIPL2 XM_937207.1 LIPL2 0.03817870804042538 
692086 SNORD17 NR_003045.1 SNORD17 0.038200153388503036 
647080 LOC647080 XM_934321.1 LOC647080 0.03830985050841766 
  ERCC-00053 ERCC-00053 ERCC-00053 0.03834869514975889 
    Hs.534809 HS.534809 0.03834879151926415 
57683 KIAA1571 XM_937234.1 KIAA1571 0.038358552981103154 
729041 LOC729041 XM_001717661.1 LOC729041 0.03836846629500259 
100127887 LOC100127887 XM_001723461.1 LOC100127887 0.03853325132203725 
6048 RNF5 NM_006913.2 RNF5 0.03860009093862527 
286464 CXorf59 NM_173695.1 CXORF59 0.038680235450205415 
340549 LOC340549 XM_293332.1 LOC340549 0.038917475446315276 
255411 LOC255411 XM_932014.1 LOC255411 0.03895963998255315 
391365 SULT6B1 NM_001032377.1 SULT6B1 0.03911302437449217 
651763 LOC651763 XM_940981.1 LOC651763 0.039244630984538384 
389031 LOC389031 XM_940482.1 LOC389031 0.03926998584035779 
338662 OR8D4 NM_001005197.1 OR8D4 0.0393256779732204 
256281 NUDT14 NM_177533.2 NUDT14 0.03936138517869517 
338751 OR52L1 NM_001005173.1 OR52L1 0.03952706246953922 
55037 PTCD3 NM_017952.4 PTCD3 0.03965831209140964 
730050 LOC730050 XM_942380.1 LOC730050 0.03970261977275519 
649469 LOC649469 XM_938551.1 LOC649469 0.039726795675571205 
647651 LOC647651 XM_936697.1 LOC647651 0.03976741733921677 
100133418 LOC100133418 XM_001714459.1 LOC100133418 0.039798961546514564 
    Hs.143909 HS.143909 0.03987953435966447 
    Hs.541752 HS.541752 0.04004451312984737 
147945 NLRP4 NM_134444.3 NLRP4 0.04005249679157248 
6288 SAA1 NM_000331.2 SAA1 0.040065832203235015 
    Hs.547175 HS.547175 0.040153296946881016 
8074 FGF23 NM_020638.2 FGF23 0.04016990512673844 
441381 LRRC24 NM_001024678.1 LRRC24 0.04029216676542084 
728343 LOC728343 XM_939774.1 LOC728343 0.040324070434557116 
    Hs.475950 HS.475950 0.0403536263781617 
375010 LOC375010 XM_927556.1 LOC375010 0.040404601611003954 
4656 MYOG NM_002479.3 MYOG 0.04050658101039191 
    Hs.437179 HS.437179 0.04052765359085568 
116449 CLNK NM_052964.2 CLNK 0.0405367112071025 
3060 HCRT NM_001524.1 HCRT 0.04065663865807545 
26740 OR1J2 NM_054107.1 OR1J2 0.04079535607325396 
146177 LOC146177 XM_370944.4 LOC146177 0.04082276324038739 
400965 LOC400965 NM_001013677.1 LOC400965 0.040887347474745844 
    Hs.580126 HS.580126 0.0410471418128887 
    Hs.545887 HS.545887 0.04111865623111575 
Cancers 2018, 10, 332 S33 of S35 
727827 LOC727827 XM_001127359.2 LOC727827 0.04112645889694715 
135656 DPCR1 NM_080870.2 DPCR1 0.04113050080090478 
647515 LOC647515 XM_001718676.1 LOC647515 0.04116426887393105 
100133348 LOC100133348 XM_001716396.1 LOC100133348 0.04126059807045334 
1447 CSN2 NM_001891.1 CSN2 0.04130424464274184 
647197 LOC647197 XM_934499.1 LOC647197 0.04144851834200355 
    Hs.157621 HS.157621 0.041452897550665085 
285479 LOC285479 XM_211908.5 LOC285479 0.04162774662655042 
23430 TPSD1 NM_012217.2 TPSD1 0.04162903602256395 
100130123 LOC100130123 XM_001726844.1 LOC100130123 0.04178163825145163 
    Hs.545230 HS.545230 0.0418944246284238 
641978 LOC641978 XM_935752.1 LOC641978 0.04193526858697818 
    Hs.583274 HS.583274 0.0419771000983454 
284099 C17orf78 NM_173625.3 C17ORF78 0.0420299255226024 
284451 ODF3L2 NM_182577.1 ODF3L2 0.042116097623423256 
    Hs.569313 HS.569313 0.04213676251389568 
148645 MGC40168 NM_153709.1 MGC40168 0.042325609228867814 
50945 TBX22 NM_016954.2 TBX22 0.042337420790947905 
    Hs.560736 HS.560736 0.042560307781693854 
100129343 LOC100129343 XM_001724611.1 LOC100129343 0.0426296711237734 
100129514 LOC100129514 XM_001724518.1 LOC100129514 0.042757097797527295 
645218 LOC645218 XM_945368.1 LOC645218 0.042789979520314755 
83481 EPPK1 XM_926068.1 EPPK1 0.0428175486064293 
3547 IGSF1 NM_001555.2 IGSF1 0.04284432572336439 
258010 SVIP NM_148893.1 SVIP 0.042926970724047234 
646280 LOC646280 XM_929223.1 LOC646280 0.043143966073033654 
51802 ACCN5 NM_017419.1 ACCN5 0.043346582974570357 
    Hs.538535 HS.538535 0.04341198215012938 
    Hs.562701 HS.562701 0.04362372092389725 
441501 FLJ46446 XM_001715413.1 FLJ46446 0.04370004734540954 
54985 HCFC1R1 NM_001002017.1 HCFC1R1 0.0437394289594447 
653060 LOC653060 XM_925779.1 LOC653060 0.043789209896504436 
    Hs.135587 HS.135587 0.04379133238179812 
    Hs.40289 HS.40289 0.04400621524649907 
652762 LOC652762 XM_945940.1 LOC652762 0.044008620289967326 
100132966 LOC100132966 XM_001714155.1 LOC100132966 0.04407882716170898 
692057 SNORD12 NR_003030.1 SNORD12 0.044299546532056915 
26812 SNORD37 NR_002602.1 SNORD37 0.04433768044660433 
728116 LOC728116 NM_144621.2 LOC728116 0.04442996576954535 
55049 C19orf60 NM_001100419.1 C19ORF60 0.04453832178515606 
100128356 LOC100128356 XM_001719204.1 LOC100128356 0.04462339465347257 
100124542 SNORA11E NR_003712.1 SNORA11E 0.04473602678130252 
100129119 LOC100129119 XM_001718523.1 LOC100129119 0.04499965944222805 
81282 OR51G2 NM_001005238.1 OR51G2 0.04508569441179958 
    Hs.582113 HS.582113 0.0451131786661592 
    Hs.537150 HS.537150 0.04516681361170144 
Cancers 2018, 10, 332 S34 of S35 
51555 PEX5L NM_016559.1 PEX5L 0.04524256321740555 
100130370 LOC100130370 XM_001715409.1 LOC100130370 0.045377009541867616 
    Hs.442504 HS.442504 0.04540920889661434 
442425 FOXB2 NM_001013735.1 FOXB2 0.04542397134263472 
644152 LOC644152 XM_927360.1 LOC644152 0.04542523508126548 
    Hs.563147 HS.563147 0.04546159300769052 
    Hs.537608 HS.537608 0.04562692161699765 
653434 LOC653434 XM_933966.1 LOC653434 0.04568770829349333 
100124540 SNORA11C NR_003710.1 SNORA11C 0.04576946351814093 
    Hs.555208 HS.555208 0.045770937282462607 
26245 OR2M4 NM_017504.1 OR2M4 0.04578649557143999 
401109 FLJ25996 NM_001001699.1 FLJ25996 0.04589285003980043 
100130141 LOC100130141 XR_038164.1 LOC100130141 0.046055871031270804 
126868 C1orf161 NM_152367.1 C1ORF161 0.04609199594523736 
285512 FAM13AOS NR_002806.2 FAM13AOS 0.046145373406548514 
402317 OR2A42 NM_001001802.1 OR2A42 0.04616272697550872 
    Hs.541191 HS.541191 0.04625642254718605 
374739 TEPP NM_199046.1 TEPP 0.04625830589891997 
285697 LOC285697 XM_941117.1 LOC285697 0.04632282358450559 
    Hs.566890 HS.566890 0.04635531669736749 
5155 PDGFB NM_033016.1 PDGFB 0.04650986869654247 
727836 LOC727836 XR_038572.1 LOC727836 0.04652114694423314 
389730 LOC389730 XR_000527.1 LOC389730 0.046547519642591115 
374378 GALNTL4 NM_198516.1 GALNTL4 0.046735817907034405 
643037 LOC643037 XM_936787.1 LOC643037 0.04679494780096214 
100302130 MIR1302-4 NR_031633.1 MIR1302-4 0.04686041799156694 
649186 LOC649186 XM_938252.1 LOC649186 0.04686938946073637 
    Hs.561430 HS.561430 0.046901961073004754 
    Hs.302412 HS.302412 0.04694635264572553 
8330 HIST1H2AK NM_003510.2 HIST1H2AK 0.046960800231884994 
    Hs.544495 HS.544495 0.04696506376407463 
    Hs.574587 HS.574587 0.0469684078568494 
100131244 LOC100131244 XM_001724055.1 LOC100131244 0.046981434770345706 
    Hs.546135 HS.546135 0.046996587342102505 
651177 LOC651177 XM_940301.1 LOC651177 0.04700075868907026 
340602 CXorf67 NM_203407.1 CXORF67 0.047001076847879825 
646570 LOC646570 XM_933711.1 LOC646570 0.04703739710584047 
    Hs.550042 HS.550042 0.047115038681197076 
1297 COL9A1 NM_001851.3 COL9A1 0.04714323250208604 
10014 HDAC5 NM_001015053.1 HDAC5 0.04722777454918724 
641995 LOC641995 XM_935775.1 LOC641995 0.047228437613621325 
729374 LOC729374 XR_038569.1 LOC729374 0.04724643599108605 
653786 LOC653786 NR_003676.2 LOC653786 0.04725527473065633 
26780 SNORA68 NR_000012.1 SNORA68 0.047285746510851566 
400019 LOC400019 XM_378349.3 LOC400019 0.047393136010094226 
140691 TRIM69 NM_080745.3 TRIM69 0.0474119722132346 
Cancers 2018, 10, 332 S35 of S35 
647234 LOC647234 XM_934553.1 LOC647234 0.047439423733171025 
56163 RNF17 NM_031994.1 RNF17 0.04767407512859314 
89932 PAPLN NM_173462.2 PAPLN 0.04768950584794584 
403314 APOBEC4 NM_203454.1 APOBEC4 0.04793759494161416 
4842 NOS1 NM_000620.1 NOS1 0.048026600103485875 
100126319 MIR216B NR_030623.1 MIR216B 0.048043630203721495 
    Hs.58089 HS.58089 0.048076218570047326 
646358 LOC646358 XM_929287.1 LOC646358 0.048107642962684015 
439941 C8orf54 XR_000579.1 C8ORF54 0.04814616528597775 
1826 DSCAM NM_206887.1 DSCAM 0.04833964991785896 
651711 LOC651711 XM_940923.1 LOC651711 0.0483643092356878 
    Hs.582594 HS.582594 0.0484084727751594 
84809 CROCCL1 XR_039823.1 CROCCL1 0.048508335050976716 
36 ACADSB NM_001609.2 ACADSB 0.04852330528721858 
149465 WDR65 NM_152498.1 WDR65 0.04853470869428911 
652510 LOC652510 XM_941981.1 LOC652510 0.04863040057616678 
1800 DPEP1 NM_004413.1 DPEP1 0.048648356765277206 
5279 PIGC NM_153747.1 PIGC 0.04869033866821056 
645651 LOC645651 XM_928665.1 LOC645651 0.048761572597092004 
644415 LOC644415 XR_018194.2 LOC644415 0.04887709279665332 
154288 ECAT1 NM_001017361.1 ECAT1 0.04888972575962395 
646187 LOC646187 XR_016991.2 LOC646187 0.04903448172268005 
645196 LOC645196 XM_928233.1 LOC645196 0.04918479829182512 
81607 PVRL4 NM_030916.1 PVRL4 0.0493173128212757 
285193 DUSP28 NM_001033575.1 DUSP28 0.0493731738586513 
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